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Note to reader 
 
For ease of reading, concision has been emphasised in preparation of this work. 
Thus the text in each chapter is condensed to principally communicate the main 
lines of argument, supported by comprehensive summary tables, concept 
drawings, elaborately annotated figures and supplemental material. In places, 
discussions have been reiterated for clarification or emphasis. The bibliography 
has been compiled chapter-wise. Experimental methods have been 
schematically illustrated, written deliberately in condensed active voice for clarity 
and organised into seven complementary sections, forming part of a Methods 
chapter that features towards the end of the document. Additionally, each 
Results chapter contains a brief summary of experimental approaches. It is 
hoped that these approaches serve to enhance clarity, maintain narrative flow 
and avoid tedium.  
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Glossary: Childhood ALL 
 
BCR-ABL1 ALL Synonymous with adverse-risk Philadelphia-chromosome 
positive (Ph+) ALL 
CNS-directed therapy Treatment designed primarily to eliminate leukaemic cells in 
the central nervous system; cranial irradiation was 
previously a major component but has now been largely 
replaced by a combination of intra-spinal and CNS-
penetrating systemically-administered cytotoxics 
Early response Microscopic (or flow-cytometric) assessment of bone 
marrow response, 8-15 days into treatment; early response 
is designated Rapid or Slow based on pre-defined criteria 
Extramedullary disease Leukaemia in anatomical sites other than the bone marrow 
Good-risk genotypes Typically, progenitor-B lymphoblasts with ETV6-RUNX1 and 
TCF3-PBX1 fusion translocations and the high 
hyperdiploidy genotype 
MRD Submicroscopic residual disease; typically estimated in the 
bone marrow using molecular techniques (quantitative PCR 
of clonal antigen receptor rearrangements) or flow 
cytometry (detection of clonal surface markers) 
Progenitor-B ALL Haematopoietic neoplasm of early B-lymphocytes.  
Synonymous but less accurate terminologies include Pre-B 
(precursor B) and B-lineage ALL  
Poor-risk genotypes Synonymous with adverse-risk genotypes. Typically, 
progenitor-B lymphoblasts with BCR-ABL1 fusion, MLL 
rearrangements, the iAMP21 abnormality and hypodiploidy  
Induction phase Refers to the initial block of ALL treatment; treatment during 
this phase usually spans 4-5 weeks, typically includes a 
combination of 4-5 cytotoxic drugs and culminates in bone 
marrow tests to assess response 
Treatment failure Recurrence of disease (relapse) or unresponsive 
(refractory) disease 
Risk Relates to the probability of treatment failure 
  
Synopsis 
Synopsis 
Background 
Although cure rates in childhood acute lymphoblastic leukaemia (ALL) approach 
90%, relapses, particularly central nervous system (CNS) relapses, pose a 
significant therapeutic challenge. Prevention of relapses requires better 
predictive biomarkers. Towards this end, global gene-expression microarray 
screens of primary ALL samples were performed. Overexpression of the 
lysosomal cysteine protease, asparagine endopeptidase (AEP) was identified in 
adverse-risk progenitor-B ALL genotypes. AEP overexpression in adult human 
epithelial cancers has been linked to metastasis and adverse prognosis.  
 
Hypothesis 
AEP overexpression promotes leukaemic cell infiltration of the CNS and other 
extramedullary sites. AEP degrades the bacterial protein, E. coli L-asparaginase 
(ASNase) and potentially mediates lymphoblast resistance to this key 
antileukaemic drug.  
 
Summary of findings  
Quantitative AEP transcript estimation validated microarray findings in the 
discovery cohort. Sample availability precluded conclusive demonstration of 
protein overexpression. Intracellular expression in SD1 cells, a model AEP-
overepressing ALL cell line, was strikingly heterogeneous and included aberrant 
peripheral localisation in endolysosomal macrovesicles. Similar findings were 
observed anecdotally in primary lymphoblasts. In SD1 cells, precursor AEP 
protein was shed in microvesicles.  
AEP’s role in cell motility was examined in human embryonic kidney (HEK293) 
cells. Contrary to published reports, ectopic AEP overexpression in HEK293 cells 
was not associated with enhanced motility.  
ASNase was consistently degraded when incubated with ALL cell lysates. In 
overexpressing disease, ASNase degradation is potentially accelerated by AEP, 
resulting in inadequate drug activity during early treatment. AEP-cleaved ASNase 
Synopsis 
fragments retain known sensitising epitopes, suggesting that AEP cleavage could 
also potentiate formation of neutralising ASNase antibodies, compounding 
ASNase treatment failure. Sole substitution at an AEP cleavage site generated 
an AEP-resistant ASNase variant. Computational protein modelling enabled 
identification of an appropriate substituting amino acid that best retains drug 
activity.    
 
Conclusions 
AEP is a candidate marker of poor treatment response in childhood ALL and is 
presently the subject of a prospective nationwide clinical biomarker study. Its 
postulated role in cell motility appears to be cell-specific and dependent on the 
concomitant upstream expression of additional candidate pro-motility molecules. 
The protease also appears to be a marker of aberrant lymphoblast vesicle 
phenotype, an observation that is currently the focus of further studies.  
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Investigating treatment failure in childhood acute 
lymphoblastic leukaemia 
 
See Box ‘Childhood acute lymphoblastic leukaemia: a summary’ (Pages 3-4)  
 
Acute lymphoblastic leukaemia (ALL) is a clonal neoplasm of progenitor 
lymphocytes. It is the commonest childhood malignancy (Figure 1.1). Once a 
uniformly fatal disease in the 1950s, cure rates in economically-advanced 
countries are now approaching 90% (Figure 1.2). This remarkable progress has 
been achieved through a combination of serendipity, astute clinical observations 
and steady refinements in treatment as a result of large-scale collaborative 
studies (Figure 1.6, Table 1.1). In tandem, cytologic and molecular genetic 
studies have underscored the biological heterogeneity of disease (Figure 1.5, 
Table 1.2). Collectively, these insights and incremental advances have enabled 
the characterisation of key treatment elements (Figure 1.8, Table 1.1) and the 
adaptation of treatment intensity to the risk of relapse (Figure 1.7).  
 
These approaches have successfully driven down the incidence of treatment 
failure in childhood ALL (Figure 1.1, Figure 1.6). Treatment failure, a term that 
collectively refers to relapsed and refractory disease, is a major adverse event 
that is consistently associated with poor outcome (Figure 1.9). Relapsed ALL is 
second only to brain neoplasms as the commonest cause of childhood cancer-
related mortality in the UK and USA [116]. Thus, prevention of relapses is a key 
objective.  
 
Risk stratification of treatment is designed to specifically achieve this goal. The 
intention is to avoid overtreatment in children at low risk of relapse while 
escalating treatment intensity in those at highest risk of treatment failure. 
Although broadly successful, estimates of risk of relapse still remain imprecise. 
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Thus relapses continue to occur across all risk categories and numerically 
predominate in the population of children with apparent good risk disease 
(Figure 1.11). Equally, the imprecision in risk estimate potentially subjects a 
significant proportion of children to overtreatment and the attendant 
complications of short- and long-term treatment toxicities. Thus, adequately 
addressing the risk of relapse necessarily requires an enhanced understanding 
of disease biology (Figures 1.12, 1.13 and 1.14, Table 1.3). 
 
The biology of central nervous system (CNS) leukaemia  
One well-recognised but still poorly understood aspect of disease biology is the 
singular propensity for leukaemic cells to infiltrate the central nervous system 
(CNS). During the early evolution of treatment in childhood ALL, disease relapse 
in the CNS was a common cause of treatment failure. The structural and 
functional peculiarities of the CNS microvasculature render it impervious to 
standard therapies and require the administration of specific CNS-directed 
treatments to eliminate leukaemic cells in this anatomical compartment (Figure 
1.15).  
 
The contemporary combination of intensified systemic and CNS-directed 
therapies has considerably decreased the risk of CNS relapse but has not 
eliminated it [128]. Importantly in modern treatment protocols, the proportionate 
incidence of CNS relapses appears to be rising (Figure 1.16). Although there is 
room for additional refinement, current treatments have probably been near-
maximally intensified. Tackling CNS relapses thus requires novel approaches 
and new therapies. Designing such strategies requires insight into the 
fundamental molecular and cellular mechanisms that drive leukaemic infiltration 
of the CNS (Figure 1.17, Table 1.4). To this end, a global gene expression 
microarray screen was performed to identify candidate molecules potentially 
contributing to the pathogenesis of CNS disease. As will be discussed in the next 
chapter, the lysosomal cysteine protease, asparagine endopeptidase (AEP) was 
identified as one such molecule.  
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Childhood acute lymphoblastic leukaemia (childhood ALL): a summary 
• Malignancy of lymphoid progenitor cells 
• Commonest childhood cancer (Figure 1.1); peak incidence 2-5 years 
• Cure rates in industrialised world approach 90% (Figure 1.2, Table 1.1) 
• Pathogenetic mechanisms are incompletely understood (Figure 1.3) 
• Diagnostic tests are prompted by characteristic clinical symptoms and are based on 
a suite of complementary bone marrow tests (microscopy, flow cytometry and 
cytogenetics) (Figure 1.4, Figure 1.5, Table 1.2) 
• Treatment is based on a complex schedule of multiagent chemotherapy (Table 1.1).  
Most drugs used in contemporary treatment were introduced in the 1950s-1970s.  
Major gains in survival have largely been achieved by progressive refinements in the 
use of these drugs, informed by large-scale collaborative clinical trials (Figure 1.6).  
• Treatment intensity is adapted to the estimated risk of relapse. This risk assessment 
is based on clinical and biological variables at diagnosis and the response to therapy 
(Figure 1.7). 
• Assessment of response to therapy is based on serial submicroscopic evaluation of 
marrow disease burden using sensitive quantitative PCR or flow cytometry tests 
(Figure 1.7). Optimal response is characteristically observed early in treatment (1-2 
weeks by microscopy, 4 weeks by submicroscopic testing). 
• Fundamental treatment elements include a Remission Induction phase, a Delayed 
Intensification phase, a Continuation phase and Central Nervous System-directed 
treatment. Additional treatment phases are administered in patients with adverse 
presentation features or unsatisfactory response to treatment (Figure 1.8). In 
contemporary management of childhood ALL, a risk-adapted, response-driven 
strategy has meant that (appropriate) treatment is currently the most powerful 
determinant of outcome [22]. 
• As corollary, the incidence of treatment failure (typically relapse, less commonly 
treatment-refractory disease) has fallen.  This is important since outcomes following 
relapse have been consistently poor by comparison (Figure 1.9) 
• Relapses can occur at variable time-points from diagnosis. A peculiar feature of 
relapsed ALL is the propensity to recur at anatomical sites other than the bone 
marrow (extramedullary sites). Timing and site of relapse together with lymphoblast 
lineage influence treatment outcomes (Figure 1.10)  
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Childhood acute lymphoblastic leukaemia: a summary (continued) 
• The predilection for central nervous system (CNS) relapse has been well-recognised 
since the 1970s. The biological basis for this is incompletely understood. Part of the 
reason is attributable to the relatively impermeable blood-brain barrier which restricts 
access of cytotoxics to the CNS. Thus, frontline treatment protocols as a rule include 
treatment elements designed to eliminate leukaemic cells in the CNS compartment. 
These treatment components typically include intra-cerebrospinal fluid drug 
administration and CNS-penetrating systemic agents (Figure 1.15) 
• Achieving comprehensive cure in childhood ALL requires a deeper understanding of 
the mechanisms contributing to treatment failure. This includes understanding the 
predilection for recurrence at extramedullary sites. As cure rates steadily improve, 
attention is increasingly focused on decreasing treatment toxicity without 
compromising cure (Table 1.1). The long-term goal is to customise therapy to the 
individual patient so as to avoid over- or under-treatment as well as short- and long-
term treatment toxicities. 
• Overlapping strategies to achieve this goal include 
(a) Improving prognostication  
Despite increasing sophistication, current estimates of relapse risk are still 
imprecise and additional biomarkers are required (Figure 1.11). Global 
microarray discovery screens have been instructive in this regard (for instance, 
by uncovering prognostically significant cryptic somatic lesions including gene 
deletions, mutations and deregulated expression [Table 1.2]). 
(b) Investigating lymphoblast biology 
Recent studies indicate that durable cure requires elimination of both leukaemic 
and pre-leukaemic clones (Figures 1.12 – 1.13). As intrinsic drug sensitivity is 
determined by biological features of leukaemic cells and interactions with the 
stromal microenvironment, investigations exploring these mechanisms are 
required to advance cure (Figure 1.14).  
(c) Investigating host pharmacogenomics 
Treatment safety and response is powerfully influenced by host 
pharmacogenomics that govern drug toxicity and pharmacodynamics.  
(d) Investigating new therapies, including further optimising current therapies as well 
as examining biologically-targeted agents that have the potential to improve cure 
and reduce toxicity (e.g. the ABL tyrosine kinase inhibitor Imatinib in Ph+ ALL). 
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Figure 1.1 ALL is the most common childhood malignancy  
Annual incidence of cancers in the UK among children <15 years old. ALL is the most 
common childhood neoplasm (25% of all cancers). The declining incidence of relapsed 
ALL places this disease category as the 9th most common form of childhood cancer in 
the UK. Importantly, after central nervous system tumours, relapsed ALL is the 
commonest cause of cancer-related mortality in young children. 
ML, acute myeloid leukaemia; Bone Tmrs, bone tumours; Germ cell, germ cell 
neoplasms; Liver, paediatric liver tumours (hepatoblastomas); Neural crest, tumours 
derived from neural-crest precursors (neuroblastomas); NOS, not otherwise specified; 
Renal, paediatric renal tumours (Wilms tumours); Retinal, retina-based tumours 
(retinoblastomas); Soft tissue sarc, soft tissue sarcomas (rhadomyosarcoma and 
Ewing/primitive neuroectodermal family tumors).  
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Figure 1.2 The average cure rate for childhood ALL in the developed world is 
~85% 
Cumulative continuous probability distribution of overall survival in childhood ALL plotted 
against time. Survival increased steeply in the two decades between 1980 and 2000 and 
is now approaching 90%. The plateau in cure rates suggests that contemporary 
treatment has probably been maximally intensified and new agents and novel treatment 
approaches are now required.  
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Figure 1.3: The aetiopathogenesis of childhood ALL is unclear in most cases. A 
two-hit transformation event is postulated in progenitor-B ALL.  
Upper panel A predisposing cause is identified only in a minority of cases and typically 
involves constitutional or acquired abnormalities of germline DNA. Trisomy 21 (Down 
syndrome, DS) is a well-recognised risk factor with a 10-20 fold increased risk [89]. 
Unlike DS-related AML, ALL in DS has an intermediate prognosis, does not co-associate 
with known favourable or unfavourable chromosome lesions, is linked with aberrant 
kinase activation (e.g., Janus family kinases) and is characterised by increased mucosal 
sensitivity to cytotoxics such as methotrexate [90]. Genome-wide association studies 
identified predisposing germline polymorphisms in IKZF1 (Ikaros family zinc finger 1, 
7p12.2), ARID5B (AT-rich interactive domain-containing protein 5B, 10q21.2), and 
CEBPE (CCAAT enhancer binding protein epsilon, 14q11.2) 
Lower panel The pathogenesis of childhood progenitor-B ALL is attributed to a two-hit 
transformation event. The first hit refers to the in utero occurrence of somatic gene 
fusions, as revealed by analysis of dried neonatal blood spot cards [91]. This in itself is 
insufficient for leukaemogenesis. A second hit results in acquisition of additional (driver) 
genomic lesions in key lymphocyte differentiation and proliferation pathways, eventually 
resulting in overt leukaemia. An infection-driven immune-mediated transformation event 
is believed to represent this second-hit and is postulated to account for the rising 
incidence of childhood ALL (1.5% increase in annual incidence) in the industrialised 
world [92, 93]. Immunological insulation in infancy (lowered herd immunity, ʻhygiene 
hypothesisʼ) followed by delayed exposure in later childhood (for instance due to 
population-mixing, [94]), synchronous with the period of maximal lymphoid proliferation 
and expansion, confers adverse ʻimmunological stressʼ and drives neoplastic 
transformation of pre-leukaemic lymphocytes. This two-hit theory accounts for the peak 
incidence of childhood ALL in children aged 2-5 years; population-mixing additionally 
explains the occurrence of case clusters, for instance due to mass emigration to areas of 
low herd immunity. These theories probably do not apply to the origin of childhood 
progenitor-T lymphocyte ALL.  
ETV6-RUNX1, chromosome fusion translocation of chromosome segments 12p13.1 and 
21q22.3, resulting in a chimaeric gene fusion; PAX5, paired box gene 5 (chromosome 
locus 9p13); CDKN2A/B, gene locus encoding cyclin dependent kinase inhibitor 2A and 
the alternating reading frame product, cyclin dependent kinase inhibitor 2B 
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Figure 1.4: Clinical presentation and routine diagnostics in childhood ALL 
Most children present with a short history of symptoms (Upper panel). Diagnosis is established by a complement of tests performed 
typically on bone marrow samples. This starts with microscopy examination of stained bone marrow aspirates (Middle panel). Normal 
haematopoietic elements in the bone marrow are near-completely replaced by characteristic large cells with scanty agranular 
cytoplasm (occasionally with cytoplasmic projections [uropod] forming hand-mirror morphological forms) and round-to-oval nuclei with 
homogenous-staining finely dispersed chromatin (lymphoblasts, morphological forms L1 and L2). Diagnosis and lineage is 
established by flow cytometry immunophenotyping of CD45+ cells (Lower panel). Immunophenotyping and morphology (typically, 
basophilic vacuolated blast cytoplasm) additionally distinguish mature-B ALL from progenitor-B disease; the former is a distinct 
disease entity characterised by rapid tumour expansion and excellent response to intensive short-term cycling multiagent cytotoxic 
therapy.  
CD, cluster of differentiation markers; cy, cytoplasmic; Ig, immunoglobulin; s, surface; TdT, terminal deoxynucleotidyl transferase  
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 Figure 1.5: Childhood ALL is characterised by non-random somatic genetic 
lesions 
Typical recurring lymphoblast genetic abnormalities detected by conventional 
cytogenetic testing (G-banded karyotyping and FISH) in childhood ALL. Structural 
somatic lesions include non-random gene fusions that either encode hybrid proteins or 
result in enhanced expression of proto-oncogenes. These lesions are well-characterised 
in progenitor-B ALL and influence prognosis. By contrast, the impact of genetic 
abnormalities on treatment outcomes in progenitor-T ALL is incompletely understood. 
ABL1, Abelson murine leukaemia viral oncogene homolog-1 (chromosome locus 9q34.1); AF10, 
mixed-lineage leukemia (Drosophila trithorax homolog) translocated to 10 (10p12); BCR, 
breakpoint cluster region (22q11.2); CALM, clathrin assembly lymphoid myeloid leukaemia gene 
(11q14-21); CEBP, CCAAT enhancer binding protein gene family; CRLF2, cytokine receptor-like 
factor 2 (pseudoautosomal region, Xp22.3, Yp11.3); ETV6, ETS (E-26 transforming specific) 
variant gene 6 (12p13.1); HOX11, T-cell leukaemia homeobox 1 (TLX1, 10q24.31); HOX11L2, T-
cell leukaemia homeobox 3 (TLX3, 5q35.1); iAMP21, intrachromosomal amplification of 
chromosome 21; IgH, immunoglobulin heavy chain locus; LMO1 and LMO2, LIM domain only 1 
(11p15.4) and 2 (11p13); MLL, mixed lineage leukaemia gene (11q23); NUP214, nucleoporin 214 
kiloDalton (9q34.3); PBX1, pre-B leukaemia homeobox 1 (1q23); RUNX1, runt related 
transcription factor 1 (21q22.3); TAL1 and TAL2, T-cell acute lymphoblastic leukaemia 1 (1p32) 
and 2 (9q31); TCF3, transcription factor family 3 (E2A, 19p13.3); TCR, T-cell receptor loci. 
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Figure 1.6 Incremental refinements in therapy rather than introduction of new drugs, accounted for the steep improvement 
in childhood ALL cure rates between the 1980s and 2000s 
Left panel: Timeline schematic indicating chronology of introduction of key cytotoxic agents and treatment strategies in childhood ALL.  
Right panel: Kaplan-Meier analysis of event (relapse or death)-free survival indicates steady improvement with successive UK 
childhood ALL treatment protocols  
6-MP, 6-mercaptopurine; Ara-C, cytosine arabinoside; ASNase, E.coli L-asparaginase; CNS, central nervous system; Cyclo, 
cylophosphamide; Dauno, daunorubicin; MTX, methotrexate; PEG, polyethylene glycol; RT, XRT, radiotherapy; VCR, vincristine  
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Figure 1.7 A general approach to risk stratification in childhood ALL.  
Risk estimate is based on probability of relapse. Clinical features, Somatic genetic 
characteristics and Response to therapy are combined to generate a three-tier risk 
stratification approach. In contemporary treatment protocols, appropriate treatment 
intensity and satisfactory (submicrosopic) response to therapy supersede all other 
prognostic variables.  
D8/15, day 8 or 15 of ALL treatment; WBC, white blood cell 
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Figure 1.8 Contemporary risk-adapted treatment design in childhood ALL 
Integral treatment elements comprise the Induction, Delayed Intensification and 
Maintenance phases and central nervous system (CNS)-directed therapy. Intermediate-
risk patients typically receive additional treatment during induction (Ext. Indn) and 
delayed intensification phases. Treatment is further intensified in patients at high risk of 
relapse (Augmented Intensification treatment blocks) and is sometimes consolidated by 
allogeneic haematopoietic stem cell transplant (allo-SCT). CNS-directed therapy typically 
consists of a combination of CNS-penetrating systemic and intra-spinal fluid (intrathecal, 
IT) cytotoxics; cranial irradiation (RT) is generally reserved for children with overt CNS 
leukaemia. Treatment intensity is directed by early and serial submicroscopic 
assessment of response.  
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Figure 1.9 Childhood ALL relapses are best prevented. 
Kaplan-Meier estimates of survival probabilities in children enrolled on CCG trials for 
relapsed ALL. Survival outcomes in all three categories of relapse (early, intermediate 
and late) have remained static over successive trial eras, spanning a period of 15 years 
[115].  
CCG, North American Childrenʼs Cancer Group  
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Figure 1.10 A risk-adapted approach is also used in the contemporary 
management of relapsed childhood ALL 
Upper panel: Treatment outcomes following relapse are strongly influenced by timing 
and site of relapse and disease lineage. Lower panel: All three variables are typically 
incorporated in the design of risk-adapted treatment strategies for relapsed disease.  
BM, bone marrow disease; EM, extramedullary disease sites; EOT, end of therapy 
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 Figure 1.11 Current strategy of relapse risk stratification in childhood ALL is still 
imprecise 
Proportion of childhood ALL disease subtypes at diagnosis and relapse. The majority of 
relapses still occur in children with apparent ʻgood-riskʼ progenitor-B ALL. 
Pre-B Good Risk refers to progenitor-B ALL with favorable risk cytogenetics (ETV6-
RUNX1, high hyperdiploidy, TCF3-PBX1, normal karyotype disease and other non-
recurrent cytogenetic lesions); Pre-B Poor Risk refers to progenitor-B ALL with adverse 
risk cytogenetics (Ph+ALL, MLL rearranged, hypodiploidy); Pre-T refers to any 
progenitor-T ALL  
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Figure 1.12: Ancestral pre-leukaemic clones are responsible for childhood ALL 
relapse 
Cartoon representation of the origins of the relapse clone in childhood ALL based on 
results of high-resolution DNA copy number analyses in matched diagnosis-relapse 
samples from children with ALL; alphabets indicate somatic genomic lesions. In ~40% of 
cases, relapse clones are either identical to or clonally evolved from diagnosis clones. 
Instructively, in more than half the cases, the relapse clone is genomically related to an 
ancestral pre-leukaemic clone. In both situations, relapse clone cells are often identified 
as minor subpopulations at diagnosis, suggesting that cytotoxic treatment more likely 
favours clonal selection rather than progression. Thus durable cure requires elimination 
of both leukaemic and pre-leukaemic disease clones [117].  
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Figure 1.13 A biological paradigm of disease origin and relapse in childhood 
progenitor-B ALL  
A pre-leukaemic clone arises in utero and acquires secondary driver genetic lesions to 
give rise to overt leukaemia [91]. Leukaemia-initiating clones responsible for disease 
relapse are similarly related to an ancestral pre-leukaemic clone [117]. Persistence of 
the ancestral clone is probably a result of both autonomous (autocrine-paracrine 
signalling and stromal remodulation, e.g. Ph+ALL) and stromal-dependent (adhesion or 
non-adhesive interaction) mechanisms. Some extramedullary sites additionally serve as 
pharmacological sanctuaries (e.g. central nervous system). Adapted from [100]. 
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Figure 1.14 Postulated mechanisms contributing to disease relapse   
Intrinsic tumour characteristics and tumour stromal properties can interact to enhance 
lymphoblast survival. This when coupled with unfavorable drug-handling host germline 
polymorphisms can lead to persistence of leukaemia-initiating subclones and eventual 
disease relapse.   
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Figure 1.15 Persistence of brain-seeking lymphoblasts results in CNS relapse 
The unique neurotropism of lymphoblasts results in infiltration of the central nervous 
system (CNS). Systemic chemotherapy limits meningeal seeding while directed therapy 
eliminates blasts already resident in the CNS. These measures complement each other, 
and are integral to the success of therapy. These treatments have probably been 
maximally intensified. Notwithstanding, CNS leukaemia is a recurring feature of relapsed 
ALL, accounting for up to a third of all relapses. Thus tackling CNS leukaemia requires 
new treatment strategies, which can only arise from a deeper understanding of the 
mechanisms that drive leukaemic neuroinfiltration.  
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Figure 1.16 The proportional frequency of CNS relapses is increasing  
Data from the UK Medical Research Council (MRC) childhood ALL trials (x-axis). While 
the frequency of ALL relapse (as a proportion of the total diagnosed) has near-steadily 
declined to now under 10%, the proportion of relapses occurring in the central nervous 
system (CNS) has increased.  Tailoring treatment intensity to residual disease burden in 
the bone marrow appears to have successfully decreased isolated marrow relapses and 
in the process, unmasked the discordance in the dynamics of disease clearance 
between medullary and extramedullary compartments.  
ʻCNS relapsesʼ refers to both isolated and combined (bone marrow & CNS) relapses  
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Figure 1.17 Putative cellular and molecular events involved in extramedullary 
infiltration by lymphoblasts  
Chemokine signals drive the egress and homing of lymphoblasts from bone marrow to 
extramedullary sites. Circulating lymphoblasts probe the endothelial surface by 
deploying podosomes, specialised actin-based structures enriched in matrix-degrading 
enzymes, including matrix metalloproteases (MMP) and lysosomal hydrolases. Selectin-
mediated endothelial rolling and integrin-based interactive endothelial adhesion trigger 
reciprocal lymphoblast-endothelial cytoskeletal reorganization and exocytosis of matrix-
degrading enzymes, resulting in basement and stromal matrix degradation and 
lymphoblast extravasation by paracellular diapedesis or transendothelial migration. 
Adhesive and non-adhesive interactions with stromal component cells contribute to 
lymphoblast persistence at extramedullary sites.  
CXCR4 chemokine (CXC motif) receptor 4; CXCL12 chemokine (CXC motif) ligand 12; 
ECM, extracellular matrix; ICAM, intercellular adhesion family of molecules;  
VEGF/VEGFR vascular endothelial growth factor/receptor 
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Table 1.1 Milestones in the evolution of treatment of childhood ALL  
Elements Year / decade 
introduced 
Opening remarks Perspective/Current 
status 
Relevance / Refinements / 
Modifications 
Key 
references 
DIAGNOSIS  
Bone marrow 
morphology 
First attempts  
in the mid-
1960s; 
systematic 
guidelines 
since 1981 
Bone marrow 
morphology and 
cytochemistry used for 
diagnosis, differentiation 
from AML and 
determination of 
adverse-risk 
morphological subtypes  
Still remains the primary 
diagnostic technique. The 
FAB classification is useful 
only insofar as identifying 
mature B-lineage ALL 
(vacuolated L3 blasts). 
Cytochemistry is no longer 
used.  
Morphological adverse-risk 
variants such as granular blasts 
and hand-mirror forms are no 
longer relevant in the 
contemporary era 
[1], [2], [3] 
Blast 
immunological 
phenotype  
Mid 1980s Monoclonal antibody 
detection of surface and 
intracytoplasmic 
lineage- and 
differentiation-specific 
antigens  
Important diagnostic tool. 
Allows rapid and reliable 
diagnosis of leukaemia 
type (lymphoid v myeloid), 
lineage (T- or B-) and 
differentiation (early 
progenitor v precursor)  
Prognostic relevance of antigen 
markers largely obviated by 
current therapy. CD10-positive 
B-lineage disease in infants is a 
good-risk feature while immature 
T-cell immunophenotype is 
associated with inferior 
outcomes. Aberrant myeloid 
antigen expression (15-20% 
cases) is no longer relevant   
[4], [5], [6], [7]
Blast cytogenetics Late 1980s Metaphase G-banded 
karyotyping and FISH to 
detect recurrent 
translocations and 
aneuploidy 
Important diagnostic, risk-
stratification and discovery 
tool 
Extremely relevant in 
contemporary classification and 
treatment schemes. Growing 
significance with biologically-
directed therapies. Enhanced 
resolution using high-resolution 
whole-genome arrays and now, 
whole-genome sequencing 
[8], [9], [10]   
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PROGNOSIS  
Presentation risk factors
Clinical risk factors Mid 1980s Several clinical risk 
factors have been 
serially examined, 
including age, 
presenting white cell 
count, sex, blast lineage 
and extramedullary 
disease 
Two powerful clinical 
features continue to  inform 
risk assignation and 
constitute the NCI-Rome 
risk criteria - age (<10 or 
≥10 years) and presenting 
WBC count (<50 or 
≥50×109/L) 
Contemporary treatment has 
rendered redundant several 
previously relevant disease 
features. The biological basis for 
the persistent prognostic 
significance of age and 
leucocyte count is not fully 
understood 
[11], [12]  
Genetic risk factors Late 1980s Blast genotype 
influences outcome 
Contemporary treatment 
consistently recognises 
three adverse-risk 
genotypes - Philadelphia-
chromosome positive ALL 
(Ph+ ALL), MLL-
rearranged ALL and blast 
hypodiploidy (<45 
chromosomes) 
Intensified therapy including 
allogeneic stem cell transplant in 
adverse-risk genotypes. 
Relapses still occur in the 
numerically-larger good-risk 
genotypes suggesting that 
current genotype-based 
stratification is still imprecise 
[13], [14] 
Response to 
therapy  
 Bone marrow remission (blasts <5%) by light microscopy is seen in ~98% of patients after 
4-weeks of treatment and is therefore a poor discriminating measure of response   
[15] 
Early prednisolone 
response 
1983 A simple measure of 
early in vivo sensitivity 
to a key agent in 
therapy, first introduced 
in ALL-BFM 83  
Circulating blast cell count 
following a prednisolone 
prophase still used to 
stratify risk on the AIEOP-
BFM protocols   
Still remains a powerful and 
widely-adopted prognostic 
determinant in risk stratification; 
biological basis uncertain and 
relevance may change in the era 
of molecular monitoring  
[16]  
Early bone marrow 
response 
1983 A measure of early 
response to therapy 
based on initial 
observations in the late 
1970s that early 
response mattered  
Residual marrow blast % 
following 1-2 weeks of 
therapy still used to stratify 
risk groups in the CCG and 
MRC ALL trials  
Poor early microscopic marrow 
blast clearance remains an 
adverse-risk feature - likely to be 
supplanted by more sensitive 
measures of early response 
such as flow cytometry 
[17], [18], [19] 
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Minimal residual 
disease monitoring 
1998 Marrow blast burden
post-induction estimated 
using somatic clonal 
genomic 
(immunoglobulin or T-
cell receptor 
rearrangements) or 
immunophenotypic 
lymphoblast markers 
 Genomic clonal marker 
determination is currently 
cumbersome and 
resource-intensive. Flow 
cytometry detection is at 
least as sensitive, has 
higher throughput and may 
be more widely available 
Powerful prognostic determinant. 
Used as risk-stratification 
determinant in contemporary 
MRC and BFM-based protocols. 
Probable surrogate marker of in 
vivo drug sensitivity. Current 
sensitivity detection threshold at 
1 blast/10,000 cells may need to 
be enhanced. Does not estimate 
extramedullary blast clearance    
[20], [21], 
[22], [23] 
TREATMENT 
MILESTONES 
 Uniformly fatal disease 
before the 1960s. 
Combination 
chemotherapy modelled 
on efficacy in treatment 
of tuberculosis and 
experimental findings in 
non-human leukaemic 
cell lines 
Remarkable combination 
of trial-and-error and 
serendipity. Intrinsic 
disease chemosensitivity 
was fortuitous and 
propelled early advances 
in therapy. Probability of 
cure mooted in early 1970 
(Simone J Cancer 1972 
30:1488-1494) 
Success of combination 
chemotherapy accords with the 
Goldie-Coldman hypothesis. 
Efficacy of post-induction 
intensification complies with the 
Norton-Simon model of 
Gompertzian tumour growth 
characteristics.  
[24], [25], 
[26], [27], [28]
 Early 1950s-
early 1960s 
Initial drugs  Efficacy of folate 
antagonists and 
antimetabolites initially 
demonstrated in a murine 
leukemia cell line and later 
as single agents in patients 
Folate antagonists and 
antimetabolites continue to 
feature as key drugs in 
contemporary therapy 
[29], [30], [31] 
 Late 1950s-
early 1960s 
Combination 
chemotherapy   
Folate antagonists, purine 
anti-metabolites and 
steroids followed by 
continuation treatment 
Rotating, iterative schedules of 
intensive therapy followed by the 
maintenance phase continues to 
remain the feature of 
contemporary therapy   
[32], [33] 
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TREATMENT 
MILESTONES 
Mid 1960s-
early 1970s 
Several key drugs 
introduced in therapy 
Vincristine, L-
asparaginase, 
Daunorubicin, Cytarabine 
and Cyclophosphamide 
These agents remain key 
components of contemporary 
treatment protocols. 
Asparaginase has a singular 
mechanism of action and is 
unique and vital in ALL therapy. 
Cytarabine is chiefly used in 
treatment of high-risk/refractory 
disease or as part of intrathecal 
triple therapy.   
[34], [35], 
[36], [37], [38] 
 Since late
1960s 
 Supportive care to 
manage complications 
of cytotoxic therapy 
Platelet transfusion, 
management of febrile 
neutropenia, prophylaxis of 
Pneumocystis jirovecii 
pneumonia, recognition of 
varicella zoster risk, 
recognition and 
management of vascular 
thrombosis 
Septic death secondary to 
neutropenia is an important 
cause of remission mortality (2-
5%). Vigilance, institutional 
protocols, early empirical 
institution of broad-spectrum 
antimicrobials, appropriate 
radioimaging and adaptation of 
antimicrobial therapy to 
microbiological investigations 
form key elements of 
management. Judicious use of 
growth factors to accelerate 
haematopoietic recovery  
[39], [40], 
[41], 
summarised 
in [42], [43] 
 Mid 1980s Etoposide  Introduced as a non-
crossresistant agent 
Risk of epipodophyllotoxin-
related secondary myeloid 
leukaemia relegated use of drug 
in relapse-refractory disease  
[44], [45] 
 1980s-2000s No new agents but 
steady improvement in 
outcomes following 
progressive refinements 
in therapy 
Optimisation of key 
treatment elements and 
improvements in 
supportive care 
Advances driven by systematic 
clinical trials conducted by 
multicentre trial consortia (the 
BFM and CCG) and large 
treatment centres (St Jude 
Children's Research Hospital, 
the Dana-Farber Cancer 
Institute)   
Reports from 
several large 
trial groups 
summarised 
in [46] 
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TREATMENT 
MILESTONES 
Late 1980s Allogeneic 
hematopoietic stem cell 
transplantation (allo-
SCT) - systematic 
evidence of benefit in 
the mid-1990s 
Ablative 
chemoradiotherapy 
conditioning followed by 
infusion of allograft from 
genotypically HLA-
matched related or 
unrelated donors; stem cell 
source may include bone 
marrow, peripherally 
mobilised or umbilical cord 
stem cells 
Contemporary risk-adapted 
intensification of therapy has 
largely confined use of allo-SCT 
to very high-risk (e.g., subsets of 
Ph+ ALL), refractory or early-
relapse disease subsets. Further 
restricted utility envisaged in line 
with future advances in 
chemotherapy. Long-term 
complications adversely impact 
overall survival.  
[47], 
summarised 
in [48] and 
[49] 
 Mid-2000s  Rationally-designed new
generation of purine 
nucleoside analogues - 
clofarabine and 
nelarabine 
First new agents in 
childhood ALL therapy 
after nearly two decades 
Use chiefly in relapsed-refractory 
disease - nelarabine has specific 
activity in T-lineage disease 
[50], [51] 
 Late 2000s Targeted therapies 
exemplified by the 
tyrosine-kinase inhibitor, 
Imatinib mesylate  
Biological therapies 
targeting cell survival 
pathways, enhancing cell 
death mechanisms or 
accelerating leukaemic cell 
clearance 
Potential role in high-risk or 
relapsed/refractory disease as 
adjuvant to chemotherapy and/or 
allo-SCT  
[52] 
RISK-ADAPTED 
THERAPY
 
Risk stratification Late 1980s Risk-adapted therapy 
enabling tailored 
intensity of treatment  
Current risk stratification 
based on presentation and 
response characteristics 
(see above). Maximally 
intensive treatment 
reserved for patients 
deemed at highest risk of 
relapse  
Risk characteristics are still 
imprecise. Sensitive measures of 
early response and additional 
biological characteristics 
(including germline 
pharmacogenomics) likely to 
result in further fine-tuning and 
probable individualisation of 
therapy 
[12], [53], 
[54], [55]  
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Minimising toxicity 
from overtreatment 
1990s As cure rates improved, 
therapy  refined to 
prevent overtreatment 
and minimise acute 
(sepsis) and long-term 
(organ dysfunction, 
growth and cognitive 
deficits, second 
neoplasms) treatment-
related complications  
Risk-adapted therapy and 
refinements in treatment 
elements (next column) 
minimises overtreatment in 
standard-risk patients at 
lowest risk of relapse 
Elimination of cranial irradiation 
(below), cumulative 
anthracycline dose reduction, 
pulsed dosing to decrease risk of 
dexamethasone-related 
avascular osteonecrosis, long-
term monitoring  
[56], [57], 
[58], [59] 
TREATMENT 
COMPONENTS
 
Induction (also 
referred to as 
remission-
induction) 
1960s Arguably the most 
important phase of 
treatment; timely 
administration is critical 
and early response to 
this phase is a powerful 
prognostic determinant 
of outcome  
4-week induction phase 
with a steroid, vincristine, 
L-asparaginase backbone, 
intrathecal therapy ± an 
anthracycline  
The now widely-adopted BFM-pioneered 
intensified induction (otherwise called Induction-
Consolidation or Protocol IA/IB) using non-cross-
resistant drugs in an 8-week schedule for 
intermediate- and high-risk disease groups 
Central Nervous 
System (CNS)-
directed treatment 
(less accurately 
referred to as CNS 
prophylaxis) 
Early 1970s The CNS is a sanctuary 
site for ALL blasts from 
a combination of CNS 
tropism of lymphoblasts 
and poor CNS 
penetration of 
chemotherapy. Non-
inclusion of this phase 
of therapy is inevitably 
attended by disease 
recurrence in the CNS 
[60] 
Intensified systemic and 
extended intrathecal 
therapy has largely 
superseded cranial 
irradiation 
Craniospinal radiotherapy (RT) 
initially, later replaced by 
combination of cranial RT and 
intrathecal therapy (IT) 
[61], [62], 
[63], [64], [65]
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CNS-directed 
treatment 
 Use of CNS-penetrating 
systemic agents, 
specifically methotrexate, 
either as a dedicated CNS 
treatment block (BFM 
protocols) or in high-risk 
disease, as a component 
of augmented post-
induction intensification; 
beneficial effect of 
dexamethasone 
Serial reduction of cranial RT 
dose - from 24Gy to 18Gy, then 
18Gy to 12Gy -  while 
intensifying systemic and 
intrathecal therapies; later 
restricting cranial RT only to 
those at high-risk of recurrent 
CNS leukaemia (overt CNS 
leukaemia at presentation, T-
lineage high-risk disease)  
[57], [66], 
[67], [68], [69]
  Significant cognitive and 
neuroendocrine sequelae 
(growth and pituitary 
gonadal failure) and 
importantly, second 
malignant neoplasms 
(gliomas) with cranial RT 
Systemic and intrathecal 
methotrexate therapy also 
associated with complications 
(acute-stroke like syndromes, 
cerebral white matter changes, 
arachnoiditis); dexamethasone 
associated with osteonecrosis 
and increased susceptibility to 
invasive fungal infections 
[70], [71], [72]
Post-induction 
intensification (less 
commonly 
described as  re-
induction) 
Early 1980s Agents used during 
induction therapy are re-
administered in hybrid 
schedules during this 
phase  
Intensification improves 
outcomes in all risk 
categories and is in 
keeping with the Norton-
Simon model 
Double-delayed intensification 
for all patients other than those 
with standard-risk disease; 
augmentation with Capizzi 
schedules (in sequence, high-
dose antimetabolite followed by 
L-asparaginase) and intensified 
L-asparaginase schedules in 
high-risk disease 
[73], [74], 
[75], [76], 
[77], [78], [79]
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Maintenance or 
Continuation 
therapy 
1960s 18-24 months of low-
dose antimetabolites (a 
thiopurine and 
methotrexate) ± pulses 
of vincristine and 
steroid. Unique 
treatment phase, now 
adopted in other 
haematological cancers 
(acute promyelocytic 
leukaemia, multiple 
myeloma, follicular non-
Hodgkin lymphoma) 
Metronomic therapy with 
dosing of antimetabolites 
to haematological 
tolerance; important phase 
of contemporary therapy 
but biological basis poorly 
understood and may 
include direct cytotoxicity 
of residual quiescent 
blasts, activation of 
immune clearance or 
promoting differentiation of 
residual blasts  
In the context of current 
treatment intensity, 
antimetabolite-based 
maintenance alone may be 
sufficient; shortening duration 
below 18 months attended by 
increased recurrence while 
lengthening therapy beyond 3 
years confers little additional 
benefit. Concern over 
antimetabolite-related second 
neoplasms [85] 
[80], [81], 
[82], [83], 
[84], [85], [86]
Adjuvant targeted 
therapy 
Late 2000s Targeted therapies will 
increasingly feature in 
future treatment 
protocols 
Biological targets 
suggested by global 
microarray technologies 
and by extrapolation of 
experience in other 
haematological 
malignancies   
Impressive early event-free 
survival when a continuous 
Imatinib dosing schedule was 
combined with conventional 
chemotherapy in childhood Ph+ 
ALL 
[87], [88]  
Collaborative childhood ALL study groups: AEIOP, Associazonie Italiana Ematologia Oncologica Pediatrica; BFM, Berlin-Frankfurt-Münster 
consortium (Germany-Austria-Hungary); CCG, North American Children's Cancer Group; UK MRC, UK Medical Research Council; FAB, French-
American-British; Gy, gray (100 Rad); HLA, human leucocyte antigen; NCI, National Cancer Institute 
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Table 1.2 Somatic genetic lesions in childhood acute lymphoblastic leukaemia (also see Fig 1.5) 
  
Progenitor-B ALL  
Numerical 
abnormalities 
Good Risk Hyperdiploidy (modal chromosome number >46), particularly high hyperdiploidy (51-65 
chromosomes), arising from somatic non-disjunction in an early committed progenitor. 
Most common genetic subtype (25-30%). Early pre-B immunophenotype. Typically 
extra copies of chromosomes 4, 6, 10, 14, 17, 18, 21, X. Subset with trisomies of 
chromosomes 4, 10, 17 experience especially good outcome. Associated FLT3-
mutations (of the activating loop or internal tandem duplications) in 20-25%, uncertain 
significance. Methotrexate sensitive. 
[95], [96], 
[97], [98] 
 Poor Risk Low hypodiploidy (35-45 chromosomes) and near-haploidy (24-34 chromosomes). 
Rare (2-3%). Arise from unbalanced translocation, single chromosome losses or 
dicentric chromosome formation.  
[99] 
Fusion 
translocations 
 Aberrant recombinase-activating-gene activity during the course of immunoglobulin (Ig) 
loci rearrangements in maturing progenitor B cells, resulting in illegitimate in-frame 
fusion rearrangements of gene segments clustered topologically in nuclear transcription 
hubs. Most occur in utero and require second hits for leukaemogenesis  
[100] 
 Good Risk ETV6-RUNX1 [t(12;21)(p13;q22)]. 20-25%, typically in children 2-6 years. Early pre-B 
immunophenotype. Cryptic lesion, detected by FISH. Helix-loop-helix domain of ETV6 
fused to DNA-binding and transactivation domains of RUNX1. Well-established in utero 
origin, second-hit lesions include deletion of wild-type ETV6 allele. Asparaginase-
sensitive 
[101], 
[102], [103] 
  TCF3-PBX1 (also E2A-PBX1) [t(1;19)(q23;p13)]. 4-6%, probable post-natal origin, 
often (25%) in late pre-B cells expressing cytoplasmic Ig. Transactivation domains of 
TCF3 fused to homeodomains of PBX1. Associated with high presenting WBC count 
and propensity for CNS relapse. Contemporary therapy has nullified previous adverse 
prognosis.  
[104], 
[105],  
[106] 
  Poor Risk BCR-ABL1 [t(9;22)(q34;q11)] associated with the Philadelphia chromosome (Ph+). 3-
5%, early pre-B immunophenotype. The typical e1-a2 BCR-ABL1 fusion encodes a 
cytoplasm-localised chimaeric 185-190 kDa molecule with aberrant ABL1 kinase 
activity. Associated with older age, high WBC count, overt CNS disease and slow early 
response. Imatinib-responsive.  
[107] 
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Table 1.2 (continued) 
Progenitor-B ALL; 
Fusion 
translocations 
Poor Risk MLL gene (11q23) rearrangements. Typically associated with infant leukaemias 
(>70%), often biphenotypic. Multiple partner genes. Chimaeric proteins with amino-
terminal MLL elements. MLL-AF4 most common [t(4;11)(q21;q23)] in ALL. Occur in 
utero, sufficient for leukaemogenesis, pro-B (often CD10 negative) immunophenotype. 
FLT3 overexpressing. Associated with high WBC count, CNS disease and poor 
response to treatment.  
[108], [109] 
  TCF3-HLF [t(17;19)(q22;p13)]. Rare (<1%). Pro-B immunophenotype, chimaera 
containing amino-terminal of TCF3 transactivation domain fused to the basic leucine 
zipper domain of HLF. Often presents with disseminated intravascular coagulopathy. 
Impaired lymphoblast apoptosis in vitro. Particularly poorly responsive. 
[110] 
Segmental 
amplifications 
Poor Risk Intrachromosomal amplification of (the long-arm segment of) chromosome 21 
(iAMP21), probably from chromosome breakage-fusion-bridge cycles. Typically 
detected by observing clustered RUNX1 signals (>3) on interphase FISH. 2-3%. Early 
pre-B immunophenotype, older age, low WBC count. Probably responsive to intensified 
methotrexate therapy.  
[9] 
Recurrent submicroscopic lesions Whole-genome single nucleotide polymorphism analyses, both in diagnostic material 
and paired diagnosis-relapse material indicate (a) a limited number of highly focal 
lesions (mean of six per case) (b) lesions are typically, deletions (c) deletions often 
involve genes encoding lymphoid transcription factors (40%, e.g. PAX5) or cell-cycle 
regulators (e.g. CDKN2A/B) (d) both diagnosis and relapse blasts demonstrate 
common clonal origins 
[10] 
 Poor Risk Deletions of Ikaros (IKZF1) noted in 80-85% Ph+ALL. On directed sequencing, 
activating mutations of Janus family kinases (JAK) in ~10% BCR-ABL1 negative ALL, 
frequently associated with IKZF1 deletion and with gene-expression profiles similar to 
Ph+ ALL. Recently reported overexpression of the cytokine CRLF2, either due to 
intrachromosomal deletion or Ig heavy-chain rearrangements, also co-associates with 
IKZF1 and Janus family kinase mutations and specifies a poor-prognosis subgroup  
[88], [118], 
[119], 
[120], [121] 
Precursor T ALL  Genetic risk-based stratification not fully characterised in T-lineage disease. Genetic 
lesion is linked to maturational stage and the latter may be a more important 
determinant of outcome in T-lineage disease.  
[111], 
[112], 
[113], [114] 
Fusion 
translocations 
 Result in aberrant activation of structurally intact proto-oncogenes (TAL1, TAL2, LIM-only domain 
proteins LMO1 and LMO2, TLX1 [HOX11], TLX3 [HOX11L2], LYL1, MYB, BHLHB1, LCK, NOTCH1, 
CKND2 )  
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Table 1.2 (continued) 
Precursor T Cell; 
Fusion 
translocations 
(continued) 
 Protooncogene activation following fusion with promoter-enhancer elements of T cell receptor (TCR) 
genes on 14q11 (TCRA/D) or 7q34 (TCRB/G) - one example is the TLX1-TCRA/D fusion 
[t(10;14)(q24;q11)] in 4-7% childhood ALL associated with cortical pre-T (CD1a+) immunophenotype 
and a favourable outcome 
  Non-TCR gene fusions, e.g. NUP214-ABL1 fusion (rare, episomal localisation, Imatinib-sensitive); 
CALM-AF10 fusion (10%, gamma-delta T-lineage blasts, poor outcome)  
Amplifications and 
deletions 
Variable risk Examples include (1) Intrachromosomal deletions resulting in overexpression of LMO2; SIL-TAL1 (or 
SIL-SCL) in 1p32, fusing the promoter of SIL with the coding region of TAL1, 25% T-lineage ALL, 
male predominance, conflicting prognostic impact (2) MYB amplification (amplified 6q22.3) 
Recurrent 
submicroscopic 
features 
Uncertain 
risk 
Spanning the spectrum of chromosomal lesions is activated intracellular Notch1 activity, primarily due 
to mutations in component molecules (>50%) or rarely, due to the t(7;9) (q34;q34.3)] translocation. 
Targeting aberrant Notch signalling has therapeutic potential in T-lineage disease 
 Secondary
driver lesion 
 Deletion in the CDKN2A/B tumour suppressor locus (75%) 
CNS, central nervous system; CRLF2, cytokine receptor-like factor 2; FLT3, fms-like (receptor) tyrosine kinase 3; FISH, fluorescent in-situ 
hybridisation 
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Table 1.3 Biology of ALL Relapse 
 
Investigations Global somatic and germline genome and transcriptome 
microarrays investigating paired  (± lymphoblast-enriched) 
diagnosis-relapse samples; correlation of gene-expression 
profiles in diagnostic lymphoblasts with designated outcome 
endpoints such as relapse-free survival or end-induction 
minimal residual disease (MRD) burden 
Clonal origin of 
relapse 
A significant proportion arise from pre-
leukaemic ancestral clones that have 
acquired second-hit somatic lesions 
[117]; Figure 1.12 
Lymphoblast 
characteristics 
An aberrant activated kinase 
expression signature associated with 
autocrine survival signalling, probably 
resulting in accelerated blast 
proliferation, chemoresistance and 
creation of autonomous tumour niches; 
traditional cancer resistance 
mechanisms such as exaggerated 
drug-efflux (e.g. through P-glycoprotein 
overexpression) or somatic TP53 
tumour suppressor gene mutations are 
not typically observed in relapse 
lymphoblasts 
[118], [88], [119], 
[120], [121], [122], 
[123] 
Host germline 
polymorphisms 
Associated with variations in drug 
metabolism (Thiopurine Methyl 
Transferase [TPMT] polymorphisms 
and thiopurine metabolism), drug 
clearance (methotrexate, etoposide) 
and intracellular drug accumulation 
(methotrexate polyglutamates) 
[124], [125] 
Role of the tumour 
microenvironment  
By restricting drug access 
(extramedullary sanctuary sites) and by 
pro-survival paracrine interactions 
mediated by adhesion-dependent or -
independent mechanisms 
[126], [127] 
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Table 1.4 Extramedullary disease in ALL: putative molecular and cellular mechanisms 
 
Event    Probable Mechanisms References
Bone marrow egress  and 
extramedullary tropism 
Subversion of the physiological trafficking behaviour of 
lymphocytes 
[129], [130] 
Candidate chemokine signalling 
mechanisms 
VEGF-VEGFR1 axis  [131], [132] 
 CXCR4-CXCL12 axis  [133], [134], [135] 
 The homing-adhesion molecule CD44 and its variant CD44v6 [136], [137], [138] 
 Other chemokine molecules: CCR7 and IL-15 [139], [140], [141] 
Stromal-endothelial adhesion Reciprocal interactions of blast cell VLA-4/VLA-5 integrins with 
stromal-endothelial cell adhesion molecules and extracellular 
matrix components; integrin activation and signalling triggers 
cytoskeletal reorganisation 
[142], [143],  [144], [145],  
[146] 
Lymphoblast extravasation Deployment of probing podosomes followed by paraendothelial / 
transendothelial diapedesis 
[147], [148], [149] 
Extracellular matrix  degradation The gelatinase family of matrix metalloproteases (MMP), MMP2 
and MMP9; may be integrin-anchored (forming a supramolecular 
complex capable of outside-in signalling and localised 
degradation) or released as soluble enzyme 
[150], [151], [152], [153] 
 Lysosomal cysteine proteases  [154], [155] 
Extramedullary nests Haematopoietic cells capable of creating novel extramedullary 
niches 
[156], [157], [123] 
 Egressed VEGFR1-positive cells may establish precursor 
extramedullary niches 
[158] 
   
36 
Chapter 1 TABLES   
 
Table 1.4 (continued)   
    Event Probable Mechanisms References
Persistence in extramedullary 
niches through chemoevasion 
and autocrine-paracrine survival 
signalling 
Prosurvival ligand-independent or ligand-hypersensitive kinase 
signalling - VEGF; CD44-CXCR4-CXCL12-p38MAPK; JAK-STAT  
[159], [160], [161] 
 Stroma-induced chemoprotection and survival signalling - 
adhesion-dependent and independent mechanisms 
[162], [163], [164], [165]  
 Tumour dormancy  [166],  [167] 
CCR7, chemokine (C-C) motif receptor 7; CLL, chronic lymphocytic leukaemia; CXCR4, chemokine (CXC motif) receptor 4;  CXCL12, chemokine 
(CXC motif) ligand 12 (also known as stromal-derived factor 1 (SDF-1); JAK, Janus family kinases; p38MAPK, p38 mitogen-activated protein 
kinase; STAT, signal transduction and activator of transcription family of transcription factors; VEGF, vascular endothelial growth factor; VEGFR1, 
vascular endothelial growth factor receptor 1; VLA-4, very late antigen 4, integrin heterodimer of α4(CD49d)-β1(CD29); VLA-5, very late antigen 5, 
integrin heterodimer of α5(CD49e)-β1 
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2 
Asparagine endopeptidase – a candidate molecular marker of 
treatment failure in childhood ALL  
 
Relapses in the CNS are a recurring and increasingly more prominent feature of 
treatment failure in childhood ALL. In an attempt to identify candidate molecular 
markers associated with this adverse disease characteristic, oligonucleotide 
microarrays were employed as discovery tools.  
 
As a first step, microarrays were used to examine the global transcript signature 
of a distinct adverse-risk genetic subtype of progenitor-B ALL [1]. This recently 
recognised genotype is characterised by intrachromosomal amplification of 
chromosome 21 (iAMP21 ALL) [2]. Adverse-risk progenitor-B childhood ALL 
genotypes are typically associated with poor early treatment response and a 
higher incidence of relapse, including high-risk relapses (Chapter 1, [95]). Thus, 
the relative risk of relapse is six-fold higher in iAMP21 ALL (Chapter 1, [95]) and 
includes a disproportionate high incidence of early CNS relapses [2].  
 
Microarray analysis was later extended to include examination of global transcript 
profiles of primary leukaemic cells across genetic and risk categories of 
childhood ALL (n=89, [1]). Comparative gene expression profiling identified 
unique overexpression of the gene encoding the lysosomal cysteine protease, 
asparagine endopeptidase (AEP), in iAMP21 ALL (Figure 2.1). Extended 
analysis indicated that the gene was similarly overexpressed in the archetypal 
adverse-risk B-lineage disease, Philadelphia-chromosome positive ALL (Ph+ ALL) 
(Figure 2.2). 
 
AEP, the invasive cancer phenotype and ALL treatment failure 
AEP is a distinct and evolutionarily conserved lysosomal cysteine protease. The 
enzyme, along with other cysteine proteases, is a well-recognised mediator of 
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host tissue invasion by parasites (Table 2.1). AEP is characterised by its singular 
cleavage specificity, typical acid pH-activated maturation sequence and restricted 
tissue expression in humans (Figure 2.3, Table 2.2) Expression is 
physiologically bimodal in B lymphocytes and occurs at the extremes of B-cell 
ontogeny, in early progenitor cells (Figure 2.4) and mature plasma cells [25].  
 
AEP overexpression is a feature of several adult human epithelial cancers 
(Figure 2.5, Table 2.3). Overexpression is associated with metastatic disease 
and adverse prognosis (Table 2.4) and analogous to observations in parasite 
pathogens, ectopic AEP expression confers human cells with a motile phenotype 
(Figure 2.6).  
 
Aberrant expression and activity of lysosomal hydrolases is well-recognised in 
cancers and putatively operates through several mechanisms to promote cancer 
cell motility and tissue invasion (Table 2.5). Overexpressed AEP in progenitor-B 
lymphoblasts could conceivably promote leukaemic infiltration of the CNS as well 
as dissemination to other extramedullary sites, where persistence of disease 
eventually manifests as relapse.  
 
Adverse-risk progenitor-B ALL genotypes are also characterised by poor 
response to conventional treatment (Chapter 1, [95]). Intrinsic drug resistance 
may in part account for this. In this context, AEP, a proteolytic enzyme, is 
potentially capable of degrading the bacterial protein drug, E. coli L-asparaginase 
(ASNase). ASNase is a critical component of childhood ALL therapy and its 
accelerated inactivation by AEP-overexpressing leukaemic cells could possibly 
contribute to inferior treatment response.  
 
AEP is thus a plausible candidate biomarker of treatment failure in childhood 
progenitor-B ALL (Figure 2.7). The subsequent chapters discuss results of in 
vitro studies investigating this hypothesis.  
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Figure 2.1 Serial comparison of microarray gene expression signatures identified 
unique overexpression of AEP in the adverse-risk progenitor-B ALL subtype, 
iAMP21 
Schematic outline of analysis workflow. To identify genes uniquely overexpressed in the 
adverse-risk ALL subtype iAMP21, step-wise comparisons of gene expression 
signatures were performed. The initial assessment was a comparison of iAMP21 
expression profile against that of all other ALL subtypes as a group. Like iAMP21, the 
genetic subtypes ETV6-RUNX1 and high-hyperdiploidy also demonstrate somatic 
aberrations of chromosome 21 but unlike iAMP21, both subtypes are associated with 
good outcome. Thus, comparative analysis of expression profiles with ETV6-RUNX1 and 
high-hyperdiploidy helped define both a unique and biologically pertinent iAMP21 
overexpression signature. This stepwise approach identified AEP as the top uniquely 
overexpressed gene in iAMP21 ALL. Adapted from [1]. 
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Figure 2.2 AEP is relatively overexpressed in adverse-risk progenitor-B ALL 
Boxplot representation of microarray analyses of AEP transcript expression in childhood 
ALL (n=89). Median relative AEP expression is higher in the adverse-risk progenitor-B 
disease subtypes, Philadelphia-chromosome positive ALL (BCR-ABL) and iAMP21, 
although there is considerable overlap in expression. Of note, these adverse-risk ALL 
subtypes are associated with a higher incidence of central nervous system (CNS) 
leukaemia at relapse. Data courtesy of Frederik van Delft and Olga Yiannikouris, CRUK 
Childrenʼs Cancer Group; reported in [1] 
The fusions translocations (BCR-ABL [or Ph+ALL], E2A-PBX1 [or TCF3-PBX1] and 
ETV6-RUNX1 [or TEL-AML1]), high hyperdiploidy (HD50), intrachromosomal 
amplification of chromosome 21 (iAMP21) and the ʻOthersʼ category represent 
genetically distinct subsets of progenitor-B ALL. Boxes encompass the interquartile (IQR, 
25th-75th percentile) ranges, horizontal bars within boxes represent median values, ʻ+ʼ 
values indicate means, whiskers denote values 1.5× IQR, outlier values are represented 
by asterisks, dashed lines demarcate off-scale outlier values. 
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Figure 2.3: Asparagine endopeptidase (AEP) is a lysosomal cysteine protease 
distinct from the papain family cathepsin enzymes. The protease is activated by 
increasing endolysosomal acidification and demonstrates strict cleavage 
specificity.  
(A) Cartoon representation indicating role of lysosomal proteases in antigen-presenting 
cells. AEP, like other lysosomal cysteine proteases, processes exogenous microbial 
peptide antigens and the invariant chain to facilitate MHC Class II molecule loading 
towards T-cell presentation (B) AEP differs from the papain family of cathepsin (CTS) 
lysosomal cysteine proteases in terms of its strict cleavage specificity and resistance to 
the pan-cathepsin inhibitors E-64 and Leupeptin. (C) As with other lysosomal cysteine 
proteases, the mature active enzyme is generated in vivo by a combination of 
acidification-triggered autocleavage and additional processing by extrinsic proteases. 
The initial unimolecular activation involves sequential autocleavage at carboxyl- 
(asparagine residue [N] at position 323) and amino-terminal (aspartate residue [D] at 
position 25) amino acid (AA) residues. Additional processing involves carboxyl-terminal 
trimming by as-yet unidentified proteases. (D) AEP demonstrates strict carboxyl-terminal 
endoproteolytic cleavage specificity for selected asparagine and (to a lesser extent) 
aspartate residues [3] 
C ter, carboxyl terminal; N ter, amino terminal; Xaa, any amino acid residue 
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Figure 2.4 Serial AEP expression across early B cell ontogeny 
AEP transcript expression at various stages of early B cell maturation, as determined by 
microarray analyses of purified isolates from human placental blood. Upper panel: 
Distinct stages of early B-cell maturation, identified by typical expression profiles of 
surface CD (cluster of differentiation) antigens and nuclear TdT expression. 
Differentation is sequentially characterised by immunoglobulin heavy chain (IgH) locus 
rearrangements, surface pre-B cell receptor (BCR) expression, immunoglobulin light 
chain locus rearrangements (rIgL) and surface IgM expression. Lower panel: A sharp 
peak in AEP expression is observed in pro-B cells, possibly suggesting a role for AEP as 
proteolytic mediator of adhesive interactions with bone marrow stromal cells, a key 
feature at this stage of early B-cell maturation [51]. (Created from data in [52]).  
CD34/Lin-, connotes putative lineage-negative haematopoeitic stem cells; cIgμ, 
cytoplasmic Ig μ heavy chain; cIg, cytoplasmic immunoglobulin M; cy, cytoplasmic; DH-JH, 
rearrangements of diversity and joining regions of IgH gene locus; TdT, terminal 
deoxynucleotidyl transferase; VH-DH, rearrangements of variable and diversity regions of 
IgH gene locus;  VDJH, completed VDJ rearrangement at IgH gene locus  
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Figure 2.5 Asparagine endopeptidase (AEP) in solid human cancers 
Select data from published reports [24, 61]. AEP overexpression has been reported to be 
a feature of many adult epithelial cancers (table). Experiments using a cell-impermeable 
doxorubicin prodrug provide surrogate evidence of extracellular AEP release. The red 
fluorescent anthracycline doxorubicin (Doxo) was tagged to an AEP-substrate linker 
sequence to create a cell-impermeable compound. Presumed cleavage of the substrate 
linker by extracellular AEP enabled free Doxo to penetrate cells, as evidenced by bright 
red fluorescent staining in AEP-expressing 293 cells (AEP+293) compared to wild-type 
controls (293-WT). A molecular basis for AEPʼs role in cell invasion is suggested by 
immunofluorescence staining showing colocalised expression of AEP and the β1-integrin 
cell adhesion subunit in AEP+293 cells.  
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Figure 2.6 Enforced expression of AEP in HEK293 cells results in a motile 
phenotype – results reported by the Scripps Institute Immunology group [24]  
Results of Boyden chamber assays using (A) uncoated and (B) Matrigel-coated cell 
inserts. AEP-overexpressing HEK293 cells (AEP-293) migrated briskly across both 
uncoated and Matrigel-coated 8μm-pore cell culture inserts. By contrast, native HEK293 
control cells were essentially immotile. Motility was attenuated by nearly 50% when cells 
were treated with the non-selective AEP inhibitor (AEPi) cystatin. Treatment with the 
non-selective MMP-2 (matrix metalloprotease 2) inhibitor (MMPi), TIMP-2 also modestly 
decreased trans-Matrigel motility, suggesting that at least part of the invasive phenotype 
could be attributed to (AEP-activated) MMP-2. The motile phenotype of AEP-293 cells 
was not modified by the broad-spectrum inhibitor of the papain family Cathepsins, E64 
(CTSi).   
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Figure 2.7 In vitro studies investigating AEP as a candidate biomarker of 
treatment failure in childhood progenitor-B ALL 
Schematic outline; proposed in vitro studies are represented in blue. Global gene-
expression microarray studies in childhood acute leukaemia identified AEP 
overexpression in the adverse-risk progenitor-B ALL genotypes, Philadephia-
chromosome positive ALL (Ph+ ALL) and intrachromosomal amplification of 
chromosome 21 (iAMP21). These observations shall be validated by transcript 
quantitation, protein expression and imaging studies. Both Ph+ ALL and iAMP21 ALL are 
associated with an increased incidence of relapse, including CNS relapse. AEP 
overexpression in leukaemic blasts of these subtypes is postulated to augment cell 
motility and contribute to extramedullary infiltration and recurrence. This pro-motility role 
of AEP would be investigated by examining the effect of ectopic AEP expression on the 
motility phenotype of human embryonic kidney fibroblasts. Another feature of adverse-
risk disease is poor response to treatment. Both slow early response and sluggish 
clearance of minimal residual disease (MRD) result in disease persistence and relapse. 
Innate drug resistance may in part account for poor response to treatment and AEP is 
postulated to be a molecular mediator of this phenotype, possibly by degrading and 
inactivating the bacterial enzyme E. coli L-asparaginase (ASNase), a vital component of 
ALL treatment. 
Chapter 2 TABLES 
Table 2.1 AEP in parasites 
 
Activation of other cysteine proteases, host tissue digestion/penetration, excystment/encystment, immune 
evasion, programmed cell death 
 
[4] 
Parasite Species Human pathology Significance of AEP homolog Reference 
Protozoa  Trichomonas
vaginalis 
Trichomoniasis Serological marker of infection and 
potential candidate for vaccine targeting 
[5], [6] 
 Blastocystis hominis Uncertain human 
pathology 
Antibody targeting of surface-localised 
homolog activates programmed death 
[7] 
Trematodes  Schistosoma
mansoni  
Human 
Schistosomiasis 
AEP homolog Sm32 in gastrodermal 
cells of adult worms and head glands of 
cercariae. Role in enteral digestion of 
host haemoglobin. Sm32 DNA vaccine 
protective against cercarial challenge in 
vivo 
[8],  [9],  [10], [11]  
  Schistosoma
japonicum 
Human 
Schistosomiasis 
Serological marker of infection. DNA 
vaccine targeting AEP homolog Sj32 
protective against cercarial challenge in 
vivo 
[12] 
 Opisthorchis viverrini Cholangitis and 
cholangiocarcinoma 
in humans 
AEP homolog Ov-AEP-1 - serological 
marker of infection and candidate target 
for therapy  
[13] 
 Fasciola hepatica Human Fascioliasis Identified in excysted juveline stage of 
parasite 
[14] 
 Clonorchis sinensis Cholangitis, 
cholangiocarcinoma  
Serodiagnostic antigen [15] 
Nematodes B malayi  Lymphatic filariasis Bm-CPI-2 cysteine protease inhibitor 
targets human AEP 
[16] 
Arachnids Ixodes ricinus Vector for Lyme 
Disease (Borreliosis) 
Homolog IrAE in gut digests host blood 
meal  
[17], [18], [19] 
 Haemophysalis
longicornis 
 Vector for Lyme 
Disease (Borreliosis) 
Homolog HlLgm2 in tick midgut  [20], [21], [22]  
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Table 2.2 Known physiological functions of mammalian AEP and implicated role in non-neoplastic disease  
  Context Comments References 
Restricted tissue expression Proximal tubular epithelial cells of the kidney, placental trophoblast, antigen-
presenting cells (activated B lymphocytes and mature plasma cells, macrophages, 
dendritic cells) and monocyte-macrophage derived cells (osteoclasts in bone, 
Kupffer cells in liver) 
[23], [24], [25] 
Adaptive immune response Redundant and context-specific role  
Antigen-presenting cells Invariant chain cleavage to facilitate MHC Class II loading  [26] 
 Redundant but preferential proteolytic processing of microbial antigen (Tetanus 
toxin C fragment) for MHC Class II loading towards T cell presentation  
[27], [28], [29] 
 Destructive processing of Myelin Basic Protein epitope may limit central tolerance 
to the immunogenic protein; redundancy with cathepsins S and G 
[30] 
 Lysosomal activation of other cysteine proteases,  e.g. cathepsin L [31] 
 Facilitating Toll-like receptor 9 signalling by activating cleavage in antigen-
presenting cells; endotoxin tolerance in monocytes associated with AEP 
downregulation 
[32], [33] 
Regulatory T cells Molecular marker of in vitro generated CD4+CD25high FOXP3-positive regulatory T 
cells; uncertain role 
[34] 
Epidermal cornification In combination with the inhibitory Cystatin M/E, forms a protease-antiprotease 
functional dyad that coordinates epidermal and hair follicle cornification through 
regulation of transglutaminase 3 activity 
[35], [36], [37] 
Bone mass regulation  Negative regulator of osteoclast differentiation, possibly acting through its C-
terminal fragment; upregulated with mechanical bone loading and osteoclast 
stimulation possibly as a feedback mechanism (murine) 
[38], [39], [40] 
Embryogenesis Implicated as one of the molecules involved in restricted trophoblast invasion 
during early placentation (bovine). Also observed in murine yolk sac lining, possibly 
with yolk sac haematopoiesis 
[41], [42] 
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Table 2.2  AEP  in physiology and non-neoplastic pathology (continued) 
Non-neoplastic disease 
Vascular disease  Overexpressed in macrophages infiltrating unstable atheromatous plaques; role in 
activating cleavage of Cathepsin L  
[43], [44], [45] 
Neuronal death Overexpressed in astrocytes and microglial cells in the peri-infarct zone following 
experimental middle cerebral artery occlusion;  promotes apoptosis following 
induction of neuronal death by inactivating cleavage of the DNase inhibitor SET 
[46], [47] 
Atopy Upregulated in monocytes in atopic dermatitis, associated with eosinophilia, raised 
IgE and mite-specific IgE levels 
[48] 
aep-null mouse model Late reduction in body weight, normal fertility, normal anatomy and morphology, 
giant lysosomes in proximal renal tubular epithelial cells with reduced two-chain 
forms of cathepsins B, H, L. Insidiously progressive haemophagocytic 
lymphohistiocytosis associated with extramedullary haematopoiesis and decreased 
NK cell numbers 
[49], [50]  
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Table 2.3 AEP in human cancers 
Expression  
Gene 
expression 
arrays 
Acute lymphoblastic 
leukaemia 
Overexpression in the adverse-risk  progenitor-B genetic subtype BCR-
ABL1 (ranked 18th of 40 top-ranked genes) 
[53] (Table 
11, Supp.) 
  Overexpressed in heterogeneous adverse-risk adult progenitor-B disease 
where expression profile matches the BCR-ABL transcription signature in 
paediatric ALL 
[54] 
  Significant overexpression in the adverse-risk progenitor-B genetic 
subtype iAMP21 
[1] 
 Multiple myeloma Twelve-fold overexpression (primary and cell line samples) compared to 
non-malignant in vitro differentiated polyclonal plasmablastic cells 
[55] 
 Follicular non-
Hodgkin lymphoma 
Top-ranked gene as part of the expression signature of monocyte-
macrophage tumour-infiltrating cells (designated immune-response 2) 
[56] 
Immuno-
histochemistry 
Colorectal cancer  AEP expressed in primary tumours (95/164 [58%] strong staining) and in 
metastases (22/33 [67%] strong staining)  
[57] 
  Significantly associated with adverse histological features  [57] 
 Breast cancer  Strong expression in 43/43 (100%) breast carcinomas [24] 
  Strong macrogranular or vesicular expression pattern in 24% (of 432) 
tumours 
[58] 
 Prostate cancer  Very strong expression in 42/56 (75%) prostate carcinomas [24] 
 Lung cancer  Strong expression in 14/24 (58%) tumours; details of histological 
subtypes not reported 
[24] 
 Ovarian cancer  Moderate-intensity expression in 17/23 (73%) tumours [24] 
 CNS tumour Moderate intensity expression in 8/8 (100%) tumours [24] 
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Table 2.3 AEP in human cancers (continued) 
Association with 
prognosis 
 
Primary tumour Colorectal cancer  Stromal or tumour AEP expression in colorectal cancer was significantly 
associated with poorer outcome (5-year estimate 40-45% v 70-75%).  
Prognostic significance retained in multivariate analysis 
[57] 
 Breast cancer Vesicular expression pattern associated with poorer outcome (5 year 
disease-free estimate 45% v 80%)  
[58] 
Tumour stroma Follicular non-
Hodgkin lymphoma 
Significantly poorer outcome with the immune-response 2 macrophage 
expression signature  
[56] 
Indirect 
associations 
 
Correlation with 
other adverse-
risk biomarkers  
Colorectal cancer  Immunohistochemistry expression of the cell growth regulator MAC30 
and the transmembrane ion regulator FXYD3 
[59], [60] 
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Table 2.4 AEP and invasion - summary of supporting observations in human cancer  
 
Molecular trafficking 
Subcellular 
localisation 
Within membranous vesicles clustered at invadopodia of migrating cells [24] 
 Induction of expression in vivo in cancer cell line xenografts associated with surface 
localisation, as demonstrated by flow cytometry; surface localisation abrogated by ex vivo 
collagenase treatment of overexpressing tumour cells. 
[61] 
Colocalisation With cortical actin in the murine brain endothelial cell line b.End.3 [24] 
 With β1 integrin subunit at cell surface in enforced-expression cells  [24] 
 With β2 integrin in transduced monocytes; colocalisation not altered by modifying the 
integrin interaction sequence motif Arg-Gly-Asp 
[43] 
Extracellular release Extracellular release of AEP by overexpressing tumours results in cleavage of a substrate-
tagged cell-impermeable prodrug to locally generate active cell permeable cytotoxic 
compound, resulting in selective tumour kill 
[61] 
 AEP from intact overexpressing murine proximal renal tubular epithelial cells cleaves 
human fibronectin in culture 
[62] 
Substrates 
Protease activation Activation of Cathepsin L  [43] 
 Redundant activation of Cathepsins B, L and H (from single chain to double-chain mature 
forms; observations in aep-null mice) 
[49] 
 Activation of matrix metalloproteinase 2 [63], [24] 
Extracellular matrix 
degradation 
Fibronectin degradation [62] 
Apoptosis inhibition Inactivating cleavage of Caspase 9 and inhibition of Cathepsin B-mediated cleavage of the 
proapoptotic Bid molecule   
[64] 
 Cleavage of Prothymosin α, potentially inhibiting Prothymosin α-regulated apoptosis 
induction; thymosin-α1 generated from cleavage is a putative growth factor and immune 
modulator 
 
 
[65], [66], 
[67]  
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Table 2.4 AEP and invasion (continued) 
 
In vitro studies 
Enforced expression Ectopic AEP-expressing human embryonic kidney 293 (HEK293) cells demonstrate 
enhanced motility and Matrigel invasion; motility blocked by the non-selective AEP inhibitor 
Cystatin but not by the pan-cathepsin inhibitor E-64 
[24] 
In vivo studies 
Mouse models Disseminated disease (50%, lung and liver metastases) and locally infiltrative masses 
associated with subcutaneous xenografts of AEP-overexpressing HEK293 cells in athymic 
mice 
[24] 
 An AEP DNA vaccination strategy targeting AEP-overexpressing tumour-associated 
macrophages generates potent cytotoxic T cell response and protects against fatal tumour 
challenge (75%), tumour dissemination (62%) and angiogenesis 
[68], [69],  
[70] 
Inverse correlation 
studies 
Cystatin E/M silencing in an oral squamous carcinoma cell line results in enhanced AEP 
and CTSB expression and increased motility 
[71] 
 Cystatin E/M expression inversely related to AEP and CTSB expression in primary human 
melanoma and metastatic cells; forced expression of Cystatin E/M associated with specific 
decline in AEP expression and cell motility 
[72] 
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Table 2.5 Aberrant lysosome biology and role of lysosome hydrolases in human cancer  
 
Overexpression 
Tumour Gene amplification (Cathepsin B) [73], [74] 
 Aberrant translation 
 • Variant transcript: exon skipping (Cathepsin B) or use of alternative promoters 
(Cathepsins B and L) 
[75], [76], [77],  [78],  
[79] 
 • Altered transcript stability  [80] 
Tumour microenvironment Typically observed in stromal macrophages but also noted in endothelial cells, 
pericytes, fibroblasts and myofibroblasts 
[81], [82], [83], [84], 
[85], [86] 
 Paracrine (cytokine-mediated) induction of lysosomal protease expression in 
tumour cells 
[87], [88] 
Aberrant lysosomal 
trafficking 
Widely observed in epithelial cancers; altered lysosome dynamics associated with 
aberrant peripheral localisation, as opposed to typical perinuclear situs; implicated 
in exaggerated cell motility or enhanced extracellular discharge of lysosomal 
contents 
[89], [90], [91], [92], 
[93] 
Enhanced cell motility Widely reported in cancer cell lines - Osteosarcoma (Cathepsins B and L), 
Glioblastoma (Cathepsin B), T-cells (Cathepsin X); experimental evidence variably 
includes enforced expression and inhibition/depletion studies 
[94], [95], [96], 
(Chapter 1, [154])  
Clustering in motility-
associated plasma 
membrane microdomains 
In caveolae (pro- and mature Cathepsin B in close proximity to β1 integrin and the 
Annexin II-tetramer complex); in podosomes (localisation directed by a Src family 
kinase, p61 Haematopoeitic Cell Kinase); in CD63-enriched tetraspannin domains 
as in the case of Cathepsin L (CD63 is an integral lysosomal membrane protein)  
[97], [98], [99], [100], 
[101], [102] 
Plasma membrane 
remodelling 
Pre-formed plasma membrane fragments from endocytic process re-used to 
rapidly generate membranes at extending cell front   
[103], [104], [105], 
[106] 
Cell adhesion/de-adhesion 
sequence 
Integrin-activation and signalling (β2 integrin heterodimers [αLβ2 in lymphocytes; 
αMβ2 in monocyte-macrophages] and Cathepsin X) 
(Chapter 1, [154]), 
[107] 
 Aberrant Rho kinase signalling implicated in disrupted lysosomal translocation [108], [109], [110] 
Activating cleavage of 
promotility zymogens 
Lysosomal cysteine proteases often cleave to activate other related zymogens or 
non-family proproteins (e.g. the pro-urokinase plasminogen receptor) 
[111], [112] 
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Table 2.5 Aberrant lysosomal biology and role of lysosomal hydrolases in human cancers (continued) 
Exocytosis Exocytosis- a key mechanism in cell motility regulation [113],  [114] 
 Results in extracellular release of active proteases  [100], [115] 
 The stroma helps activate and stabilise  extracellular proteases 
 • Inactive precursor proteases released by tumour cells (Cathepsins B, C, L, X) [109], [116] 
 • Low pH of tumour microenvironment (including in the bone marrow) facilitates 
both release and extracellular activation of lysosomal proteases 
[117], [118], [119], 
[120] 
 • Stromal glycosaminoglycans also help activate and stabilise extracellular 
proteases  
[121], [122]  
 Discharged proteases degrade structural components of extracellular matrix  [123], [124], [125] 
Altered cell signalling 
Exocytosis Release of bioactive molecules tethered to extracellular matrix; once liberated, 
these molecules participate in a multitude of pro-oncogenic signalling processes, 
including cell proliferation and angiogenesis (akin to the wound healing response) 
[112], [126] 
Intracellular substrate 
cleavage 
Degradation following endocytosis  
 • Extracellular matrix components (e.g. CTSB and collagen) [127] 
 • Surface signalling receptors (e.g. C-terminal inactivating cleavage of human 
epidermal growth factor receptor 2 in breast cancer cells) 
[128] 
Drug resistance 
 
Aberrant lysosome trafficking links with accelerated exosome export to contribute 
to cisplatin drug resistance in an ovarian carcinoma cell line  
[129] 
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3 
AEP expression in childhood acute lymphoblastic leukaemia 
 
Microarray gene expression analysis indicated predominant overexpression of 
AEP in adverse-risk progenitor-B ALL.  This chapter discusses results of studies 
to validate and extend these findings. Validation studies were performed on the 
microarray discovery cohort.  
 
Experimental methods 
Full details of all procedures, including materials, reagents, protocols and 
optimisation-validation steps are available in the Methods chapter. The following 
account is a summary.   
Primary samples 
Mononuclear cells were isolated from diagnostic bone marrow samples by 
density-separation. Isolated cells were either directly lysed in TRIzol reagent 
towards RNA isolation or cryopreserved in liquid nitrogen (Figure 3.1). All 
research samples were obtained from patients treated on national protocols and 
processed after explicit patient/parental consent for sampling, storage and use of 
material for ethically-approved research (Supplementary Table 3.1). The studies 
were approved by the Tameside and Glossop Local Research Ethics Committee, 
Manchester, UK (Reference 07/Q1402/56).    
 
Cell lines 
Full details are available in the companion Supplemental section (Appendix A, 
Supplementary Table S3.2). Unless otherwise specified, cells were washed in 
PBS and pelleted by centrifugation at 300g for 5 minutes at room temperature. In 
all experiments, low-passage cells (typically, less than 15) were used and cell 
counts and viability (Trypan blue staining exclusion) were strictly determined.   
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Two-step quantitative real-time PCR for estimation of AEP transcript expression 
RNA was isolated from cells lysed in TRIzol using the one-step guanidinium 
thiocyanate-phenol-chloroform phase extraction procedure [1]. Five hundred 
nanogram RNA was used as template for first-strand cDNA synthesis. AEP 
transcript expression was quantitated using on-demand Taqman (hydrolysis 
probe) gene expression assays (Supplementary Table S3.3, Appendix B) and 
the ABI Prism 7700HT instrument system. The delta-delta CT approximation 
method was used to estimate relative normalised AEP transcript expression, 
using β2M expression as endogenous reference and normalised expression of 
the HRC57 cell line as calibrator.  
 
Protein immunoblotting 
Total protein was extracted by whole cell lysis in NP40- or acidified citrate-based 
lysis buffers and quantitated using a modified Lowry assay. Uniform quantities of 
denatured whole cell protein lysates were resolved by discontinuous SDS-PAGE 
and transferred semi-dry to PVDF membranes. Following blocking, membranes 
were serially probed with primary and HRP-conjugated secondary antibodies. 
Protein bands were detected by chemiluminescence. (Figure 3.2) Membranes 
were subsequently stripped and probed for estimation of loading control or for 
detection of alternative proteins.  
 
AEP activity assay  
Pre-quantitated whole cell lysates in acidified NP40-citrate lysis buffers were 
incubated with a synthetic fluorogenic aminomethyl coumarin conjugated-peptide 
substrate, without or in the presence of the selective AEP inhibitor, MV026630 
(AEPi). Enzyme activity corresponded to the net intensity of fluorescence 
generated following substrate cleavage and was read off a standard curve.  
 
Cytofluorescence staining   
Formalin-fixed cell cytospins were permeabilised, blocked, probed serially with 
primary and secondary antibodies and mounted with DAPI as nucleus 
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counterstain (Figure 3.3). In some experiments, cells were live-labelled with the 
fluorescent acidotropic probe, LysoTracker Red DND-99 or with the BODIPY 
fluorophore-conjugated azaepoxy-asparagine peptidyl AEP activity-based probe 
(Figure 3.4; [2]) prior to fixation. All experiments included parallel negative 
controls (Chapter 8, Figures 8.6-8.9). Image acquisition details are provided in 
the figure annotations. The Adobe Photoshop software package was used to 
process images.   
 
AEP immunohistochemistry 
Formalin-fixed paraffin tissue sections were deparaffinised, rehydrated, treated to 
quench endogenous peroxidase and biotin activity, serially probed with primary 
and secondary antibodies, counterstained, dehydrated and DPX-mounted. 
Photomicrograph acquisition details are provided in the figure annotations. All 
experiments included parallel negative controls (Chapter 8, Figure 8.10). Images 
were processed using the Adobe Photoshop software package.   
 
SD1 microvesicle isolation 
Microvesicles were isolated from cell-free supernatants of near 100%-viable SD1 
cells cultured in serum-unsupplemented growth medium, using serial standard 
and high-velocity centrifugation steps (Figure 3.14A). 
 
Results 
Quantitative PCR validates microarray analysis of AEP transcript expression 
As shown in Figure 3.5, relative quantitation of AEP transcript expression 
parallels microarray findings (Supplementary Table S3.4). Although median 
AEP transcript expression is highest in poor-risk progenitor-B ALL, there is 
considerable overlap in expression with good-risk progenitor-B disease. This is in 
part due to smaller sample numbers in the poor-risk B-lineage category. Part of 
the overlap is also attributable to AEP overexpression being largely restricted to 
the adverse-risk progenitor-B ALL genotypes, Ph+ ALL and iAMP21 ALL. AEP 
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overexpression is essentially not a feature of progenitor-T ALL and acute myeloid 
leukaemia.  
 
AEP protein expression imperfectly matches transcript expression 
Figures 3.6 and 3.7 discuss these findings. The observations are clearly limited 
by inadequate sample sizes. In cell lines and primary cells, estimated AEP 
activity matched immunoblot protein expression and suggested expression of 
fully functional protease. Relative AEP transcript expression and enzyme activity 
however correlated imperfectly (Figure 3.7, Supplementary Table S3.5, 
Appendix D).  
 
Progenitor-B lymphoblasts demonstrate heterogeneous intracellular AEP 
expression, including localisation in peripherally-sited macrovesicular 
endolysosomal compartments  
SD1 cells 
Intracellular expression was investigated in SD1 cells, a model AEP-
overexpressing poor-risk genotype (Ph+) progenitor-B ALL cell line. Labelling, 
using both an antibody and the activity-binding probe, indicated remarkable 
heterogeneity of expression of intracellular AEP. Stippled perinuclear staining 
suggested typical lysosomal distribution (Figure 3.8, upper panel). Additionally, 
some cells strikingly demonstrated peripherally localised macrovesicular AEP 
staining (Figure 3.8, middle and lower panels). Dual staining with lysosomal 
markers, LysoTracker Red and antibody to LAMP1, characterised these 
peripherally-localised AEP+ macrovesicles as endolysosomal organelles (Figure 
3.9).  
Primary cells 
Tissue section immunostaining localised AEP expression to lymphoblasts 
(Figure 3.10). Cytofluorescence staining in iAMP21 primary lymphobasts 
mirrored observations in SD1 cells; distinct peripherally-localised acidified AEP+ 
vesicles were similarly observed (Figure 3.11) 
 
59 
Chapter 3   AEP expression 
SD1 cells shed preproAEP in microvesicles  
Microscopy observations of peripheral AEP localisation suggested extracellular 
lysosomal discharge of mature active AEP. Fixed-cell imaging supported this 
probability (Figure 3.12). AEP immunoblotting and enzyme activity studies 
however consistently failed to detect active AEP in SD1 cell supernatants. 
Instead, AEP immunoblotting detected preproAEP in cell-free SD1 supernatants. 
Despite stringent measures to avoid cell contamination, preproAEP detection in 
cell supernatants was invariably associated with trace detection of β-actin 
(Chapter 8, Figure 8.15). Phase-contrast microscopy provided an explanation. In 
culture, SD1 cells were associated with apparent granular ‘debris’ that on higher 
magnification, were membranous microparticles characteristic of microvesicles 
(Figure 3.13). AEP immunoblots of microvesicles harvested from cell-free SD1 
supernatants similarly detected preproAEP, suggesting extracellular release of 
the zymogen in microvesicles (Figure 3.14B). Confirmation of preproAEP 
detection was provided by AEP immunoblot of microvesicle isolates lysed in acid 
citrate buffer; low pH of the buffer triggered autoactivating cleavage of preproAEP 
in the lysate, resulting in the additional detection of the intermediate proAEP 
precursor (Figure 3.14C).   
 
Discussion 
Global gene-expression microarray was used as a discovery tool for novel 
prognostic biomarkers in childhood ALL. AEP was identified as one such 
candidate. AEP was overexpressed in adverse-risk progenitor-B ALL genotypes, 
predominantly in the iAMP21 and Ph+ ALL subsets, and this observation was 
corroborated by quantitative PCR on the same sample cohort. The wide range 
and overlap of expression may in part be due to inadequate sample numbers but 
the variability in expression may also be a reflection of the current imprecision of 
cytogenetic stratification as an estimate of risk and prognosis. Indeed, restricted 
overexpression in poor-risk genotypes would have raised doubts over the 
usefulness of AEP as an independent risk variable.  The question of concomitant 
AEP protein overexpression remains an open one and will need to await results 
60 
Chapter 3   AEP expression 
of an ongoing prospective biomarker study. Related issues are highlighted in 
Tables 3.1 and 3.2.  
 
Table 3.3 sets out the limitations of microscopy studies. Importantly, the 
observations are largely based on findings in the model high-risk SD1 cell line, 
with only anecdotal corroboration in primary cells. Despite the acknowledged 
limitations, microscopy observations demonstrate striking heterogeneity of 
intracellular AEP expression, including localisation to atypically distributed 
peripheral macrovesicular endolysosomes. Taken together with the observation 
of preproAEP exocytosis in SD1 microvesicles, the findings suggest that poor-
risk ALL is potentially characterised by perturbed lysosome homeostasis, 
involving aberrant antegrade lysosome trafficking and extracellular discharge 
(Figure 3.15).  This phenotype could conceivably be mechanistically implicated 
in many of the adverse-risk characteristics of lymphoblasts, including 
exaggerated transvascular motility and drug resistance (Chapter 2, [129]). 
Targeting lysosomes may therefore be a feasible therapeutic option in childhood 
ALL. Indeed, in the case of mature-B lymphoid neoplasms, the therapeutic effect 
of a subset of anti-CD20 monoclonal antibodies is directly attributable to 
lysosomal disruption and downstream activation of non-apoptotic cell death [5].  
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Figure 3.1 Schematic outline of mononuclear cell isolation from bone 
marrow/peripheral blood by density gradient centrifugation 
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Figure 3.2 Schematic outline of protein immunoblotting using discontinuous 
reducing SDS-PAGE  
 
Figure 3.3 Schematic outline of cytospin immunostaining procedure 
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Figure 3.4 Cartoon representation of fluorescent in vivo labelling of mature active 
AEP by the AEP activity-binding probe (AEP-ABP) 
Sequential carboxyl- and amino- termini cleavages during the process of AEP maturation 
(Appendix C) preclude labelling of the active AEP protease using traditional terminal-
tagged fluorescent reporters. The AEP-ABP circumvents this problem by binding directly 
to the catalytic site of mature AEP. The probe, a gift from Dr. Matthew Bogyo's lab at 
Stanford University in California, is a fluorophore-conjugated cell-permeable compound 
and its azaepoxy-dipeptidyl warhead sequence determines its reactivity as well as 
binding specificity. 
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Figure 3.5 Quantitative PCR validates microarray analysis of AEP transcript 
expression 
Boxplot representations of AEP transcript expression in leukaemic cells as determined 
by microarray analysis (left) and quantitative PCR (RQPCR, right). Validation by RQPCR 
was performed on the microarray sample cohort. Median AEP transcript expression is 
higher in high-risk progenitor-B ALL than in other categories of acute leukaemia, 
although there is considerable overlap with standard-risk B-lineage disease. 
High-risk pre-B refers to adverse-risk genetic subtypes of progenitor-B ALL (BCR-ABL1, 
MLL rearranged, hypodiploidy, iAMP21); standard risk pre-B refers to all other genetic 
progenitor-B ALL subtypes. Boxes encompass the interquartile (IQR, 25th-75th percentile) 
ranges, horizontal bars and ʻ+ʼ within boxes represent median and mean values 
respectively, whiskers denote values 1.5× IQR, outlier values are represented by open 
and filled circles. Microarray analysis was performed on Affymetrix HG_U133A 
oligonucleotide arrays and evaluated using the GeneSpring analysis package (v7.3.1). 
RQ-PCR was performed using on-demand Taqman assays and reported using the ΔΔCt 
approximation method with β2M expression as endogenous reference and HRC57 cell 
line expression as calibrator.  
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Figure 3.6 AEP enzyme activity matches immunoblot protein expression 
AEP immunoblots (A) and relative enzyme activity (B, fluorescent substrate cleavage 
assay) in whole cell lysates from malignant lymphoid (SD1, REH, SupB15, HRC57, 697, 
RPMI-8402, U266) and myeloid (MV4:11, K562, HL60) cell lines. Enzyme activity 
parallels immunoblot detection, suggesting expression of wild type AEP. The doublet 
56kDa immunoblot detection bands in U266 probably represent different glycosylation 
states of the AEP zymogen. AEP enzyme activity is expressed relative to the reference 
HRC57 cell line.   
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Figure 3.7 AEP transcript and protein expressions do not necessarily correlate 
Upper panel: AEP immunoblot on primary ALL bone marrow mononuclear whole cell 
lysates (polyclonal anti-AEP antibody). Lower panel: Paired relative AEP transcript 
expression and enzyme activity in primary ALL samples; expression is normalised to the 
HRC57 cell line (dashed horizontal). While AEP activity parallels protein expression, 
transcript expression is discordant (lower panel, UPN 2 and 10, highlighted by vertical 
arrows).  High transcript-low protein expression (UPN10) may be attributed to transcript 
silencing or accelerated protein degradation. Low transcript-high protein expression 
(UPN2) could be a consequence of post-translation negative feedback [3].  
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Figure 3.8 AEP expression in SD1 cells is heterogeneous, from stippled, 
predominant perinuclear expression to giant peripheral macrovesicular staining 
Fluorescence imaging of cytospin preparations of SD1 cells. In panels A and B, formalin-
fixed and permeabilised SD1 cells were serially probed with goat polyclonal anti-human 
AEP (1:100) and an Alexa Fluor 488 conjugated secondary (green). In panel C, SD1 
cells were live-labelled with a BODIPY 530/580-tagged aza-epoxypeptide class AEP 
activity-binding probe (AEP-ABP, red; 1μM, 2×105cells, 2 hour incubation, 37°C) prior to 
cytospin preparation and formalin-fixation. In both cases, DAPI (blue) counterstained the 
nucleus. Images were acquired using the Olympus BX51 microscope (equipped with the 
Photometrics CoolSnap HQ cooled CCD camera) and the Zeiss Axiovert 200M inverted 
low-light microscope system (equipped with the Photometric Cascade II:1024 EMCCD 
camera), both operated by the Metamorph advanced imaging software. Representative 
images are presented.  
The pattern of AEP expression in SD1 cells is strikingly heterogeneous. Stippled 
predominantly perinuclear staining [Panels A (40×), B (a)] reflects typical lysosomal 
distribution. Coarser macrovesicular staining is also noted [Panel B, (c), (d)] and often, a 
mixed expression pattern is observed [Panel B, (b) and (f)]. Of note, macrovesicular AEP 
staining is distributed largely towards the cell periphery [Panels B, (e), (f); C (a)] and is 
sometimes characterised by impressive giant vesicular expression [Panel C (b)]. 
 
A 
Chapter 3 FIGURES 
69 
 
B 
C 
Chapter 3 FIGURES 
70 
Figure 3.9 AEP in SD1 cells is distributed in peripherally localised acidified 
LAMP1-positive vesicles  
Fluorescence imaging of cytospin preparations of SD1 cells. In Panels A, B and D, SD1 
cells were live-labelled with the acidotropic LysoTracker Red DND-99 probe (LyTR; 
500nM, 45 minutes, 37°C; red) followed by cytospin preparation, formalin-fixation, 
permeabilisation and serial probing with a polyclonal anti-AEP primary and an Alexa 
Fluor 488-conjugated secondary. In Panel C, SD1 cells were live-labelled with the AEP 
activity-based probe (AEP-ABP) and subsequently, cytocentrifuged, formalin-fixed, 
permeabilised and probed serially with monoclonal anti-LAMP1 primary (murine HA-43 
clone, 1:100) and an Alexa Fluor 488 conjugated secondary. DAPI (blue) counterstained 
the nucleus. Images were acquired using a Zeiss Axiovert 200M low-light microscope 
system equipped with an Optovar module and an EMCCD camera operated by the 
Metamorph imaging system. Representative images are shown.  
SD1 cells demonstrate large peripherally localised acidified (i.e. LysoTracker Red 
labelled) vesicles (Panel A). Dual staining localises AEP to these acidified vesicles 
(Panel B, Panel D [cell in centre, merged image]), which on account of the low 
intravesicular pH, must largely exist as the mature protease. This is supported by dual 
staining using the AEP-ABP and the anti-LAMP1 antibody (Panel C). Here, mature AEP 
is observed in distinct peripherally-localised LAMP1-ringed endolysosomal vesicles, 
possibly on the verge of exocytosis. Also observed is peripheral localisation of AEP 
independent of LyTR labelling (Panel D, arrow highlight), suggesting additional 
perimembranous localisation of immature AEP-containing vesicles.  
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Figure 3.10 AEP-expressing lymphoblasts at testicular relapse of iAMP21 ALL 
H&E and AEP-immunostained sections of testicular tissue in a 10-year old boy with 
gonadal relapse of iAMP21 ALL. Upper panel: H&E section. Prepubertal seminiferous 
tubules are surrounded by a prominent intersititial infiltrate of uniform small round blue 
cells (20×, 75μ scale bar) Lower panel: AEP immunohistochemistry. Whorls of AEP-
expressing (brown) lymphoblasts (40×/0.75NA, 50μ scale bar) demonstrate fine granular 
and coarse vesicular (arrow) cytoplasmic staining (100×/1.35NA, 25μ scale bar). Images 
were acquired using an Olympus BX51 microscope equipped with a Photometrics 
CoolSnap HQ CCD camera operated by the Metamorph advanced imaging software.   
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Figure 3.11 Peripherally localised acidified AEP-containing vesicles are also 
observed in primary ALL cells 
Fluorescence imaging of primary progenitor-B lymphoblasts obtained from a cryostored 
mononuclear cell isolate of diagnostic bone marrow cells sampled from patient UPN9 
with iAMP21 ALL.   
Upper panel: Flow cytometry and light microscopy confirmation of a predominant (>95%) 
progenitor-B lymphoblast population in sample. Thawed cells were incubated with 
fluorophore-conjugated anti-CD19 and anti-CD10 monoclonal antibodies (singly and 
combined, 4°C, light-shielded, 30 minutes) together with 7-aminoactinomycin D as cell 
viability marker; events were acquired on the BD-LSRII flow cytometer and examined 
using the FlowJo analysis package (Tree Star). The majority of gated viable cells were 
CD10+CD19+. Light microscopy of an MGG-stained cytospin preparation reveals large 
cells with scanty cytoplasm, homogenous open chromatin and prominent nucleoli, all 
features typical of lymphoblasts.  
MGG, May-Grünwald Giemsa; PE, phycoerythrin; PE-Cy7 phycoerythrin-Cyanine 7 
tandem fluorochrome. 
Lower panel: Cytospins of LysoTracker Red (LyTR, 500nM; red) live-labelled cells were 
formalin-fixed, permeabilised and serially incubated with the goat polyclonal anti-AEP 
antibody (1:100) and an Alexa Fluor 488-conjugated secondary (green); cell nucleus was 
counterstained blue with DAPI. Images were acquired using the Zeiss Axiovert 200M 
inverted low-light microscope system equipped with a Photometrics Cascade II EMCCD 
camera operated by the Metamorph advanced imaging software; a representative image 
is shown. The arrow highlight indicates typical colocalised fluorescence (yellow) in a 
distinct peripherally-sited vesicle. In this field alone, several cells demonstrate peripheral 
vesicular LyTR labelling, often colocalised with AEP staining. 
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Figure 3.12 Fluorescence imaging of SD1 cells suggests exocytosis of mature 
AEP 
SD1 cells labelled live with the AEP activity-based probe (AEP-ABP, green) and seeded 
on fibronectin-coated (10μg/mL) circular glass coverslips (10mm diameter, 4 hours, 
37°C); post-labelling, cells were formalin-fixed, stained for filamentous actin (Alexa Fluor 
647-labelled phalloidin, red) and DAPI-counterstained for nucleus (blue). Composite of 
images captured using the Zeiss Axiovert 200M inverted low-light microscope system 
equipped with a Photometrics Cascade II EMCCD camera operated by the Metamorph 
advanced imaging software.  
The SD1 cell in the centre demonstrates a green blush of mature AEP extending beyond 
the cell boundary (as outlined by filamentous actin staining), suggesting exocytosis of 
the active protease.  
F-actin, filamentous actin, 100× /1.45NA objective, 10μ scale bar 
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Figure 3.13 SD1 cells shed microvesicles in cell culture 
Phase-contrast microscopy images of SD1 cells in culture. On low-power magnification, 
fine suspended particulate matter is noted surrounding pleomorphic SD1 cells (20× ; 
scale bar, 10μ). On higher magnification (40×, 10μ scale bar), sub-micrometer spherical 
membranous particles (asterisks) are observed, characteristic of microvesicles 
 
Figure 3.14 SD1 cells shed preproAEP in microvesicles 
(A) Microvesicle isolation protocol. Care was taken to ensure that cell viability was 
~100% at time of microvesicle harvest to control for passive extracellular leak of 
cytoplasmic contents. Serum-free cell culture for 48 hours was sufficient for an adequate 
yield of microvesicles (MV).  
(B) AEP and Cathepsin B (CTSB) immunoblots of whole cell lysates (WCL) and lysates 
of SD1 microvesicles (SD1-MV) created in NP40 lysis buffer. PreproAEP but not mature 
AEP is detected in SD1-MV isolates. β-actin served as loading control and the detection 
of this cytoskeletal protein in SD1-MV lysates suggests plasma membrane shedding. 
Unlike AEP, active heavy chain subunits of the lysosomal protease CTSB (24-27kDa) 
are uniformly detected in all samples. SB15, SupB15 
(C) AEP immunoblot of acidified citrate-NP40 SD1-MV lysates (SD1MV-CitLB1 and 
SD1MV-CitLB2) and MV-free supernatant (S/N). Evidence for the presence of 
preproAEP in SD1-MV comes from AEP immunoblot of SD1-MV lysates prepared in acid 
citrate-NP40 lysis buffer (pH 5.0). The lower 47kDa band detected in acidified MV 
lysates represents intermediate pro-AEP generated by autoactivating cleavage of 
preproAEP in acid pH. Note the presence of free preproAEP in supernatant isolated from 
a low-viability culture of SD1 cells.  
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Figure 3.15 Summary cartoon representation of the postulated consequences of 
aberrant lysosomal dynamics in lymphoblasts  
A lymphoblast is depicted interacting with extracellular components (stromal cell and 
matrix) through integrin-ICAM (intercellular adhesion family molecule) associations, often 
at sites of podosome protrusion. Acidified, aberrantly localised large peripheral 
endolysosomes discharge active hydrolases, include AEP, into the stroma.  Active 
lysosomal enzymes degrade extracellular matrix molecules (e.g. AEP and fibronectin), 
activate counterpart enzymes (e.g. AEP and papain-family cathepsins) and liberate 
matrix-bound growth factors (including cytokines that potentially amplify these 
interactions). Peripheral localisation of lysosomes and postulated interaction of 
lysosomal hydrolases with integrin receptors (e.g. AEP RGD domain and β-integrin 
subunit) suggest a role in lymphoblast plasma membrane remodeling (*). Aberrant 
trafficking also probably results in extracellular release as secretory lysosomes (**).   
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Figure 3.16 Microarray analyses of AEP transcript expression in an independent 
sample cohort (St Jude Childrenʼs Research Hospital) indicates broad overlap of 
expression among the early progenitor-B ALL subtypes 
Boxplot representations of normalised relative AEP expression across subtypes of 
childhood ALL. Median AEP expression is uniformly high in subtypes of early progenitor 
B ALL, including both adverse-risk Ph+ALL (BCR-ABL) and good-risk (TEL-AML1 and 
high-hyperdiploid [HD50]) subtypes, probably reflecting the physiological expression 
pattern in early stage B-lineage precursors. Low AEP expression in both very early and 
late B-lymphocyte progenitors is similarly mirrored by the neoplastic counterparts, MLL-
rearranged [MLL(ALL)] and E2A-PBX1 ALL respectively.  
Boxes encompass the interquartile (IQR, 25th-75th percentile) ranges, horizontal bars 
within boxes represent median values, ʻ+ʼ values indicate means, whiskers denote 
values 1.5× IQR, outlier values are represented by asterisks, dashed lines demarcate 
off-scale outlier values  
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Figure 3.17 In an independent sample cohort (University Malaya), similar relative 
AEP transcript overexpression in Ph+ ALL is observed  
Boxplot representation of normalised relative fold AEP transcript expression as 
determined by quantitative PCR, in leukaemic blasts from a prospective cohort of 
consecutively enrolled children (n=145) with distinct genetic subtypes of progenitor-B 
ALL. Although there is considerable overlap, median relative AEP expression is higher in 
Philadephia chromosome positive ALL (BCR-ABL).  
Genetic subtypes were identified by PCR identification of recurrent somatic fusion 
transcripts (FT): BCR-ABL, ETV6-RUNX1, TCF3-PBX1, MLL-AF4. The subset of 
progenitor-B ALL without identifiable fusion transcripts (ʻNo FTʼ) includes aneuploid (i.e., 
high hyperdiploid and hypodiploid) lesions. Data courtesy of Dr. Hany Ariffin, Department 
of Paediatrics, University Malaya, Malaysia 
Boxes encompass the interquartile (IQR, 25th-75th percentile) ranges, horizontal bars 
within boxes represent median values, whiskers denote values 1.5× IQR, outlier values 
are represented by circles (≤3× IQR) and asterisks (>3× IQR), dashed lines demarcate off-
scale outlier values  
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Figure 3.18 AEP upregulation in iAMP21 ALL is not associated with variant-
transcript expression 
Heatmap and line graph representations of microarray analysis of exon-level expression 
of AEP in children with iAMP21 (blue) and high hyperdiploid (HH, red) ALL. Each 
datapoint represents averaged normalised expression of probes for each putative exon 
within the coding region of the AEP transcript (reference transcript sequences 
NM_005606.5 and NM_001008530). Expression is uniformly high across all eight 
interrogated exons in iAMP21 ALL, suggesting the absence of exon-skipping and 
aberrant transcript expression associated with AEP overexpression in this ALL subtype. 
Data courtesy of Frederick W van Delft and Olga Yiannikouris.  
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Table 3.1 Investigation of AEP transcript expression - experimental limitations  
   
Preanalytical 
variables  
Percentage lymphoblasts 
in clinical samples 
Research samples are typically last 
in the sequence of multiple bone 
marrow aspirates from a single 
pass. The samples are therefore 
likely to be diluted. This lowers % 
blast count, even in the case of 
diagnostic samples where the bone 
marrow is ~100% infiltrated by 
leukaemic cells. An enrichment 
strategy for lymphoblasts would 
have addressed this concern but 
would also have resulted in loss of 
material  
 Sample integrity  This is a lesser concern. Most 
samples were processed within 
less than 24 hours of collection. 
Adequate-quality RNA isolates 
(established by electropherogram 
profiles) from these samples were 
used for microarray studies. β2M 
transcript expression was used as 
an additional surrogate estimate of 
sample integrity.  
Validation of 
microarray analysis 
Relative quantitation of 
AEP transcript expression 
was performed on the 
same sample set used for 
microarray analysis 
Although relative transcript 
quantitation helped validate results 
of microarray analysis, a more 
informative approach would have 
been to examine relative AEP 
expression in an independent 
sample cohort. This is now being 
investigated (see Table 3.2) 
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Table 3.2 AEP expression in ALL - some as yet unresolved questions  
Issue State of knowledge 
Is AEP overexpression (genomic region 
14q32.1) merely an epiphenomenon of 
somatic rearrangement events occurring 
at the neighbouring immunoglobulin 
heavy chain locus (14q32.3) in a 
progenitor-B cell? 
This for the moment remains an open 
question. Microarray analysis from the St 
Jude group indicates broad overlap in 
expression among distinct genetic ALL 
subtypes sharing an early progenitor-B 
immune phenotype (Figure 3.16) 
suggesting that AEP expression is merely 
an ontogenic marker. Conversely, 
prospective examination of AEP transcript 
expression in an independent patient cohort 
indicated relative median overexpression in 
adverse risk Philadelphia-chromosome 
positive ALL (Figure 3.17) 
What is the correlation between AEP 
transcript and protein expression? 
This would be specifically addressed by an 
ongoing prospective biomarker study 
undertaken by the Children's Cancer Group. 
This study, a component of the current UK 
childhood ALL trial (ALL2003), is in part, 
examining potential associations between 
AEP transcript/protein expression and other 
risk variables  (clinical, genetic and 
response)  
Is AEP upregulation associated with 
aberrant transcript or protein expression?
Limited indirect evidence suggests that this 
is probably not the case.  
• AEP transcript overexpression is not 
associated with exon-skipping in iAMP21 
ALL (Figure 3.18)  
• Immunoblot protein overexpression is 
matched by elevated AEP enzyme activity 
 At the transcript level, use of complementary 
Taqman primer-probe pairs for AEP 
transcript quantitation or direct sequencing 
of transcript in an unbiased sample would 
be able to better address the question of 
variant AEP transcript expression  
What is the mechanism of AEP 
overexpression in adverse-risk progenitor 
B childhood ALL?   
This is at present not known. RUNX1 for 
instance is among the transcription factors 
predicted to bind to the putative AEP 
promoter [4]* and may account for the 
overexpression observed in iAMP21 ALL.  
 Gene amplification may be a mechanism 
and may account for AEP overexpression 
observed in High Hyperdiploid ALL where 
somatic whole chromosome 14 duplications 
are common. Of note though, AEP 
overexpression is not a uniform feature in 
this genotype.  
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Table 3.2 AEP expression in ALL (continued) 
Issue State of knowledge 
Mechanism of AEP overexpression in 
adverse-risk progenitor B childhood ALL 
(continued)   
Rearrangements at the 14q32.1 genomic 
locus may also drive AEP overexpression 
but have not been specifically investigated. 
This is pertinent since rearrangement at the 
pseudoautosomal region of somatic sex 
chromosomes results in upregulated 
expression of CRLF2 (cytokine receptor like 
factor 2), a cytokine receptor subunit 
molecule recently reported to be strikingly 
overexpressed in adverse-risk progenitor B 
ALL.  
 Additional mechanisms such as enhanced 
transcript or protein stability may also be 
operative but are not readily investigated.  
Does AEP expression correlate with 
adverse clinical outcomes? 
This question is being investigated as part 
of the ALL biomarker study alluded to 
earlier. Multivariable analysis will be 
performed to examine whether a pre-
determined threshold of AEP transcript or 
protein expression independently influences 
minimal residual disease clearance or risk of 
relapse 
*Supplementary Material, Additional File 2, Reference [4] 
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Table 3.3 Microscopy investigations of intracellular AEP expression – 
experimental limitations 
   
Issue Limitation Measures to address 
Cytospin 
preparations 
Although the easiest technique 
for microscopy examination of 
cells in suspension, 
cytocentrifugation and air-
drying of smears potentially 
introduce morphology artifacts 
In situ examination of leukaemic 
cells allowed to adhere to 
coated/treated coverslips or 
glass-bottomed dishes will 
partially address this concern but 
the strategy of induced adhesion 
may in itself, not be 
representative 
Examination of 
single-cell 
populations  
Microscopy examination of  
single populations of 
leukaemic cells is informative 
but ignores interactions with 
the microenvironment   
In situ examination of leukaemic 
cells co-cultured with stromal and 
endothelial cells would be more 
representative; acquiring 
appropriate optical sections is 
more challenging in this context  
Fixed cell 
imaging 
Formalin-fixation and 
permeabilisation potentially 
introduce morphological 
artefacts 
Live cell imaging of intracellular 
AEP and lysosomal dynamics in 
leukaemic cells using non-toxic 
cell-permeable probes would be 
more representative but also 
technically more challenging 
AEP-activity 
based probe 
(AEP-ABP) 
Specificity of the AEP-ABP has 
not been rigorously 
demonstrated. Validation 
experiments were limited by 
availability of the AEP-ABP 
compound but a gift of 
additional probe has recently 
been obtained. 
To better establish probe 
specificity, the following 
approaches would be informative: 
(a) Is there colocalisation of 
florescence following dual AEP 
labelling using both the AEP 
antibody and activity-based 
probe?; and (b) Is AEP-ABP 
labelling absent in mutH148A-
AEP+ cells where the AEP 
catalytic site is inactivated?  
Primary ALL 
cells 
Observations on intracellular 
AEP distribution have been 
essentially based on 
investigations in ALL cell lines. 
This is set to change. A 
biorepository of childhood ALL 
samples has been in operation for 
the past two years and would be 
a source of primary diagnostic 
material for microcopy analysis 
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4 
AEP expression and cell motility 
 
Relapses in the central nervous system (CNS) pose a major therapeutic 
challenge in childhood ALL. It is postulated that aberrant lymphoblast trafficking 
and motility results in blood-borne infiltration of the CNS through an orchestrated 
process of homing, endothelial adhesion-signalling, cytoskeletal reorganisation 
and matrix degradation (Chapter 1, Figure 1.17). In solid cancers, AEP 
expression is associated with local invasiveness and tumour metastasis, 
suggesting that in overexpressing leukaemic cells, the protease could potentially 
function as a mediator of aberrant motility.  
 
Investigators at the Scripps Research Institute (Liu C and colleagues, 
Department of Immunology) have previously reported enhanced in vitro and in 
vivo motility of human embryonic kidney (HEK293) cells engineered to ectopically 
overexpress AEP (Chapter 2, [24]). Observations in the model AEP-
overexpressing poor-risk invasive progenitor-B ALL cell line, SD1 corroborate 
these findings. AEP downregulation, either by transcript depletion or chemical 
inhibition, significantly attenuated SD1 cell motility (Figure 4.1). AEP accelerates 
cell motility through mechanisms that presumably include extracellular matrix 
degradation, activating cleavage of pro-motility molecules and signalling 
interactions with β-integrin receptors. This chapter describes in vitro motility 
studies of ectopic AEP-overexpressing HEK293 cells. Although non-
representative, HEK293 cells were chosen primarily for ease of transfection. 
Motility assays were performed as prelude to proposed studies of AEP-
interacting proteins and identification of candidate pathways associated with the 
motile phenotype. However as elaborated in this chapter, the observations 
diametrically differed from findings of the Scripps group. Reasons for this 
discordance are discussed.  
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Experimental methods 
HEK293 cells 
Native and modified cells were routinely maintained in serum-supplemented 
DMEM and passaged at 75-80% confluence; modified cells were additionally 
maintained in selection agent-supplemented complete medium. Typical cell 
handling steps included trypsin EDTA mobilisation-neutralisation, PBS washes 
and 300g room temperature centrifugation. Early passage (less than 20) near-
100% viable cells were used in all experiments. Native HEK293 cells were 
sourced from CRUK Central Cell Services.  
 
AEP expression plasmid constructs 
Full-length AEP cDNA insert (Appendix A) was amplified, purified, sequence-
verified (Figure 4.2) and placed in destination mammalian expression vectors 
(Table 4.1), either by restriction-enzyme site ligation or Gateway recombination 
(Figure 4.3). 
 
Creation of AEP-overexpressing HEK293 cells 
HEK293 cells were lipid-transfected with AEP expression plasmid constructs. 
Transfected cells were maintained and propagated in the presence of selection 
agents to establish stable polyclonal constitutive (enforced) and inducible AEP-
expressing HEK293 cells (Figure 4.4). The inducible expression system is 
designed to enable tighter regulation of baseline and activated gene expression 
(Figure 4.5).  
 
Boyden chamber motility assays 
Assays were performed in 24-well formats. Modified HEK293 cells, passaged to 
subconfluence 48 hours prior, were reconstituted in serum-free medium and 
seeded into porous (8µm) upper chamber cell inserts; lower chambers contained 
serum-supplemented growth medium (Figure 4.6). Inserts were coated with 1:50 
dilution Matrigel in some assays. Matrigel at this dilution forms a thin non-
obstructive membranous protein coat that facilitates cell adhesion and migration 
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[1]. Assays using dilute Matrigel-coated cell inserts essentially reflect non-barrier 
cell motility and do not materially differ from uncoated-insert assays. Lower 
chamber cell counts were estimated 24 hours later by coulter counter or by 
microscopy of stained cell inserts (Figure 4.7). All assays were performed with 
parallel controls, including in some cases the PC3 human prostate carcinoma cell 
line as reference positive control.  
 
Complete details on reagents, materials and optimisation-validation experiments 
are available in the Methods chapter.  
 
Results 
Ectopic AEP overexpression does not confer a motile phenotype to HEK293 cells 
Contrary to observations of the Scripps group, inducible and enforced AEP-
expressing cells did not demonstrate enhanced motility. Lower chamber cell 
counts of AEP-expressing HEK293 cells, estimated using both coulter counting 
(Figure 4.8, Supplementary Table S4.1) and stained cell insert microscopy 
(Figure 4.9), did not significantly differ from controls. Performing extended 
timepoint Boyden chamber assays did not alter these conclusions (Figure 4.10, 
Supplementary Table S4.2).  
 
Discussion 
The objective of these experiments was to investigate the role of AEP in cell 
motility. In studies in leukaemic cell lines sharing the BCR-ABL1 genotype, AEP-
overexpressing SD1 cells were significantly more motile than non-expressing 
SupB15 cells. This motility was attenuated following AEP inhibition suggesting a 
pro-motility role for the lysosomal protease.   
In reports from the Scripps Institute, enforced expression of AEP resulted in 
increased motility of HEK293 fibroblasts. As described in this Chapter, these 
observations were however not replicated, despite adopting a similar 
experimental approach. Dissimilarities in cell clonality, genotype and assay 
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methodology may partly account for this discrepancy (Table 4.2). The 
observations were also limited by failure to establish and investigate clonal 
populations of low, intermediate and high-expressing cells (Table 4.3).  
Despite the limitations highlighted above, the observation of a lack of effect of 
ectopic AEP expression on cell motility is corroborated by other findings from 
within the group.  In these studies, the SD1 cell line has served as a 
representative high-risk model, associated as it is with both the BCR-ABL1 
genotype as well as with CNS disease when injected into mice (Figure 4.1).  
Data from experimental studies suggest that the pro-motility role of AEP in SD1 
cells is contingent upon the simultaneous co-expression of a fundamental 
complement of adhesion and signalling molecules that include the LFA-1 integrin 
(αLβ2)::ICAM-1 (intercellular adhesion molecule 1) dyad and the small-molecule 
G protein second messenger molecule Rac2. Thus, in SupB15 cells that lack 
these key adhesion-signalling molecules, sole ectopic AEP overexpression had 
little impact on the motility phenotype. Although enforced AEP overexpression in 
REH cells did result in a significant increase in motility compared to wild-type 
cells, the extent of increase was still far less than that observed in constitutive 
AEP-expressing SD1 cells (Figure 4.11). As noted in Chapter 7 (Figure 7.2), 
studies are underway investigating the consequence of ectopic candidate 
molecule co-expression (e.g. AEP and Rac2) on REH and SupB15 cell motility. 
These studies have now been expanded to systematically investigate the 
mechanistic basis for lymphoblast motility, including determination of the requisite 
repertoire of adhesion, signalling and lysosomal matrix-degrading molecules in 
leukaemic cells as well as microscopy studies of lymphoblast-stromal and 
lymphoblast-endothelial interactions that govern transvascular motility. Results 
from these studies will be validated on primary material.  
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Figure 4.1 The Philadelphia chromosome-positive progenitor-B ALL cell line, 
SD1, overexpresses AEP, demonstrates brisk in vitro motility across basement 
membrane barriers that is in part AEP-dependent, and infiltrates the central 
nervous system when introduced into immunocompromised mice.  
(A) AEP immunoblot of cell line whole cell lysates. Both SD1 and the B-lymphoblastoid 
cell line HRC57, overexpress AEP. SupB15 (SB15) is another Philadelphia 
chromosome-positive progenitor-B ALL cell line; REH is an ETV6-RUNX1 progenitor-B 
ALL cell line. Doublet detection bands associated with the precursor protein represent 
different states of glycosylation. β-actin serves as loading control.  
(B) Lower chamber cell counts (cells/mL) following 24-hour Boyden chamber assays 
using 5-micron pore Matrigel-coated (1:10 dilution, ~1mg/mL) cell inserts seeded with 
1×105 cells. SD1 is at least 5-6× more invasive across Matrigel basement membrane 
barrier when compared to SupB15 and REH cell lines. Matrigel invasion is significantly 
reduced (by between 50-60%, p=0.0003) when SD1 cells are treated with a non-toxic 
dose of a cell-permeable AEP inhibitor (AEPi, MV026630) or when AEP transcript in SD1 
cells is stably depleted by lentiviral shRNA silencing (p=0.006). Irrelevant lentiviral 
transcript silencing (ʻnon-specific silencingʼ) or AEPi vehicle treatment (DMSO, data not 
shown) had no impact on SD1 motility. Summary data from three experiments, error bars 
represent standard error of means, asterisks represent p values from 2 sided unpaired t 
tests  
(C) Low-power magnification (4×) of GFP immunostain of sagittal section of brain from a 
SCID-Beige immunocompromised mouse, 4-6 weeks after tail vein injection of GFP-
expressing SD1 cells. A dense leptomeningeal deposit of GFP-positive SD1 cells is 
observed overlying the cerebellum and occipital cortex.  
GFP, green fluorescent protein; shRNA, short hairpin RNA; SCID, severe combined 
immunodeficiency. Invasion data and mouse brain section histology, courtesy of Mark 
Holland and Fernanda Castro  
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Figure 4.2 Plasmid cloning, Step 1 
Schematic outline of the initial steps in plasmid cloning, including bacterial 
transformation, amplification by bacterial culture, plasmid isolation (small-scale or large-
scale) and sequence verification 
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Figure 4.3 Schematic outline of plasmid cloning, Step 2 
Upper panel: Isolation of full length (FL) AEP cDNA insert from source plasmid by 
restriction enzyme digestion and purification after gel electrophoresis (left) followed by 
introduction into the multiple cloning site of an inducible-expression system destination 
vector (right)  
Lower panel: Introduction of AEP insert into a mammalian enforced expression plasmid 
using Gateway cloning technology (Invitrogen) 
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Figure 4.4 Creation of stably-transfected enforced and inducible polyclonal AEP-
overexpressing HEK293 cells 
(A) Schematic outline. HEK293 human embryonic kidney fibroblasts were lipid-
transfected with expression plasmid containing full-length AEP cDNA insert (NCBI 
RefSeq NM_005606.5, Appendix B) and were later treated with selection agents to 
establish a stable polyclonal population of enforced (AEP.293) and inducible 
(AEP.293GS) AEP-overexpressing cells.  
(B) Left: AEP immunoblot in whole cell lysates using a goat polyclonal anti-human AEP 
antibody (R&D); β-actin served as loading control. Right: Estimation of AEP enzyme 
activity in citrated whole cell lysates using a fluorescent substrate cleavage assay; 
activity in the HRC57 cell line served as reference. Note that AEP expression (as 
estimated by activity) in AEP.293 cells is nearly 2× higher than in SD1 cells.  The 
additional immunoblot band noted between precursor and mature AEP detection bands 
in AEP.293 probably represents an intermediate form of AEP. REH and SupB15 (SB15) 
are non-AEP expressing progenitor-B ALL cells. EV.293 refers to mock-transfected 
controls (AEP insert-free plasmid).  
(C) AEP immunoblot in whole cell lysates with β-actin as loading control. Treatment of 
AEP.293GS cells with the inducing agent, Mifepristone (Mfp, 10nM, 24 hours) strongly 
activates AEP expression. There is minimal basal AEP expression in untreated AEP.293 
cells. Mifepristone treatment has no effect on mock-transfected controls.   
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Figure 4.5 Schematic outline of the mechanism of the dual–plasmid inducible-expression system 
Mifepristone-induced conformational activation of a regulatory chimaeric protein results in transactivation of target gene expression 
as well as autoactivation of the regulatory protein 
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Figure 4.6 Schematic outline of Boyden chamber motility assay work flow 
For optimal confluence, ectopic AEP-overexpressing HEK293 cells were passaged 48 
hours prior to assay. AEP expression was activated in inducible-expressing cells 24 
hours prior to assay (Mifepristone, 10nM). Cells were trypsin-mobilised, reconstituted in 
serum-free DMEM and seeded at a density of 1×105 cells in 8-micron pore (Matrigel-
membrane coated or -uncoated) upper chamber inserts in a 24-well format.  Complete 
growth medium was placed in lower chamber wells to provide a chemotactic gradient. 
Following 24-hour incubations in humidified cell culture incubators, lower chamber cell 
counts were estimated by coulter counting and/or microcopy counts of crystal-violet 
stained cell inserts. Modified AEP non-expressing HEK293 cells served as negative 
controls in assays.  
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Figure 4.7 Schematic outline of Boyden chamber assay cell counts 
Upper panel: Lower chamber cell counts by Trypsin-EDTA mobilisation of adherent cells 
in cell inserts followed by coulter counting; Lower panel: Crystal-violet staining of 
adherent cells on undersurface of cell inserts   
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Figure 4.8 Ectopic overexpression of AEP in HEK293 cells does not enhance 
cell motility 
Summary boxplot representations of lower chamber cell counts (cells/mL) from 24-hour 
Boyden chamber assays in enforced (right) and inducible (left) AEP-overexpressing 
HEK293 cells.  
Left: Summary of 6 experiments. Motility of inducible AEP-expressing HEK293 cells 
(AEP.293GS, mifepristone-treated [Mfp+]) across Matrigel-coated (1:50) 8-micron pore 
inserts did not significantly differ from non-induced and vehicle-treated controls (p=0.07, 
one-way ANOVA).  
Right: Summary of 3 experiments. Enforced AEP-overexpressing HEK293 cells 
(AEP.293) did not migrate more briskly across 8-micron pore cell inserts when compared 
to mock-transfected controls (EV.293) (p=0.96, two–sided unpaired t-test). The PC3 
human prostate carcinoma cell line served as positive control. 
Boxes encompass the interquartile (IQR, 25th-75th percentile) ranges, horizontal bars and 
asterisks within boxes represent median and mean values respectively, whiskers denote 
values 1.5× IQR, outlier values are represented by circles.   
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Figure 4.9 AEP-overexpressing HEK293 cells are minimally motile 
Representative images of crystal violet-methanol stained porous cell inserts from 
Boyden chamber motility assays. In contrast to PC3 prostate cancer cells, AEP-
overexpressing HEK293 cells are not observed on the undersurface of cell inserts.  
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Figure 4.10 AEP-overexpressing HEK293 cells continue to remain relatively 
immotile on extended timepoint Boyden chamber assays  
(A) Coulter counts of enforced AEP-expressing (AEP.293) and mock-transfected 
(EV.293) HEK293 cells at various timepoints following seeding in 6-well plates (1×106 
cells/well, average of 3 wells/timepoint/cell-line). Counts of the two cell lines are 
comparable between 12 and 80 hours of observation (dashed vertical lines, Pearson 
coefficient of determination, r2=0.87; error bars represent standard deviations) (B) Lower 
chamber cell counts (cells/mL) at various timepoints in Boyden chamber assays using 
uncoated 8-micron pore cell inserts. AEP.293 cells continue to remain relatively immotile 
over the 12-80 hour assay timepoints (error bars represent standard deviations).  
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Figure 4.11 The pro-motility role of AEP is cell-context specific and suggests 
requirement of additional co-operating molecules 
Lower chamber cell counts (cells/mL) following 24-hour Boyden chamber motility assays 
of clonal lentivirally-transduced ectopic AEP-overexpressing progenitor-B ALL cell lines 
AEP+REH and AEP+SupB15, across Matrigel-coated (1:10 dilution, ~1mg/mL) 5-micron 
pore cell inserts seeded with 1×105 cells; complete growth medium was placed in the 
lower chamber. Ectopic AEP overexpression in REH cells resulted in ~3.5-fold increase 
in cell motility (p=0.002) that was still ~2.5-fold less than that observed with constitutive 
AEP-overexpressing SD1 cells. In striking contrast, ectopic AEP overexpression in 
SupB15 cells had no effect on motility. Taken together with observations in SD1 cells, 
the findings suggest that the role of AEP as a pro-motility molecule is facilitatory and cell-
context specific, likely dictated by availability of additional pro-motility molecules. 
WT, wild-type REH and SupB15 cells; Mock, cells transduced with insert-free lentivirus; 
asterisks, estimated p-values from two-sided unpaired t-tests; error bars, standard error 
of means; summary of three experiments. Data courtesy of Seema Alexander 
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Table 4.1 Insert and Plasmid Vectors 
 
Material Features 
Insert Full length AEP cDNA (NCBI Reference Sequence 
accession NM_005606.5, Appendix B) 
Kozak sequence ACCATGG 
C-terminal hexa-histidine tag 
Source Vector The pcDNA-DHFR plasmid expression vector with the 
full-length AEP cDNA insert cloned into EcoRV-Not1 
sites (gift from Dr. Colin Watts, University of Dundee, 
Dundee, UK)  
AEP.pGene A/V5-His 
GeneSwitch inducible 
mammalian expression 
plasmid (Invitrogen)  
• AEP cDNA insert cloned in-frame into EcoRI-Not1 
sites 
• Expression regulated by a combination of six GAL4 
Upstream Activating Sequences and the 
Adenovirus E1b TATA sequence 
• Mifepristone-induced expression through 
conformational activation of a hybrid protein, 
GAL4/hPR-LBD/AD (GAL4 DNA binding 
domain/ligand binding domain of the human 
progesterone receptor/p65 activation domain of 
human NFκB) encoded by the co-transfected 
pSwitch plasmid 
• Ampicillin and Zeocin resistance genes for 
transformation and transfection selection 
AEP.pENTR 3C Gateway 
entry plasmid (Invitrogen) 
• AEP cDNA insert cloned in-frame into EcoRI-Not1 
sites  
• Flanking attL1 and attL2 sites for LR recombination 
with a Gateway destination vector 
• Negative selection with the ccdb gene located 
between the recombination sites 
• Kanamycin resistance gene for selection in E. coli 
AEP.pcDNA3.1/nV5-DEST 
Gateway destination 
mammalian expression 
plasmid (Invitrogen) 
 
• AEP cDNA insert following LR recombination with 
the pENTR 3C Gateway entry vector 
• Human cytomegalovirus (CMV) immediate-early 
promoter/enhancer  
• Recombination sites attR1 and attR2 enclosing the 
ccdb gene downstream of the CMV promoter for 
recombinational cloning 
• pUC origin for high copy replication and ampicillin 
resistance gene for selection in E. coli  
• SV40 driven aminoglycoside resistance gene for 
selection of stably transfected cells using Geneticin 
(G-418) 
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Table 4.2: The influence of ectopic AEP overexpression on motility of HEK293 
cells: comparison and contrast with observations of the Scripps group (Ch 2, [24]) 
Similarities 
• In both studies, lipid-based transfection was used to introduce full length AEP 
expression plasmid constructs.  
• The AEP cDNA inserts (reference transcripts Y09652 and NM_005606.5) in both 
instances encode identical protein products 
• Boyden chamber motility assays were performed using eight micron-pore cell 
inserts  
Differences  
• HEK293 cells used in the two studies may not necessarily be identical. Non-
homogeneity is a well recognised phenomenon in widely used experimental cell 
lines such as HeLa and HEK293 and arises as a consequence of genetic drift 
from repeated and extended passages [2, 3]. Cell line authentication would have 
addressed this concern. 
• The Scripps group observed increased motility of a clonal population of stably 
transfected G418-selected (0.4mg/mL) AEP-overexpressing HEK293 cells. Data 
on the intensity of AEP overexpression in the experimental clone is not available. 
By contrast, polyclonal transfected cells were used in this report.  
• The Scripps group’s data on motility of AEP-overexpressing HEK293 cells were 
reported relative to wild type HEK293 cells. Comparison with mock-transfected 
isogenic cells additionally controls for off-target effects of transfection. 
• Lower chamber cell counts in the Scripps study were performed solely by crystal 
violet staining of cell inserts. Inadequate scrape-removal of upper chamber 
contents can potentially represent a source of false-positive error. 
• The Scripps groups also observed increased motility in a tetracycline-regulated 
AEP-expressing HEK293 cell line. Full experimental details are not available. 
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Table 4.3 Experimental limitations of motility assays on ectopic AEP-expressing HEK293 cells 
 
  Rationale Limitation
Choice of 
experimental cell 
line 
HEK293 cells were chosen for their ease of 
transfection. Once established, the first step was 
to perform motility studies in an attempt to 
replicate the findings of the Scripps group and as 
prelude to extended studies such as investigation 
of AEP-interacting molecules. 
Clearly a non-representative cell line.  
AEP's role in cell motility would 
undoubtedly be part of a coordinated 
molecular machinery and is therefore likely 
to be cell-specific, determined by the co-
expression of partner molecules. Creation 
of stable AEP-expressing progenitor-B ALL 
cell lines requires a more onerous lentiviral 
approach and these modified cell lines 
have now been established.  
Clonality A stable polyclonal population of overexpressing 
cells was created principally for experimental 
ease. It was anticipated that the motile phenotype 
in modified cells would manifest even in a 
polyclonal population, especially since native 
HEK293 cells were essentially immotile. Of 
interest, despite the absence of clonal selection, 
AEP overexpression in the Mifepristone-regulated 
system appeared fairly tightly clustered (as 
evidenced by flow cytometry), perhaps as an 
inadvertent  consequence of use of transfection 
selection reagents 
The role of AEP in cell motility would have 
been better clarified by performing motility 
assays on clonal populations of low, 
intermediate and high AEP-expressing 
HEK293 cells (intensity relative to SD1 
AEP expression). Of note, in the 
progenitor-B ALL cell line SupB15, variable 
intensity of AEP expression in engineered 
clones had no influence on cell motility 
relative to wild-type cells (data not shown). 
Experimental 
methodology 
Pore size of upper chamber cell inserts used in 
Boyden chamber assays was maintained at 8 
micron. This is the standard in motility experiments 
on adherent cell lines and was also the pore size 
used in the Scripps group's experiments.  
Boyden chamber assays could have been 
performed using cell inserts with larger 
pore sizes (e.g. 12 micron).  
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5 
AEP and Asparaginase 
 
In contemporary treatment of childhood ALL, both appropriate speed [1] and 
depth (Chapter 1, [22]) of response powerfully influence outcome. Adverse-risk 
genotypes of progenitor-B childhood ALL are characterised by poor early 
treatment response (Chapter 1, [95]) and disease clearance (Chapter 1, [22]). 
Intrinsic lymphoblast chemoresistance probably accounts for this [2, 3] but 
conventional drug-resistance pathways (drug efflux, cell quiescence, acquired 
genetic mutations) have not been implicated (Chapter 1, [111]), [4]. In this 
chapter, a novel mechanism of lymphoblast drug resistance is postulated. 
Lymphoblast lysosomal proteases AEP and Cathepsin B (CTSB) degrade the 
drug L-asparaginase and potentially mediate resistance to this cytotoxic.  
 
 
L-asparaginase 
The protein drug L-asparaginase is a key therapeutic agent in childhood ALL 
(Table 5.1) and a critical component of the 4-drug mainstay of early treatment 
(Figure 5.1). Although still a matter of debate, the therapeutic effect of the drug is 
customarily attributed to extracellular depletion of asparagine (Asn) and selective 
apoptosis of lymphoblasts incapable of de novo Asn synthesis. Both therapeutic 
preparations, E. coli L-asparaginase (ASNase) and Erwinia carotovora L-
asparaginase (Erwinase) are bacterially-derived. The longer circulating half-life of 
ASNase favours use of this preparation in frontline treatment protocols. A major 
treatment limitation is the development of hypersensitivity to these non-native 
proteins. Hypersensitivity occurs with repeated treatment exposures, is clinically 
overt in some cases but is typically characterised by silent neutralising antibodies 
that antagonise drug activity late in therapy.  
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Poor early ASNase activity and speculative role of lymphoblast AEP 
A pilot study of serial serum ASNase activity in children with progenitor B-ALL 
(n=44) (Figure 5.2) during the initial (induction) and later (post-induction) phases 
of treatment indicated that nearly 10% of treated children experienced decline in 
drug activity during the later treatment phase. Although not specifically 
investigated, this observation is consistent with the development of silent drug-
neutralising antibodies. Curiously, despite appropriate dosing, adequate drug 
activity was not obtained in up to a third of patients during the crucial early 
treatment phase. As this stage of treatment also coincides with the period of 
maximal disease burden, it is conceivable that intrinsic lymphoblast-derived 
mechanisms, specifically proteolytic degradation, account for the failure to 
establish adequate ASNase activity during early therapy. In this context, poor 
response to ASNase is also a feature of the AEP-overexpressing adverse-risk 
progenitor-B ALL genotype, Ph+ALL [41]. Together, these observations 
prompted the speculation that proteolytic degradation of ASNase could be 
mediated by AEP in overexpressing lymphoblasts, resulting in inadequate drug 
activity early in therapy. As a vital component of early therapy, suboptimal early 
ASNase activity would plausibly result in unsatisfactory early treatment response 
and eventual poor outcome. 
 
Experimental methods 
This work was supervised by and performed in partnership with Naina Patel (NP). 
The methodology is summarised in Figure 5.3. ASNase digestions, gels and 
immunoblots and synthesis of recombinant wild-type ASNase and variants were 
performed by NP. Experimental planning and analyses were jointly undertaken.   
 
Results 
AEP degrades ASNase  
Purified recombinant human AEP (rhAEP) uniformly degraded all 
pharmacological preparations of ASNase, including a long-acting conjugated 
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version of the drug (PEG-ASNase) (Figure 5.4, Supplementary Figure S5.1). 
By contrast, the therapeutic alternative, Erwinase remained intact.  
 
A combination of AEP and CTSB in lymphoblast cell lysates degrades ASNase 
Whole cell lysates of progenitor-B ALL cell lines and primary samples 
consistently degraded ASNase (Figure 5.5A). In non AEP-expressing REH cells, 
lysate pretreatment with a broad-spectrum cocktail of protease family inhibitors 
(PIC) prevented ASNase degradation. To narrow in on the peptidase family 
responsible for ASNase degradation in REH cells, lysates were serially 
pretreated with individual component inhibitors of PIC (Supplementary Figure 
S5.2); pretreatment with Leupeptin alone was sufficient to prevent ASNase 
degradation, pointing to a papain family cathepsin as the ASNase-degrading 
protease in REH. Cathepsins B, L and H are the commonly implicated cathepsins 
in this peptidase family. Pretreatment of REH lysates with selective inhibitors to 
these enzymes identified Cathepsin B as the responsible protease (Figure 5.5C).  
When extended to AEP-expressing SD1 cells, ASNase degradation was 
prevented only when cell lysates were pretreated with a combination of the 
selective CTSB inhibitor CA-074Me (CTSBi) and the AEP-specific inhibitor 
MV026630 (AEPi) (Figure 5.5B).  
These observations suggest that CTSB is a generic ASNase-degrading protease 
in ALL cells; in AEP-expressing cells, ASNase is additionally degraded by AEP. 
The inference is supported by ASNase digestion-inibition studies in primary 
samples (Figure 5.6, Supplementary Figure S5.3, Appendix D) 
 
Cathepsin B is probably a basal ASNase metabolising enzyme 
Recombinant human CTSB degraded all L-asparaginase preparations, including 
Erwinase (Figure 5.7A, Supplementary Figure S5.1). Microarray analysis of 
CTSB gene expression in a cohort of diagnostic acute childhood leukaemia 
samples indicated near-uniform expression in childhood ALL, suggesting 
constitutive housekeeping expression in this disease (Figure 5.7B). Limited 
analysis of protein expression supported this observation (Figure 5.7C). These 
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additional findings strengthen the assumption that CTSB functions as a basal 
ASNase metabolising enzyme.  
 
Discussion 
Despite acknowledged limitations (Table 5.2), the above in vitro observations 
provide a compelling explanation for the observation of poor early ASNase 
activity in a subset of patients with progenitor-B ALL. AEP in overexpressing 
lymphoblasts potentially accelerates ASNase cleavage resulting in suboptimal 
drug activity during the critical early phase of therapy (Figure 5.8). The fastidious 
cleavage specificity of AEP was exploited to both map cleavage sites (Figure 5.9, 
upper panel) and synthesise variant ASNase recombinants mutated at AEP-
cleaved residues. Sole substitution at the N24 residue was sufficient to render 
ASNase resistant to AEP cleavage (Figure 5.9, lower panel), additionally 
suggesting that AEP cleavage of ASNase is sequential and commences at the 
N24 residue.  
 
There is another facet to these observations that potentially extends the impact of 
lymphoblast AEP expression beyond the early phase of ASNase therapy. 
Cleavage fragments generated by AEP degradation of ASNase retain known B-
cell epitope determinants. Conceivably, these AEP-generated antigenic 
fragments can trigger hypersensitivity responses, resulting in the formation of 
neutralising antibodies and late ASNase inactivation (Figure 5.10). This may 
explain why a proportion of patients (11% in pilot study, Figure 5.2) with 
inadequate ASNase activity during early therapy continue to demonstrate 
unsatisfactory drug activity during later treatment.  
 
As part of the current UK childhood ALL trial protocol, a nationwide prospective 
clinical study is examining association between lymphoblast AEP expression at 
diagnosis and ASNase activity and hypersensitivity. AEP expression will be 
investigated for its significance as an independent predictive (ASNase therapy) 
and prognostic (clinical outcome) biomarker in childhood ALL. If borne out as a 
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predictive marker, AEP-expressing disease would warrant use of alternative 
asparaginases (Erwinase or engineered AEP-resistant ASNase) especially 
during early therapy. If identified as a significant prognostic risk variable, it would 
make a persuasive case for the development of therapeutic small-molecule AEP 
antagonists. In this context, restricted physiological tissue AEP expression and 
functional redundancy would make drug targeting a safe approach.  
 
This work was published [71]. 
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Figure 5.1 E. coli L-asparaginase (ASNase) is a key component of early 
childhood ALL treatment and therefore, a critical determinant of early treatment 
response 
Schematic of fundamental treatment elements in childhood ALL therapy. Although 
treatment duration spans ~2.5 years, the quality of response to the first 1-2 weeks of 
treatment powerfully influences outcome. ASNase is an integral component of early 
chemotherapy and therefore a key determinant of treatment outcome. The long-acting 
polyethylene glycol (PEG)-conjugated version of ASNase is highlighted below.  
CNS, central nervous system; D0-D8, days of treatment; IT, intrathecal therapy; MTX, 
methotrexate; ʻ×ʼ represents day of drug administration 
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Figure 5.2 AEP overexpression in progenitor-B lymphoblasts could possibly account for the early inadequate serum 
ASNase activity observed in a subset of patients  
Serum ASNase activity [68] estimated during the induction and post-induction treatment phases in children with ALL (n=44). The 
observation of low serum ASNase activity during the early induction phase, especially in children with high-risk disease, prompted the 
speculation that AEP overexpressed by lymphoblasts in high-risk disease, could possibly be involved in the enzymatic cleavage and 
inactivation of ASNase, a bacterial protein, during early treatment. Inadequate serum activity noted in nearly 10% of patients in the 
post-induction phase is probably a consequence of formation of neutralising antibodies to ASNase (Data courtesy of Nick Coe, 
University of Salford, Manchester) 
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Figure 5.3 ASNase degradation by lysosomal proteases: schematic outline of experiments  
Investigations are in blue. E. coli L-asparaginase (ASNase) was incubated with (a) purified recombinant preparations of human AEP 
or CTSB and (b) whole cell lysates of ALL cell lines or primary lymphoblasts in acid citrate digests. To identify cellular proteases 
primarily responsible for ASNase degradation, whole cell lysates in some experiments were serially preincubated with selective 
inhibitors of AEP and CTSB as well as with inhibitors of different peptidase families, either singly or in combination. AEP cleavage 
sites were mapped to synthesise recombinant variant ASNases capable of resisting AEP degradation.   
PIC, Protease inhibitor cocktail 
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Figure 5.4 AEP degrades ASNase but not Erwinase 
Coomassie Blue stained SDS-PAGE of E. coli (ASNase) and E. carotovora (Erwinase) L-
asparaginase (4μg) incubated with (+) and without (-) activated purified recombinant 
human AEP (rhAEP, 0.4μg) in citrate buffer digests (pH 4.5, 37°C, 3 hours). AEP 
degrades all pharmacological preparations of ASNase, including a high molecular weight 
polyethylene glycol (PEG)-conjugated form (note distinct lower molecular weight band 
with AEP+ digests), resulting in ~50% decline in ASNase activity (Supplementary 
Figure S5.1). No similar degradation is observed when Erwinase is incubated with AEP.  
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Figure 5.5 ASNase is degraded by the lymphoblast lysosomal proteases, AEP 
and CTSB  
(A) ASNase immunoblot of digests of purified ASNase (2μg) incubated with B-lineage 
lymphoblast cell line lysates (citrate buffer, pH 4.5, 37°C, 12-16 hours). ASNase 
degradation is observed following incubation with all cell lysates (horizontal arrow, subtle 
in the case of SupB15 cell lysate) but is most prominent in the AEP-expressing cell lines, 
SD1 and HRC57 (inset, AEP immunoblot)  
(B) ASNase immunoblots of ASNase digests incubated with SD1 cell line lysates pre-
treated with combinations of protease inhibitors, including AEPi (MV026630, selective 
AEP inhibitor), PIC (protease inhibitor cocktail containing broad-spectrum inhibitors of 
cysteine-, aspartate-, serine- and amino-peptidases), E-64 and Leupeptin (papain family 
cathepsin inhibitors, also components of PIC) and CTSBi (CA074-Me, selective 
cathepsin B [CTSB] inhibitor). Controls included untreated SD1 cell lysate and reagent 
vehicle (DMSO). ASNase degradation was completely prevented when SD1 cell lysates 
were pre-treated with a combination of [AEPi + PIC], [AEPi + Leupeptin/E-64] and [AEPi 
+ CTSBi]. Dotted vertical lines demarcate different immunoblots 
(C) ASNase immunoblots of ASNase digests incubated with the non-AEP expressing 
REH cell line lysate pretreated with inhibitors as above. Pre-treatment with CTSBi alone 
prevented ASNase degradation 
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Figure 5.6 ASNase is similarly degraded by AEP and CTSB in primary 
progenitor-B lymphoblasts 
Composite of AEP, CTSB and β-actin loading control immunoblots (A) and AEP enzyme 
activity (relative to the HRC57 cell line) (B) in selected primary whole cell lysates (UPN 3, 
8-10). UPN3 and UPN9 lymphoblasts overexpress AEP; CTSB expression is higher in 
UPN3.  UPN8 and UPN10 lymphoblasts solely express CTSB. These expression 
patterns determine ASNase digestion profiles (C). CTSBi pre-treatment alone prevents 
ASNase degradation by UPN8 and UPN10 lysates, AEPi pretreatment alone is sufficient 
in the case of UPN3 digests and a combination of AEPi and CTSBi is required to prevent 
ASNase degradation in UPN8 digests. 
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Figure 5.7 CTSB probably basally degrades asparaginases 
(A) Coomassie stained SDS-PAGE of digests of Erwinase and various preparations of 
ASNase incubated with (+) or without (-) recombinant purified human CTSB (0.5μg, 
citrate buffer pH 4.5, 37°C, 3 hours). CTSB degrades all asparaginases, including 
Erwinase.  
(B) Boxplot representation of microarray analyses of CTSB transcript expression in acute 
childhood leukaemias (n=120). Near-uniform expression across all categories of acute 
leukaemia suggests a housekeeping role for CTSB in asparaginase metabolism. (Boxes 
encompass the interquartile [IQR, 25th-75th percentile] ranges, horizontal bars within 
boxes represent median values, ʻ+ʼ values indicate means, whiskers denote values 1.5× 
IQR and outlier values are represented by circles [≤3× IQR] and asterisks [>3× IQR]). 
Pre-B, progenitor-B ALL; T-ALL, progenitor T-ALL 
(C) CTSB immunoblot of primary progenitor-B ALL whole cell lysates UPN1-12. With the 
exception of UPN12, active CTSB protein is detected in all primary samples, suggesting 
constitutive expression in ALL. SB15, SupB15 cell line 
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Figure 5.8 AEP derived from overexpressing high-risk progenitor-B lymphoblasts 
accelerates degradation of ASNase and potentially contributes to inadequate 
drug activity during the early treatment phase of childhood ALL 
Cartoon summary of in vitro observations and interpretations. CTSB basally degrades 
ASNase. AEP, expressed by high-risk progenitor B lymphoblasts, accelerates ASNase 
degradation.  
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Figure 5.9 Substitution of the N24 residue alone is sufficient to generate an 
ASNase variant resistant to AEP  
Upper panel: AEP cleavage sites (red) mapped by N-terminal Edman sequencing of 
SDS-PAGE-resolved AEP-digested ASNase (Aberdeen Proteomics). AEP cleaves 
ASNase at the carboxyl-end of three amino acid residues - N24, D124 and N143. This 
selective cleavage specificity is characteristic of AEP. Lower panel: ASNase immunoblot 
of digests of native and variant recombinant ASNase proteins incubated with (+) and 
without (-) activated purified recombinant human AEP (rhAEP, 0.4μg, citrate buffer pH 
4.5, 37°C, 3 hours). Amino acid substitution at the N24 cleavage site is sufficient to 
render ASNase resistant to AEP degradation, suggesting that AEP cleavage is initiated 
at this site. Modifying the conserved D124 ASNase residue abrogates protein expression. 
N, asparagine residue; D, aspartate residue; G, glycine residue 
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Figure 5.10 Retention of known sensitising epitopes of ASNase in AEP-cleaved 
fragments can potentially trigger generation of neutralising anti-ASNase 
antibodies, leading to late failure of ASNase treatment.   
AEP-cleaved ASNase fragments retain known sensitising epitopes (upper panel, 
underlined blue, [69]). These antigenic fragments potentially trigger formation of 
neutralising ASNase antibodies (lower panel), resulting in inadequate ASNase activity 
late in therapy, long after clearance of lymphoblasts (ʻlate indirect ASNase activationʼ) 
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Table 5.1 E.coli L-Asparaginase (ASNase): a synopsis  
Aspects  Comments Key references 
Mechanism of action Hydrolysis of amide bonds of asparagine and to a lesser extent, glutamine, resulting 
in extracellular depletion of these amino acids 
[5], [6], [7] 
 Lymphoblasts are considered asparagine auxotrophs, lacking the capacity to 
synthesise asparagine de novo; asparagine deprivation triggers the amino-acid 
deprivation response, resulting in inhibition of mTORC1 signalling and triggering of 
apoptosis. At higher doses, glutamine deprivation augments cytotoxicity. Normal cells 
retain the ability to upregulate asparagine synthetase (ASNS) and generate 
asparagine de novo 
[8], [9], [10] 
 Conformational change in intracellular proteins, triggering the unfolded protein 
response and eventual cell death 
[11] 
Structure-function 
relationship 
Active molecule is a homotetramer or a dimer of homodimers formed of 330 amino 
acid 36 kDa subunits. Assembly as a tetramer creates a substrate pocket containing 
active catalytic sites for substrate nucleophilic attack; threonine at positions 12 (T12) 
and 89 (T89) are the principal active residues. A surface loop delimited by residues 
T12 and tyrosine 25 (Y25) functions as a substrate clamp for the active site   
http://tinyurl.com/ASNa
se-model (last 
accessed, 8 Sep 2010) 
Initial drug development ASNase activity in guinea pig serum inhibited growth of the 6C3HED Gardner murine 
lymphoma cell line 
[12], [13],  [14], [15] 
 Isolation and purification of Type II ASNase from E.coli anaerobic cultures  [16] 
Early results of therapy First reports of unsustained remissions (median 122 days) when used as single agent 
in untreated or relapsed childhood ALL 
[17] 
 Maximal efficacy in paediatric lymphoid malignancies; less impressive results in 
treating paediatric solid tumours; both intravenous and intramuscular routes of  
administration were effective; no advantage with intrathecal therapy  
[18] 
 Efficacy in combination with Vincristine and steroid for advanced or relapsed disease [19], [20], [21] 
 Better responses with intensification of ASNase therapy, first in relapsed disease, 
then de novo disease 
[22], [23] 
Importance in ALL therapy Key agent in both induction and the post-induction intensification components of 
therapy  
[24] 
 Early response to ASNase of prognostic significance and intensification of therapy  
associated with better outcomes, both indicating a key role for ASNase in ALL 
therapy 
[25], [26] 
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 Intensified ASNase therapy permitted safe dose reductions of other treatment 
elements associated with adverse long-term complications (e.g. anthracyclines) 
Chapter 1, [56] 
 Sustained asparagine depletion consequent to intensified ASNase dosing is key to 
efficacy; thus using an equipotent ASNase preparation with a shorter half-life yields 
an inferior outcome 
[27], [28] 
 Timed sequence of antimetabolite followed by ASNase (the Capizzi schedule) is a 
vital component of augmented post-induction intensification in high-risk disease 
Chapter 1, [76];  [29] 
 ASNase is particularly effective in the ETV6-RUNX1 genotype (20-25% of childhood 
ALL) 
[30] 
ASNase resistance 
Intrinsic mechanism 
Lymphoblast ASNS 
expression  
Lymphoblast upregulation of ASNS enables de novo synthesis of asparagine. 
Supporting observations from murine lymphoid and  unmanipulated human leukaemic 
cell lines, human leukaemic cell lines manipulated to inhibit or overexpress ASNS, 
global gene expression studies and from ASNS transcript expression in primary non-
ETV6-RUNX1 genotype lymphoblasts 
[31], [32], [33], [34], 
[35], [36], [37] 
 Discordant observations from the exquisitively ASNase-sensitive but ASNS-
expressing ETV6-RUNX1 genotype lymphoblasts, suggesting alternate mechanisms 
of ASNase cytotoxicity 
[37], [38], [39], [40] 
Other T-lineage and Philadelphia-chromosome positive lymphoblasts are intrinsically less 
sensitive to ASNase; the mechanisms are unclear   
[41] 
Extrinsic mechanisms Exogenous asparagine supplied by niche stromal cells  Chapter 1, [126] 
 Antibody-mediated accelerated clearance of bacterial protein, often clinically silent 
but sometimes associated with overt hypersensitivity (up to 60% incidence in high-
risk patients treated with multiple ASNase doses) 
[42], [43] 
Alternative preparations 
Erwinia carotovora ASNase Equipotent in effecting asparagine depletion but has a considerably shorter half-life 
(half that of E.coli ASNase, 0.65 v 1.28 days), requiring more frequent dosing. Useful 
E.coli ASNase substitute as does not cross-react with neutralising antibodies; also 
less immunogenic. Established role in relapsed disease; a longer-acting PEG 
preparation holds promise 
[44], [45], [46], [47], 
[48-49] 
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PEG-ASNase E.coli ASNase covalently conjugated to monomethoxypolyethyleneglycol (PEG). 
Extended half-life (~6 days) resulting in sustained activity and asparagine depletion; 
lower immunogenicity but cross-reacts with antibodies to native E.coli ASNase. 
Neutralising anti-PEG antibodies may also develop.  
[44], [50], [51], [52] 
Complications Clinical hypersensitivity (10-20%), coagulopathy with risk of cerebral venous 
thrombosis (5%), pancreatitis (5-15%), hepatotoxicity (glutaminase activity), non-
thrombotic encephalopathy and metabolic abnormalities (glucose intolerance, 
hypertriglyceridaemia); by contrast, myelosuppression is not a major limiting adverse 
effect  
[53], [54], [55], [56], 
[57] 
Unresolved issues 
Pharmacokinetic - 
pharmacodynamic 
correlations 
The threshold cytotoxic dose of ASNase [58] 
 The importance of monitoring ASNase activity as opposed to asparagine levels and 
the clinical utility of using levels to prospectively inform therapy decisions 
[59], [60] 
  The importance of achieving asparagine depletion in the central nervous system as 
well as the need to monitor the same 
[51], [61], [62] 
 The relation between high ASNase activity and toxicity and the optimal route of 
administration (intravenous v intramuscular) 
[63], [64] 
 Mechanism of drug elimination - probably by the reticuloendothelial system (which 
may account for the very high liver tissue concentration, presumably localised to liver 
macrophages) 
[65], [66], [67] 
 
124 
Chapter 5 TABLES 
 
Table 5.2 ASNase degradation by lysosomal proteases - experimental limitations 
 
Limitation  Comment
In vivo relevance The postulated role of AEP in accelerating early ASNase degradation and augmenting the risk of ASNase 
hypersensitivity is based solely on in vitro observations. An ongoing study, part of the current frontline 
childhood ALL trial, is prospectively examining associations between lymphoblast AEP expression and serum 
ASNase activity, submicroscopic disease clearance and risk of serological and clinical ASNase 
hypersenstivity. Multivariable analysis will be performed to determine the independent predictive and 
prognostic significance of lymphoblast AEP expression.  
Degradation of PEG-
conjugated ASNase  
All in vitro observations examined the degradation of unconjugated ASNase. The conjugated version, PEG-
ASNase is increasingly used in contemporary therapy. Although AEP appeared to similarly degrade PEG-
ASNase, additional experiments examining the extent of loss of activity or potential alteration in the cleavage 
profile as a result of PEG conjugation, were not performed    
Extracellular release of 
active AEP  
Robust direct evidence of this has yet to be adduced. Indirect evidence comes from in vitro observations of the 
Scripps group (liberation of cell-permeable doxorubicin from a cell-impermeable doxorubicin prodrug 
conjugated to an AEP-specific substrate). Limited direct evidence is available from AEP immunoblots of 
human bone marrow plasma (Chapter 2, [40]). Although not directly investigated, the size of the ASNase 
macromolecule probably precludes endocytic uptake and makes the alternative possibility, that of intracellular 
lysosomal degradation, less likely.  
ASNase degradation and 
progenitor-T ALL  
Relative resistance to ASNase has been observed in progenitor-T ALL blasts [41]. In vitro investigations did 
not examine the role of lysosomal proteases in mediating this resistance.  
Erwinase Although the primary focus of investigations was to examine ASNase degradation, similar investigations of the 
alternative asparaginase  Erwinase, would have been additionally informative, especially since Erwinase is 
used as a therapeutic substitute for ASNase 
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Additional lines of investigation 
Expression of AEP by tumour-associated macrophages (TAMs) in 
paediatric solid cancers 
Experiments performed with Hany Ariffin, University Malaya, Malaysia  
AEP expression in a spectrum of paediatric solid cancers was investigated using 
tissue immunohistochemistry (n=57). Stromal AEP expression was a feature in 
several tumours (~75%) and was localised to tumour-associated macrophages 
(TAMs) (Figure 6.1, Figure 6.2).  
TAMs comprise the inflammatory component of the tumour stroma. Several in 
vitro studies and clinical observations suggest that TAMs promote tumour 
progression and are associated with adverse prognosis. These macrophages are 
similar to the M2-polarised macrophages that participate in physiological wound 
repair. By establishing paracrine signalling loops with tumour cells, TAMs are 
believed to facilitate tumour progression through mechanisms that include matrix 
remodelling, angiogenesis and suppression of tumour-directed adaptive immune 
responses (for comprehensive reviews, [1], [2]).  
AEP expressed by TAMs presumably has a role in both matrix degradation and 
paracrine tumour signalling. In this context, a DNA vaccine strategy targeting 
AEP-expressing TAMs in experimental models strikingly protected against fatal 
tumour challenge, tumour dissemination and angiogenesis (Chapter 2, [67]).  
Details of materials, immunohistology protocols and experimental optimisation-
validation procedures are provided in the relevant sections in the Methods 
chapter.   
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Design of an equipotent AEP-resistant E. coli L-asparaginase 
In collaboration with Marc Offman, Marcin Krol and Paul Bates, Biomolecular 
modeling laboratory, CRUK London Research Institute, London  
Amino acid substitution at the asparagine 24 (N24) residue was sufficient to 
prevent proteolytic cleavage of E. coli L-asparagine (ASNase) by AEP. Although 
replacement at this site did not disrupt the tetramer configuration of the protein 
necessary for function, the substituting glycine residue resulted in a variant 
protein (N24G) with considerably diminished enzymatic (asparagine deamidation) 
activity. Subsequent biomolecular modelling studies suggest a critical role for the 
N24 residue in determining enzyme activity. The residue forms part of a surface 
lid-loop sequence that functions as a substrate clamp. This sequence is delimited 
by the catalytic residues, T12 (threonine) and Y25 (tyrosine). The N24 residue 
participates in a local hydrogen bond network that stabilises the catalytic residues, 
maintains appropriate orientation of catalytic residue side chains towards 
substrate nucleophilic attack and regulates the flexibility of the lid-loop (and thus, 
substrate lock) (Figure 6.3). Substitution with an alanine residue at 24 (N24A 
ASNase) recapitulates these hydrogen-bond arrangements, allowing 
preservation of activity while resisting AEP cleavage. Additional substitution at 
the monomer-monomer interface of the ASNase tetramer (Arginine 195 residue) 
was predicted to optimally decrease undesirable glutaminase activity of the 
protein. Enzyme activity and cytotoxicity assays confirm these predictions 
(Figure 6.4).   
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Figure 6.1 Stromal expression of AEP in paediatric solid cancers is localised to tumour-associated macrophages. 
Left panel: AEP immunohistology, paraffin section, poorly differentiated neuroblastoma. Distinct stromal staining (brown) is noted 
(scale bar, 50μ). Right panel: Dual immunohistofluorescence staining for AEP (green) and the macrophage marker, CD68 (red) in 
glioblastoma multiforme (high grade anaplastic glioma). Sections were deparaffinised, rehydrated, heat-treated for epitope retrieval, 
and serially layered with primary and fluorophore-labelled secondary antibodies. Fluorescence colocalisation (yellow) localises AEP 
expression to stromal tumour-associated macrophages (scale bar, 10μ). Images were acquired using an Olympus BX51 microscope 
equipped with a Photometrics CoolSnap HQ CCD camera operated by the Metamorph advanced imaging software.   
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Figure 6.2 Magnified view of AEP expression in a Tumour-associated macrophage 
Photomicrographs of dual-antigen immunohistofluorescence staining of a glioblastoma multiforme (anaplastic high-grade glioma) 
paraffin tissue section. CD68 is a human pan-macrophage/monocyte marker. Note the characteristic coarse vesicular staining of AEP.  
Images were acquired using an Olympus BX51 microscope equipped with a Photometrics CoolSnap HQ CCD camera operated by 
the Metamorph advanced imaging software.  100?/1.35NA Oil immersion, 10μ scale bar. 
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Figure 6.3 Cartoon representation of the hydrogen bond network that surrounds 
the ASNase lid-loop sequence 
The N24 residue is part of a lid-loop sequence that includes the catalytic residues T12 
and Y25. The residue participates in a local hydrogen bond network (dotted lines) that 
also involves neighbouring residues D281 and E283. The hydrogen bond interaction 
determines flexibility of the lid-loop as substrate clamp, stabilises the catalytic residues 
and maintains the appropriate nucleophile attack orientation of the T12 hydroxyl side 
chain.  
Alphabet codes for amino acid residues: D, aspartate; E, glutamate; N, asparagine; T, 
threonine; Y, tyrosine. AS, active substrate docking site of ASNase formed at the 
monomer-monomer interface of the homotetramer molecule 
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Figure 6.4 Computational modelling enables rational design of a potential next-generation ASNase molecule with 
equivalent efficacy, potentially longer in vivo activity and potentially reduced toxicity 
Purified recombinant AEP-resistant [asparagine (N) 24 substituted] ASNase variants exhibit varying asparagine and glutamine 
hydrolysis activities relative to wild type (WT) recombinant. Compounds were tested in cytotoxicity assays using the ASNase-
sensitive ALL cell line, SupB15; half-maximal inhibitory concentrations (IC50, IU/mL) are reported relative to WT ASNase.  Near-
complete abolition of glutaminase activity also results in diminished cytototoxic efficacy (N24A|Y250L).  The N24A|R195S variant with 
attenuated glutaminase activity retains asparaginase activity and demonstrates cytotoxicity equivalent to WT. This variant is therefore 
a promising next-generation ASNase candidate, with anticipated longer half-life in AEP-expressing disease and potential for reduced 
toxicity (lower glutaminase activity).   
WT, wild type; N24G, glycine at position 24; N24A, alanine at position 24; N24A|R195S, alanine at position 24, serine instead of 
arginine at position 195 adjacent to the monomer-monomer interface of the ASNase tetramer; N24A|Y250L, alanine at position 24, 
tyrosine replaced by leucine at position 250 adjacent to the monomer-monomer interface of the tetramer. Results are reported 
relative to purified recombinant WT (horizontal dashed line); N24G was not tested in cytotoxicity assays. Similar results were 
obtained with ASNase-resistant (REH) and intermediate-sensitive (MV4:11) leukaemic cell lines.  
With thanks to Naina Patel (synthesis of ASNase recombinants and asparagine hydrolysis assay), Protein Production Laboratory, 
University of York (recombinant purification) and Jizhong Liu (cytotoxicity assays); for glutaminase activity assay methodology, see 
Supplementary Table S6.1  
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Summary and Ongoing Studies 
Summary 
Microarray studies identified overexpression of the lysosomal protease AEP as a 
candidate biomarker of the adverse-risk phenotype in progenitor-B ALL. 
Validation studies performed in the discovery cohort confirmed AEP transcript 
overexpression; limited sample availability precluded conclusive demonstration of 
concurrent protein overexpression.  Microscopy studies, largely in cell lines, 
indicated a heterogeneous pattern of intracellular AEP expression and aberrant 
localisation in peripheral endolysosomal macrovesicles. Cell line observations 
additionally suggested constitutive shedding of precursor AEP protein in 
microparticles, which together with the microscopy findings, suggest aberrant 
vesicle trafficking as a feature of ALL pathobiology. Functional studies 
investigated the role of AEP as a pro-motility molecule and as a mediator of 
lymphoblast resistance to the key anti-leukaemic drug, L-asparaginase. Contrary 
to published reports, enforced and induced ectopic overexpression in human 
embryonic kidney fibroblasts was not accompanied by enhanced motility. 
Discordant motility phenotypes in constitutive and ectopic AEP-overexpressing 
progenitor-B ALL cells suggest that AEP’s pro-motility role is cell context-specific, 
requiring concomitant expression of other pro-motility molecules. In vitro 
observations suggest that accelerated degradation of E. coli–derived L-
asparaginase (ASNase) by AEP-overexpressing lymphoblasts provides a 
plausible explanation for poor early plasma ASNase activity observed in some 
clinical samples. Additionally, proteolytic degradation by AEP can potentially 
trigger ASNase hypersensitivity and formation of ASNase-neutralising antibodies, 
resulting in sustained treatment failure with this vital drug. AEP expression is 
currently being evaluated as part of a prospective UK-wide biomarker study of 
treatment failure (ASNase activity and hypersensitivity, submicroscopic disease 
clearance kinetics) in childhood ALL. A summary of the work is outlined in Figure 
7.1.  
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Additional studies  
This work is best viewed within the framework of ongoing research activities in 
the Children’s Cancer Group. The overarching research goal is to improve 
outcomes in children with adverse-risk childhood ALL. The group leads and 
participates in international clinical trials investigating new treatments in this 
group of patients. In the laboratory, work is progressing on several interlinked 
fronts to unravel mechanisms leading to treatment failure (Figure 7.2). To avoid 
reductionism, the candidate molecule AEP has been used as a lead-in to wider 
investigation of putative adverse-risk molecular and cellular phenotypes. Here, 
the AEP-expressing Ph+ ALL progenitor-B ALL cell line, SD1 has proven to be a 
particularly informative disease model. Candidate adverse-risk markers from 
discovery proteomics in SD1 cells have already been observed to be over-
represented in early studies of high-risk clinical samples. Perturbed vesicle 
homeostasis emerges as a recurring theme in studies on SD1 cells and detailed 
investigations of aberrant vesicle biology are proposed (Figure 7.3). In 
undertaking these studies, the major drawback of cell line-derived information is 
well-recognised and is being actively addressed by attempting to corroborate all 
observations in clinical material. The ongoing national AEP biomarker study in 
childhood ALL represents one such endeavour to prospectively validate in vitro 
observations. To enable implementation of this study, a national biospecimen 
repository has been established (Centre for Integrated Genomic Medical 
Research, University of Manchester) to receive, fractionate and store plasma, 
lysates and cells from clinical samples. Global microarray technologies have 
been applied to interrogate adverse-risk determinants in clinical samples from 
patients treated on the European Phase III trial of Imatinib mesylate in Ph+ ALL 
(EsPhALL). Candidate markers shall be investigated in other high-risk ALL 
categories to establish their broad relevance as adverse-risk determinants. The 
longer term objective is to juxtapose these findings with results from in vitro 
studies to discover conserved molecular and cellular determinants of the 
adverse-risk phenotype suitable for therapeutic targeting.  
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Figure 7.1 Summary of experimental observations  
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Figure 7.2 Broad schematic outline of ongoing laboratory investigations in the Children?s Cancer Group.  
Chapter 7 FIGURES 
137 
Figure 7.3 Microvesicle biology: schematic outline of proposed experimental studies 
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Chapter 8 Section 1  Non-reagent material  
Section 8.1 Material - non-reagent components  
 
GENERAL  
(a) Class II laminar flow hood  
(b) Refrigerated centrifuges for 15-50mL (swinging bucket) and 0.5-2.0mL 
volumes (Eppendorf) 
(c) Tissue culture incubators (37°C, humidified 5% CO2; Binder CB series) 
(d) Thermal cyclers (Biorad) 
(e) The Nanodrop ND-1000 UV-Vis spectrophotometer for DNA and RNA 
quantitation in microliter volumes 
(f) Microplate reader - FLUOstar Omega (BMG Labtech, Aylesbury, UK) for UV 
absorbance spectrometry and fluorescence intensity readout  
(g) Others  
Pipettes (0.1-10µL, 2-20µL, 20-200µL, 200-100µL, Gilson) 
Sterile pipette tips (filtered and non-filtered)  
Serological pipettes (5mL, 10mL, 25mL volumes) and Pasteur pipettes 
Electronic pipettors  
Sterile polypropylene microcentrifuge tubes (0.5-2.0mL) 
Sterile polypropylene conical centrifuge tubes (15-50mL) (BD, Sarstedt) 
Cryotubes – 1.8mL, internal thread screw-cap tubes (Nunc) 
Sterile flat-bottomed polystyrene multiwell plates (6-96 well) (BD) 
Sterile vented tissue culture flasks (25, 75, 175 cm2, Corning) 
Refrigerators (2-8°C, Liebherr) and freezers (-20°C, 80°C; Sanyo) 
Liquid nitrogen vessel 
Laboratory ice machine (Scotsman), dry-ice storage vessel, ice buckets  
Racks for microcentrifuge and conical centrifuge tubes 
Others – vortex mixers, 700W microwave, dry heat blocks, water bath, 
Neubauer haemocytometer cell counting chamber 
  
DNA CLONING 
(a) Incubators (37°C) – for agar plates and liquid cultures (agitated, aerobic) 
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(b) The Sorvall RC 5B Superspeed centrifuge for large-scale plasmid purification 
(c) Horizontal gel electrophoresis unit with power supply pack  
(d) UV gel imaging unit (Syngene, Cambridge, UK) 
(e) 30mL and 250mL polypropylene screw-cap plasmid fixed-angle rotor 
centrifuge tubes for large-scale plasmid DNA isolation 
 
RNA ISOLATION, REVERSE TRANSCRIPTION, QUANTITATION 
(a) Optical 384 well reaction plate with optical adhesive film (Applied Biosystems) 
(b) The epMotion 5070 automated pipetting system (Eppendorf) 
(c) ABI Prism 7900HT Fast Real Time PCR system for 96 and 384 well plates, 
operated by the Sequence Detection System package (Applied Biosystems) 
 
IMMUNOBLOTTING 
(a) Protein electrophoresis unit – including gel casting stand and frame, casting 
plates (short and 1.0mm integrated spacer glass plates), 10-well 1.0mm gel 
combs, electrophoresis tank and sample loading guide (MiniProtean3, Biorad) 
(b) Gel loading tips (2-20µL, Anachem) 
(c) Semi-dry protein blot transfer unit (Biorad) 
(d) PVDF protein blotting membranes (Immobilon P, Millipore; 7cm × 10cm) 
(e) High current power supply unit (400mA, Biorad) 
(f) Extra-thick blot paper for protein transfer sandwich (Biorad) 
(g) Rocking platform unit  
(h) Atraumatic non-serrated forceps for membrane handling (Millipore) 
(i) Imaging films (Kodak MXB blue-sensitive X-ray films, 30 × 40cm) 
(j) X-ray film cassette 
(k) Film developer station (dark room) 
(l) Others – square petri dishes for immunoblotting (BD), plastic sheet envelope 
for PVDF membrane, membrane roller, walk-in cold-room for overnight and 
extended 4°C antibody incubations 
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MOTILITY ASSAYS 
(a) 8-micron pore transparent polyethylene terephthalate cell-culture inserts for 
24-well plates (BD Falcon) 
(b) Particle Counters 
The CASY-DT cell counter (Innovatis AG, Reutlinger, Germany) 
The Z1 single-threshold Coulter counter (Beckman Coulter) 
(c) Others – Fine pointed forceps with curved head to handle cell culture inserts,  
maintained sterile by immersion in absolute ethanol; cotton-buds to scrape-
remove cells from growth surface of inserts; microscope eyepiece square-grid 
graticule for cell counting 
 
IMMUNOSTAINING 
(a) Staining tray  
(b) Microscope slides (1mm thick, 76mm × 26mm; Menzel-Glaser) 
(c) Glass coverslips (No. 1.5, rectangular 22mm × 50mm, square 22mm × 22mm) 
(d) Shandon Cytospin III cytocentrifuge 
(e) Cytospin funnels, filter papers and stainless-steel clips (Shandon) 
(f) Hydrophobic marker pen (Vector laboratories) 
(g) Others – 35mm petri-dish with water (to maintain humidity), slide tray, black 
cover sheet for light protection 
 
IMMUNOHISTOCHEMISTRY  
(a) Formalin-fixed paraffin-embedded tissue samples (University Malaya) 
(b) Five-micron tissue sections on poly-L-lysine or silane-treated microscope 
slides 
(c) Stainless steel slide rack 
(d) Pressure cooker, maximum setting 125°C  
(e) Staining troughs 
(f) Staining tray with lid  
(g) Hydrophobic marker pen 
(h) Automated glass coverslipper (CV5030, Leica Microsystems) 
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(i) The automated MIRAX digital histology platform (Zeiss) 
 
MICROSCOPES 
(a) The Nikon Eclipse TS100 inverted trinocular microscope for phase contrast 
microscopy with 10×/0.30NA PlanFluor and 20×/0.40NA Ph1 phase objectives 
and the DS-Fi1 camera supported by the DS-L2 software (Nikon) 
 
(b) The Olympus BX51 upright microscope with fluorescence filter cubes, 
10×/0.3NA UPlanFL, 20×/0.5NA UPlanFL N, 40×/0.75 UPlanFL N, 40× 
Oil/1.30 UPlanFL N and 100× Oil/1.35NA UPlanFL N objectives (Olympus) 
and the Photometrics CoolSNAP HQ CCD camera (Molecular Devices) 
operated by the Metamorph Advanced Imaging system (Molecular Devices) 
 
(c) The Zeiss Axiovert 200M low-light system with Sedat fluorescence filter 
wheels, the Optovar module, 60× Oil/1.40 NA PlanApo (Olympus) and 100× 
Oil/1.45 NA AlphaPlanFluar (Zeiss) objectives and the Photometrics Cascade 
II:1024 EMCCD (electron-multiplying charge couple device) camera 
(Molecular Devices) operated by the Metamorph Advanced Imaging system 
(Molecular Devices) 
 
ANALYSIS PACKAGES 
(a) Lasergene suite of applications for genome analysis (DNAStar, v7.2) 
(b) Sequence Detection System for data analysis on the ABI Prism 7900HT 
quantitative real-time instrument (SDS v2.0, Applied Biosystems)  
(c) Adobe Photoshop (Creative Suite 3) image processing software (San Jose, 
CA, USA) 
(d) Statistical Package for Social Sciences (SPSS) software application for 
Windows (v16.0, now part of IBM) and the Microsoft Excel spreadsheet 
application (Microsoft Windows XP Professional, 2001) 
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 MICROVESICLE ISOLATION FROM CELL-FREE SUPERNATANT 
(a) Thin-walled 36mL polyallomer ultracentrifuge tubes (Beckman Coulter) 
(b) The Sorvall Discovery M120 SE refrigerated ultracentrifuge with the AH-629 
swinging rotor equipped with 36mL aluminium buckets (DuPont Instruments) 
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Section 8.2 Reagents, Buffers and Reaction Mixes 
 
Unless specified, all chemicals were sourced from Sigma-Aldrich. 
 
GENERAL LAB REAGENTS (CENTRAL LAB SERVICES, PATERSON INSTITUTE) 
1 Sterile Phosphate buffered saline (calcium, magnesium free) 
One Dulbecco ‘A’ tablet* dissolved in 100mL distilled water (pH 7.4) 
Sodium Chloride 137mM   0.8g  
 Potassium Chloride 2.7mM  0.2g 
Na2HPO4** 8mM    1.15g  
KH2PO4*** 1.5mM   0.2g 
* Oxoid Ltd., part of Thermo-Fisher Scientific 
** Disodium hydrogen phosphate ***Potassium dihydrogen phosphate 
 
Sterilised by autoclaving (121°C, 20 minutes)  
  
2 Sterile deionised water 
Two-step purification (ELGA Optima 15 followed by ELGA Purelab Ultra 
purification systems) to generate ultra-pure deionised water (18.2 mohm.cm 
resistivity) sterilised by either UV- or autoclave- (121°C, 20 minutes) 
treatment; dispensed in borosilicate bottles 
 
3 Luria-Bertani agar plates and liquid medium 
 
4 Virkon solution, 1%, for overnight disinfection of biohazardous waste 
 
 
DNA CLONING  
 
1  Tris Borate EDTA (TBE) buffer for agarose gel electrophoresis 
 For a 1L 10× stock solution,  
 Tris base 0.89M   108g 
 Boric acid 0.89M     55g 
 Tetrasodium EDTA 0.02M   9.3g  
 
2  Agarose for horizontal gel electrophoresis 
Dedicated preparation area, ethidium bromide alert 
 For a 0.8% agarose gel preparation, 
 Agarose*     0.8g 
 TBE buffer to    100mL 
*Ultrapure standard melting temperature agarose (Invitrogen) 
 
Cover with thin plastic film and dissolve by heating in a 700W microwave 
(medium setting, 3min 40sec) 
Cool, add ethidium bromide (10mg/mL) 1µL and pour on to a gel platform 
with sealed-off walls. Place gel comb and allow to set.   
144 
Chapter 8 Section 2                                                Reagents, Buffers and Reaction Mixes 
3 Tris-EDTA buffer, pH 8.0 
 For a 100mL 10× solution, 
 Tris base 0.1M    1.21g 
 Disodium EDTA  0.01M  0.37g 
 Adjust pH to 8.0 with 5N hydrochloric acid 
 
4 Antibiotics for selection 
Ampicillin 50mg/mL in sterile water 
Kanamycin 50µg/mL in sterile water,  
Syringe-filtered (0.22 micron) and stored in aliquots at -20°C 
 
5 Small-scale plasmid DNA purification kit (Wizard Plus SV, Promega) 
 Components include: 
 Resuspension solution (Tris-EDTA with RNase A) 
 Cell lysis solution (sodium hydroxide with SDS) 
 Proprietary DNA-binding silica membrane minicolumns 
 Neutralisation solution (guanidine hydrochloride, potassium acetate) 
 Column wash solution (ethanol, potassium acetate, Tris-EDTA) 
 Nuclease-free water for elution of bound DNA  
 
6 Large-scale endotoxin-free plasmid DNA purification kit (Maxiprep, Qiagen) 
 Components include: 
 Buffer P1 (with RNase) Bacterial resuspension solution 
 Buffers P2 and P3  Bacterial lysis 
  Spin columns   Proprietary plasmid DNA binding resin 
 Buffer QBT   Equilibration of spin column 
 Buffer QC   Column wash  
 Buffer QF   Elution of bound DNA  
 
7 Isolation of plasmid DNA insert following agarose gel electrophoresis (Wizard 
SV Gel and PCR clean-up kit, Promega) 
 Components include: 
 Membrane binding solution - chaotropic agents (guanidine isothiocyanate, 
potassium acetate) to free DNA fragment from agarose gel  
 Spin columns - Proprietary DNA-binding silica columns 
 Ethanol-based membrane-wash solution – with potassium acetate, EDTA 
 Nuclease-free water for elution  
  
8  Restriction endonucleases (New England Biolabs) 
 EcoR1 (100,000 U/mL) and Not1 (50,000U/mL)   
 
9 Reaction mix for restriction enzyme plasmid digestion 
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For a 100µL reaction mix, 
Plasmid DNA    0.75-1.0µg DNA (typically 10µL) 
5’ restriction enzyme   1.0µL (typically 50-100U/µL) 
3’ restriction enzyme   1.0µL (typically 50-100U/µL) 
Compatible diluent buffer, 10×* 10µL 
BSA enhancer*     5.0µL 
PCR-grade water to              100µL 
Incubation conditions   37°C, 2 hours 
 
10 Reaction mix for 5’ dephosphorylation of digested vector termini  
For a 30µL reaction mix, 
Digested vector plasmid mix  20µL (see above) 
Shrimp Alkaline Phosphatase* 1.0µL (typically 1U/µL) 
10× reaction buffer*   3.0µL 
PCR-grade water to    30µL 
Incubation conditions   37°C, 15 minutes; followed by 
      65°C, 15 minutes, to inactivate 
 *Promega  
  
11 Reaction mix for cDNA insert ligation using the T4 DNA Ligase 
A 20µL reaction volume using the T4 DNA Ligase in pre-constituted 
microfuge tubes (GE Healthcare)  
Trial of different ratios of insert cDNA* and destination vector**  
 Destination vector (µL)  Insert cDNA (µL) 
  0.5     3.5 
  1.0     3.0 
  1.0     5.0 
  1.0              10.0 
PCR-grade water to 20µL 
Incubation conditions   16°C, 60 minutes (minimum)  
* Derived from source plasmid following digestion, isolation by gel electrophoresis 
and purification 
** 100ng/µL DNA, linearised and 5’ dephosphorylated at termini 
   
12 Reaction mix for plasmid DNA sequencing  
Stock sequencing primer oligonucleotides (100µM) 
Supplied lyophilised, reconstituted with PCR-grade water using 
manufacturer-recommended volumes, mixed well by pipetting to 
resuspend and stored at -20°C 
For use in sequencing reactions, 1µL of 100µM primer was diluted 1-in-10 
with PCR grade water for a 10µM interim working concentration; 1µL of 
10µM working concentration of primer was further diluted with 6µL PCR-
grade water (total volume, 7µL) for a final 1.5 picomole/µL primer 
concentration 
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 A 12µL reaction mix containing 
 Plasmid DNA    350-500ng  
 Sequencing primer   1.5 picomole  
 PCR-grade water   to 12µL 
 
Samples for sequencing were submitted to the Paterson Institute’s Molecular 
Biology Core Facility. Automated sequencing performed using the Applied 
Biosystems 3130 16-capillary genetic analysis system  
 
13 Reaction mix for LR recombination reactions using the Gateway cloning 
system (Invitrogen) 
Appropriate Gateway Entry Vector with in-frame cDNA insert and flanking 
attL recombination sites 
Suitable Gateway Destination Vector with attR recombination sites 
 
A 20µL reaction mix containing, in sequence 
Entry Vector (300ng/µL)  1.0µL 
Destination Vector (300ng/µL) 1.0µL 
Diluent buffer, 5×   4.0µL 
Tris-EDTA buffer    10µL  
LR Clonase enzyme mix*  4.0µL 
*Thaw for 2 minutes on ice from -80°C, pulse vortex (twice, 2 seconds each), add to 
above reaction mix, return to -80°C immediately after use 
 
Incubation conditions   25°C, 60 minutes 
       
Terminate reaction by adding Proteinase K, 2µL (4µg, pulse vortex to mix) 
and incubating at 37°C for 10 minutes  
 
Reaction mix is used directly to transform competent E. coli cells (Top10 
chemically competent cells, Invitrogen) 
 
14 Glycerol bacterial stocks  
 Liquid E coli culture    850µL 
 Glycerol     150µL 
 Vortex vigorously to mix, snap-freeze on dry ice, store -80°C 
 
15 Others 
Sample loading buffer and DNA size markers for electrophoresis, SOC 
bacterial growth medium 
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BLOOD/BONE MARROW MONONUCLEAR CELL ISOLATION  
 
1 Lymphoprep density separation solution of sodium diatrizoate and a 
polysaccharide (density 1.077g/mL) for isolation of mononuclear cells (Axis-
Shield UK) – 1 part solution to 2 parts blood or bone marrow (diluted 1:1 with 
PBS)  
 
2 Trypan blue (0.4%) reagent for dye exclusion staining of viable cells – filtered 
(0.22 µm) to exclude precipitates and aggregates 
1 part reagent mixed with 1 part cell suspension, 10µL mix applied 
immediately to each chamber of the Neubauer haemocytometer 
 
3 Glacial acetic-acid (3%) with methylene blue (Stem Cell Technologies, 
Grenoble, France) for selective staining of mononuclear cells in the presence 
of heavy red cell contamination of cell suspension 
 
4 Cryoprotectant (DMSO 10% (v/v) FBS 20% (v/v) in growth medium) 
 Liquid culture media (RPMI 1640 or DMEM) with 10% DMSO and 20% FBS 
Add 20mL FBS and 10mL DMSO to 70mL growth medium. Mix, filter (0.22 
micron) and store in 3mL aliquots at -20°C to -80°C 
 
RNA ISOLATION 
 
All steps were carried out in a dedicated level II laminar flow hood.  
 
1 TRIzol reagent (Invitrogen), containing phenol and guanidine isothiocyanate 
 
2 Others – chloroform, isopropanol, 75% ethanol and DEPC-treated RNase-
free water 
 
QUANTITATIVE RNA ESTIMATION 
 
All procedures were carried out in a dedicated level II laminar flow hood. Sterile 
DEPC-treated RNase-free water was the diluent in all reactions 
 
1 RNA priming mix 
 For a 12µL reaction volume in a 0.2mL thin-walled PCR tube*  
 Whole cell total RNA**   Volume equivalent to 500ng 
 Random hexamers***   1.5µL (150ng) 
 Water to 12µL 
 *Applied Biosystems 
 **Total RNA extracted using the TRIzol reagent isolation protocol (Invitrogen) 
 **Prepared from 20µg lyophilised stock solution (Promega) 
 Cycling condition   70°C for 5 minutes 
       Returned immediately to ice 
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2 Reverse transcription mix for first-strand cDNA synthesis 
Reaction mastermix prepared for (n+2) samples*; for an 18µL unit reaction 
volume: 
 dNTPs 2.5mM**   10µL 
 MMLV-RT enzyme***     2µL (400U) 
 5× RT reaction buffer     6µL  
*Dispensed 18µL reaction mix to each primed sample above to bring total reaction 
volume in each tube to 30µL 
 ** Nucleotide mix from10mM each of dATP, dTTP, dCTP, dGTP 
***The RNase H-minus point mutant Murine Moloney Leukaemia Virus (M-MLV 
reverse transcriptase) 200U/µL from Promega 
 
 Cycling conditions   42°C, 60 minutes 
       95°C, 5 minutes to terminate reaction 
 
Residual RNA duplexed with cDNA removed by adding RNase H 2µL (2U, 
GE Healthcare) each sample  
Cycling condition   37°C, 20 minutes 
  
3 Quantitative RNA reaction mix for 96-well plates 
 For each sample, target and reference genes are assayed in triplicate 
For ‘n’ cDNA samples, estimate volume equivalent to [(n+1)×4]µL for each 
gene assayed  
 Unit reaction volume: 25µL per well 
Quantitative PCR mastermix*, 2× 12.5µL 
Taqman probe-primer mix**, 20× 1.25µL 
Sample DNA    1.0µL*** 
Water to  25µL 
*Contains hot start AmpliTaq DNA polymerase with 5’-exonuclease activity, 
deoxynucleotide mix (with dUTP replacing dTTP), uracil-N-glycosylase to minimise 
carryover contamination and the ROX passive reference dye (Applied Biosystems) 
**Human gene-specific Taqman on-demand probe-primer mix for real-time 
quantitation from Applied Biosystems containing exon-spanning FRET labelled 25-
mer oligonucleotide probes (5’FAM reporter and 3’ non-fluorescent quencher) and 
flanking forward and reverse exon-specific primers in a probe:primer molar ratio of 
1:9 
***Equivalent to 16.1ng template RNA 
 
4 Quantitative RNA reaction mix for automated loading of 384-well plates  
 For each gene, target and reference genes are assayed in triplicate 
 Reaction mix for cDNA loading  
  Sample cDNA      10.0µL 
  Water     102.5µL 
  Automated volume load/well      4.5µL* 
  *Equivalent to 6.4ng template RNA 
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 Reaction mix for Taqman probe-primer and PCR reagent* 
For ‘n’ cDNA samples, estimate volume equivalent to [(n+1)×4]µL for each 
gene assayed 
 Unit loading volume per well: 5.5µL  
  Quantitative PCR mastermix, 2×    5.0µL 
 Taqman probe-primer mix, 20×  0.5µL 
 
 Final reaction volume loaded/well: 10µL  
 
5 Cycling conditions for RNA quantitative PCR 
 Uracil N-glycosylase activation  50°C, 2 min 
 AmpliTaq DNA polymerase activation 95°C, 10 min 
 PCR cycles, repeated 40 times:  
  Strand denaturation    95°C, 15 sec 
  Primer annealing/strand extension 60°C, 1 min 
 
 
PROTEIN IMMUNOBLOTTING 
 
1  Lysis Buffers 
 
A Non-ionic non-denaturing detergent lysis buffer (Nonidet P-40 based) 
• Alkaline pH (pH 8.0), 0.1% NP-40 solution 
  For a 100mL solution, 
  Tris base 50mM   0.606g 
  Sodium Chloride 150mM  0.880g 
  Adjust pH to 8.0 with concentrated hydrochloric acid  
  Bring volume to 100mL with sterile deionised water 
  Add 100µL Igepal CA-630 (NP-40 equivalent)  
  
  Filter (0.22 micron) and store at 4°C 
To 50mL, add 1 Complete Protease Inhibitor Cocktail tablet (Roche), mix 
well to dissolve, create 500µL aliquots in microfuge tubes and store at -
80°C   
 
• Acid pH (pH 5.0), 0.8% NP-40 solution 
 For a 50mL solution, 
 Tri Sodium Citrate, 50mM  0.736g 
 Adjust pH to 5.0 with concentrated hydrochloric acid 
 Bring volume to 50mL with deionised water and filter (0.22 micron) 
  
 Create 3mL aliquots in 7mL Bijoux tubes and store at -20°C 
To thawed 3mL aliquot, add 1.1µL 2-mercaptoethanol (effectively 5mM) 
before use 
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In some experiments, 10% CHAPS 10µL was added to 2mL (effectively, 
0.05% CHAPS) NP-40 citrate lysis buffer to achieve more complete 
solubilisation of membrane-bound proteins 
 
B  SDS sample buffer for gel loading 
 For 10mL of a 5× solution, 
 Tris buffer 1.0M, pH 6.8  2.5mL (see 2B below) 
 SDS     1.0g 
 Glycerol     5.0mL 
 Bromophenol blue   2mg 
 Create 500µL aliquots and store at -20°C  
 Thaw by briefly heating at 65°C. Add 50µL 2-mercaptoethanol before use 
 
2 Protein assay  
 Modified Lowry assay; detergent-compatible (DC) reagents from Bio-Rad 
 Protein assay reagent A  Alkaline copper tartrate solution 
 Protein assay reagent B  Dilute Folin reagent 
 Protein assay reagent S  Surfactant 
 
 BSA standards  
Prepared from stock solution of BSA 5mg/mL (50mg in 10mL protein lysis 
buffer, mix well to dissolve while avoiding excessive frothing, dispense as 
100µL single-use aliquots, store at -20°C) 
 
3  Gel constituents 
 
A Resolving gel buffer (1.5M Tris, pH 8.8) 
 For a 100mL solution,  
 Tris base  1.5M    18.2g  
 Adjust pH to 8.8 with concentrated hydrochloric acid 
 Bring the volume to 100mL with deionised water  
 Filter (0.22 micron) and store at 4°C    
  
B Stacking gel buffer (1.0M Tris, pH 6.8) 
 For a 100mL solution, 
 Tris Base 1.0M    12.1g 
 Adjust pH to 6.8 with concentrated hydrochloric acid 
 Bring the volume to 100mL with deionised water 
 Filter (0.22 micron) and store at 4°C  
 
C Resolving gel mix 
 For a 20mL 10% polyacrylamide gel solution, add in sequence 
 Deionised water   7.9mL 
 Acrylamide 30%*   6.7mL 
 Tris 1.5M, pH 8.8   5.0mL 
 SDS 10%*    0.2mL 
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 Ammonium Persulphate** 10% 0.2mL 
 TEMED     0.008mL  
 *National Diagnostics (Acrylamide ratio 37.5:1 acrylamide:bisacrylamide)  
**Ammonium persulphate (electrophoresis grade, GE Healthcare Life Sciences) 
0.5g in 5mL deionised water; 500µL aliquots at -20°C   
 
Mix well and allow 2 minutes for initiation of polymerization. To each vertical 
1.0mm-spacer glass plate assembly, dispense 4.5–5.0mL of mix and overlay 
with 0.01% SDS (10µL 10% SDS added to 10mL deionised water). 
Polymerisation time, 45 minutes – 1 hour 
 
D Stacking gel mix 
 For a 10mL solution, add in sequence 
 Deionised water   6.8mL 
 Acrylamide 30%   1.7mL 
 Tris 1.0M, pH 6.8   1.25mL 
 SDS 10%    0.1mL 
 Ammonium persulphate 10%  0.1mL 
 TEMED     0.01mL 
  
Immediately dispense 1mL of mix and place gel combs. Polymerisation time, 
15 minutes; remove combs and wash vigorously to remove residual 
unpolymerised material   
 
4 Electrophoresis (running) buffer 
Freshly prepare. For a 500mL 1× solution,  
Tris Glycine SDS buffer 10×*  50mL 
 Deionised water   450mL 
 
*Tris 0.25M, Glycine 1.92M, SDS 1% (w/v) (pH 8.3, Bio-Rad) 
  
5 Gel transfer buffer  
 Freshly prepare. For a 500mL 1× solution,  
 Tris base  25mM   1.52g 
 Glycine 192mM    7.20g 
 Methanol (Fisher Scientific)  100mL (20% v/v) 
 Deionised water to 500mL 
 
 Maintain chilled. Gels, membranes and blot papers are presoaked in chilled 
transfer buffer prior to membrane transfer 
 
6 Blocking solution (5% non-fat dried milk solution, NFDM) 
 Non-fat skimmed milk powder (Marvel, Premier Foods, UK), 5% (w/v) in 
 PBS-Tween 20 0.05% 
 To 50mL PBS-Tween 20 0.05%, add 2.5g milk powder   
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7 Methanol 
For hydrophilic activation of PVDF membranes (15 second treatment)  
Activated PVDF membranes are maintained rocking in transfer buffer until 
use 
 
8 Antibodies
A Primary antibodies (diluent, 5% non-fat milk* in PBS-Tween 20 0.05%) 
• Anti-AEP  
 Goat polyclonal anti-human (AF2199, R&D Systems) 
  Dilution 1:2500 (80ng/mL)  
  Volume: 12-20mL / membrane in square petri dishes 
  Incubation: 2 hours, room temperature; 12-16 hours, 4°C; rocking 
 
• Anti-CTSB 
 Rabbit polyclonal anti-human (Biomol SA-361, Enzo Life Sciences) 
 Dilution 1:10,000  
 Volume: 12-20mL / membrane in square petri dishes 
 Incubation: 12-16 hours, 4°C; rocking 
 
 Other anti-CTSB antibodies tested included: 
Mouse monoclonal anti-human IgG-2a, clone CA10, directed to an epitope 
in the CTSB heavy chain (IM27L, Merck Biosciences) 
 
Mouse monoclonal anti-human IgG1, clone 155714 (MAB2176, R&D 
Systems) 
 
Two other rabbit polyclonal anti-human antibodies from Merck biosciences 
(product codes 219408 and PC41)  
 
• Anti-β-actin 
Mouse monoclonal IgG1, broad species specificity, clone AC-15, directed 
to an N-terminal epitope (A5441, Sigma-Aldrich); dilution 1:5000 – 
1:10,000  
 
B Peroxidase-conjugated secondary antibodies (diluent as with primary 
antibodies) 
• Anti-goat  Donkey anti-goat IgG (sc-2020, Santa Cruz)  
   Dilution 1:10,000 (40ng/mL)   
• Anti-rabbit  Goat anti-rabbit IgG (P0448, Dako)   
   Dilution 1:20,000 
• Anti-mouse  Goat anti-mouse IgG (31430, Pierce) 
   Dilution 1:5000–1:10,000 
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9 Others 
  
A Precision Plus dual-colour pre-stained protein electrophoresis standards 
(Bio-Rad); 10-12µL unit loading volume 
 
B Phosphate Buffered saline with Tween 20 0.05% 
 To a 500mL PBS solution, add 250µL Tween 20; mix well  
 
C SuperSignal West Dura extended duration chemiluminescence substrate kit 
containing Luminol (with an enhancer) and peroxide buffer (Pierce) –1:1 ratio 
of reagents 
 1.5mL/membrane, 5 minute incubation, ensure uniform layering, light-
protection unnecessary 
 
D ‘Restore’ proprietary membrane stripping buffer from Pierce 
 
AEP ACTIVITY ASSAY 
1 Assay buffer
 For a 50mL 10× solution 
 Citric acid 395mM    3.79g   
 Na2HPO4* 1.21M    8.59g (anhydrous salt) 
 Na2EDTA** 10mM    0.186g 
 *Disodium Hydrogen Phosphate 
 ** Disodium EDTA 
 
2 Other reagents
• CHAPS      10% (w/v) 
  0.25g CHAPS to 2.5mL ddH2O  
 
• DTT      0.5M stock 
 
• 7-Amino Methyl Coumarin (7-NHMeC) 20mM in DMSO stock 
 
• AEP substrate Z-Ala-Ala-Asn-NHMeC* 10mM in DMSO stock 
 
• AEP inhibitor MV026630**   10mM in DMSO stock 
 *Bachem **Cancer Research Technology, CRUK (Jon Roffey) 
 
  
CELL CULTURE 
 
All work related to cell culture was carried out in a Level II laminar flow hood. 
1 Foetal Bovine Serum (Sera Laboratories International) 
 Complement inactivation by heating to 56°C for 30 min 
 Filtered (0.22 micron), aliquots stored at -20°C to -80°C 
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2 L-Glutamine 200mM stock solution (PAA Laboratories) 
 Stock aliquots (5mL) stored at -20°C 
 For a 2mM solution, 5mL stock added to 495mL liquid medium  
 
3 Complete liquid culture reagents 
 
A Routine culture media, without antibiotics or selection agents 
• RPMI 1640 and DMEM Glutamax liquid media (Invitrogen) 
  Foetal Bovine Serum (FBS) 10%  
  Add 55mL FBS to 500mL medium for a 10% FBS solution 
 
• Ham F-12, 7% FBS (for the PC-3 prostate carcinoma cell line) 
To a 40mL aliquot of medium, added 3mL FBS and 400µL 200mM L-
Glutamine 
 
B With selection agents 
• Hygromycin B 50µg/mL and Zeocin 400µg/mL in complete DMEM (both, 
Invitrogen) for the mifepristone-inducible GeneSwitch protein-expressing 
HEK293 cells 
To a 40mL aliquot of complete DMEM, add Hygromycin B 40µL (50mg/mL 
stock solution) and Zeocin 160µL (100mg/mL stock solution) just before 
use 
  
• Geneticin (G-418 sulphate, PAA) 0.6mg/mL in complete DMEM for the 
enforced protein-expressing HEK 293 cells 
G-418 sulphate 5mg dissolved in 50mL sterile PBS, filtered (0.22 micron) 
and stored in 5mL aliquots (100mg/mL) at -80°C. Thawed aliquots are 
maintained at 4°C 
To a 40mL aliquot of complete DMEM, add 240µL G-418 sulphate 
(100mg/mL stock). Refresh every 48–72 hours  
 
4 Trypsin-EDTA (Sigma-Aldrich, Lonza) 
 Porcine trypsin 0.5% (w/v) with tetrasodium EDTA 0.2g/L 
Aliquots stored at -20°C, prewarmed (37°C) before use 
  
 Typical volumes used (undiluted) 
  100mm dishes   56cm2    3mL  
  T75 flasks    75cm2     5mL 
  T175 flasks  175cm2  10mL  
 
 Treatment time  2-5 minutes, 37°C/5%CO2   
 
 Neutralisation Equivalent volumes of growth medium with 10% FBS; 
in special circumstances, growth medium with 1% 
FBS   
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LIPID-BASED TRANSFECTION OF ADHERENT HUMAN CELL LINES 
 
All steps carried out in a level II laminar flow hood; optimal cell density 1.0 – 2.0 × 
105 cells/well in a 6- or 12-well plate (BD Falcon) 
 
1 Lipofectamine 2000 lipid transfection reagent (Invitrogen) 
Proprietary liposome formulation containing a synthetic polycationic lipid and 
a neutral phosphatidyl ethanolamine lipid 
 
2 DNA-OptiMEM I reaction mix 
 Unit reaction volume (100µL)*  
 Plasmid DNA**     10µL (100ng/µL) 
 OptiMEM I***    90µL 
*Final volume estimated for ‘n+2’ samples to be transfected with a given plasmid, 
i.e. [(n+2) × 100µL] 
**High-purity endotoxin-free sequence-verified vector plasmid isolated by large-
scale purification (Maxiprep, Qiagen); typically 1.5-2.0µg/mL, adjusted to 100ng/µL 
in sterile water   
*** Reduced serum liquid growth medium with Glutamax (Invitrogen) 
 
Mixed by pulse vortex at room temperature 
  
3 Lipofectamine-OptiMEM I reaction mix 
 Unit reaction volume (100µL)* 
 Lipofectamine reagent     4µL 
 OptiMEM I    96µL 
*Final volume estimate: (total number of samples to be treated + 2)× 100µL 
 
Mixed by pulse vortex and allowed to stand at room temperature for 5 
minutes 
 
4 Final transfection mix  
Unit volume of 200µL for each sample, containing a 1:1 mixture of DNA-
OptiMEM I and Lipofectamine-OptiMEM I  
  
Estimated volume of final transfection mix = [(n + 2) samples to be 
transfected with a given plasmid × 200µL] 
  
Mixed by pulse vortex and allowed to stand at room temperature for 20 
minutes 
 
DNA-free transfection mix prepared in parallel by adding OptiMEM I only to 
the Lipofectamine-OptiMEM I mix in a 1:1 ratio 
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CELL STAINING  
 
1 1% (w/v) BSA in PBS 
Prepared in a level II laminar flow hood; for a 50mL solution, 
 BSA    0.5g 
Sterile PBS   to 50mL  
Mix well but gently to avoid frothing. Syringe-filter (0.22 micron) and store in 
10mL aliquots at -20°C 
 
2 Neutral buffered formalin 
Prepared centrally by the Institute’s core Histology services 
For a 1L 3.7% solution, 
Formaldehyde 37%   100mL 
PBS     900mL  
 
3 Triton X-100 0.25% in PBS 
For a 10mL 1% (v/v) solution of Triton X-100 in PBS, add 100µL Triton X-100 
to 10mL PBS. Vortex to mix 
Add 500µL 1% Triton X-100 to 1500µL PBS to obtain a 2mL 0.25% solution 
of Triton X-100 
 
4 Live cell labelling reagents 
Performed in a level II laminar flow hood 
A The LysoTracker Red DND-99 (Molecular Probes, Invitrogen) red-fluorescent 
acidotropic probe for labelling low pH organelles (excitation 575nm, emission 
590nm) 
For a labelling concentration of 100nM, dilute 1µL of the thawed 1mM probe 
stock solution in 10mL liquid growth medium (cell density 1×105 cells/mL, 
absolute cell count 1×106 cells) 
For a labelling concentration of 500nM, dilute 2µL of the thawed 1mM probe 
stock solution in 4mL liquid growth medium (cell density 2.5×105 cells/mL, 
absolute cell count 1×106 cells) 
Incubation time 45–60 minutes, 37°C/5%CO2
Post-incubation, pellet cells to wash off excess unbound probe  
 
B The BODIPY-labelled (excitation 530nm, emission 580nm) aza-epoxide class 
peptidyl (amino acid residues: P1 asparagine, P2 proline) cell-permeable 
AEP activity binding probe (Matthew Bogyo, Stanford University, CA, USA) 
for vital staining of mature (active) intracellular AEP 
 For a labelling concentration of 1µM, dilute 1µL of the thawed 1mM probe 
stock solution (in DMSO) in 1mL of liquid growth medium (cell density 2×105 
cells/mL); final DMSO concentration at non-toxic 0.1% (v/v)  
 Incubation time 2 hours, 37°C/5%CO2  
 Post-incubation, pellet cells to wash off excess unbound probe 
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5 Pre-immune animal sera (Vector laboratories) 
Goat- and rabbit-derived pre-immune serum as blocking reagents in 
immunostaining 
Remove aggregates (level II laminar flow hood) by syringe-filtration (0.22 
micron) followed by high-speed centrifugation (16,200g, 5 minutes, 4°C). 
Store in aliquots at -20°C  
Use as 10% solution (v/v) in 1% BSA (for a 1mL 10% serum solution, add 
100µL serum to 900µL 1% BSA) 
 
6 Antibodies 
A Unconjugated primary antibodies (diluent, 1% BSA) 
• Anti-AEP  
 Goat polyclonal anti-human (AF2199, R&D Systems); 1:100 (2µg/mL) 
• Anti-LAMP1 (lysosomal associated membrane protein 1, CD107a) 
Mouse monoclonal anti-human IgG1κ, clone HA-43 (product code 555798, 
BD Biosciences); 1:100 (5µg/mL) 
 
B Fluorophore-conjugated secondary antibodies (diluent, 1%BSA) 
Short centrifuge to pellet suspended aggregates before use 
 
Alexa Fluor 488 (Excitation 495nm, Emission 519nm) conjugated secondary 
antibodies (Molecular Probes, Invitrogen), 1:1000 dilution (2µg/mL) 
 
• Rabbit anti-goat IgG F(ab’)2 (A21222) cross-adsorbed against human and 
mouse serum proteins to minimise cross-reactivity  
  
• Goat anti-mouse IgG (A11029), highly cross-adsorbed against bovine, 
goat, rabbit and human IgG as well as human serum  
 
7 May-Grünwald Giemsa staining 
A Sørenson buffer  
 Buffer of monobasic and dibasic phosphate salts 
  
 For a 100mL, 20×, 0.67M solution of monobasic phosphate solution 
  Potassium dihydrogen phosphate   9.1g 
  Deionised water to 100mL 
 
 For a 100ml, 20×, 0.67M solution of dibasic phosphate solution 
  Disodium hydrogen phosphate  9.5g (anhydrous) 
  Deionised water to 100mL 
 
 For a 200mL, 1×, 0.033M solution of Sørenson buffer 
  Monobasic phosphate solution, 20× 10.2mL 
  Dibasic phosphate solution, 20×     9.8mL 
  Deionised water to 200mL 
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  Adjust pH to 6.8 with 5N hydrochloric acid 
 
B May-Grünwald staining solution 
 Diluted 1 in 2; for a 40mL staining solution in a Coplin jar,  
  May-Grünwald reagent    20mL 
  Sørenson buffer, 1×    20mL 
  Staining time     20 minutes 
  
C Giemsa staining solution 
 Diluted 1 in 10; for a 40mL staining solution in a Coplin jar, 
  Giemsa reagent      4 mL 
  Sørenson buffer, 1×     36mL 
  Staining time      30 minutes    
  
8 Mounting medium with DAPI 
DAPI 1mg/mL stock solution prepared in a level II laminar flow hood by 
diluting dried powder (10mg, Roche) in 10mL sterile deionised water 
 
For a 1µg/mL solution of DAPI in fluorescent mounting medium 
 Fluorescent mounting medium*  1mL 
DAPI 1mg/mL     1µL  
* Product code S3023, Dako  
 
Vortex briefly to mix; stored light-protected at 4°C 
 
9 Filamentous actin (F-actin) staining 
Stock solution of far red fluorescent Alexa Fluor 647-conjugated phalloidin in 
methanol (200 units/mL; -20°C storage; Invitrogen). Pulse-centrifuge to 
sediment protein aggregates before use. 
 
 Use 250µL of diluted conjugated phalloidin (1:50 dilution, 5µL stock solution 
to 200µL 1%BSA) for each coverslip sample staining. Incubate light-
protected for 20 minutes at room temperature followed by two 5-minute PBS 
washes  
 
10 Fibronectin coating of cover slips 
Stock solution (1 mg/mL) diluted 1 in 10 with sterile PBS for a 10µg/mL 
solution. Aliquots stored at -20°C.  
Acid-alcohol (absolute ethanol: concentrated hydrochloric acid 9:1) sterilised 
glass coverslips were placed in a petri dish and coated with 10µg/mL 
fibronectin. Following incubation for 30-45 minutes at 37°C, excess 
fibronectin was removed with PBS washes. Coated coverslips were used 
immediately in experiments.  
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MOTILITY ASSAYS 
 
1 Matrigel (BD Biosciences), 8-10mg/mL (batch-dependent), 10mL 
Extracellular matrix secreted by the murine Engelbroth-Holm-Swarm 
sarcoma cell line 
Chief components   
Laminin, collagen IV and entactin (nidogen) 
 Heparan sulphate proteoglycan 
Growth factors – transforming growth factor beta, insulin-like growth factor, 
epidermal growth factor, fibroblast growth factor, tissue plasminogen 
activator 
 
 Does not contain fibronectin 
 
 Stored frozen (-20°C), thawed strictly on ice, 1mL aliquots created in level II 
laminar flow hood using pre-chilled pipettes, aliquots stored at -80°C 
 For 1:50 working dilution, ice-thawed 1mL aliquot diluted in chilled 49mL 
serum-free DMEM (0.15-0.2mg/mL, Matrigel membrane coating); 3mL 
aliquots stored at -80°C (in level II laminar flow hood) 
 
For invasion assays, 100µL 1:50 diluted ice-thawed Matrigel allowed to 
uniformly coat bottom of 8-micron pore inserts overnight in a level II laminar 
flow hood. When coating, ensure level dispensing and avoid air bubbles (by 
setting dispensing volumes to 102µL and avoiding purge-dispensing). Before 
use, rehydrate Matrigel coating by adding chilled serum-free DMEM (250µL 
per insert) to inserts; incubate at 4°C for 2 hours 
 
2 Mifepristone (Invitrogen) 
For induction of AEP expression in the GeneSwitch dual plasmid inducible 
expression system in stably transfected HEK293 cells 
 
Reconstitution (in a level II laminar flow hood) 
For a 1mM stock solution, 100µg of mifepristone (429.6g/mol) in 233µL 
absolute ethanol; 110µL aliquots stored at -20°C, caps parafilm-wrapped to 
minimise evaporation losses 
 
For a 10µM working solution, 100µL 1mM mifepristone in 10mL absolute 
ethanol; 1mL aliquots, paraffin-wrapped caps, -20°C 
 
For induction of AEP expression  
To 10mL of cells in growth medium, add 10µL 10µM mifepristone solution to 
obtain a final mifepristone concentration of 10nM 
Incubate for 24 hours for maximal induction of expression 
 
3 Crystal violet solution (0.1%) for staining of cell inserts 
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Stock solution (2.3% crystal violet in 20% ethanol) diluted 1 in 20 (1mL to 
19mL deionised water) 
Inner contents of inserts removed by pipette aspiration and cotton bud 
swabbing and inserts fixed by placing in methanol (15 minutes) followed by 
staining in 0.1% crystal violet for 15 minutes 
Excess stain removed by washing twice in distilled water followed by drying 
As inserts are unlabelled, care is necessary when staining; adhere to a 
standard multi-well plate template when handling inserts during staining 
 
4 Isotonic diluent fluid (Isoton, Beckman Coulter) for suspending cells towards 
counts on the particle counter 
 
IMMUNOHISTOCHEMISTRY 
 
1 Tris-EDTA heat antigen retrieval buffer  
 Tris-Base, 10mM  1.21g 
 Disodium EDTA, 1mM  0.37g 
 Water    to 1L 
 Tween-20   0.5mL to 1L (0.05% v/v) 
 
2 Citrate heat antigen retrieval buffer 
 100mM 10× Citrate stock buffer, 500mL 
 Trisodium citrate  10.51g 
 Deionised water  to 500mL  
 pH adjusted to 6.0 
 
 Working solution: 1 in 10 dilution of 10× stock in deionised water 
 
3 Methanol-peroxide solution   
Methanol 9 parts; 3% Hydrogen Peroxide 1 part 
 
4 Avidin-biotin blocking solution (Vector laboratories) 
 Avidin blocking solution 4 drops to 1mL PBS 
Biotin blocking solution 4 drops to 1mL PBS 
PBS-Tween 0.05%  250µL Tween 20 to 500mL PBS 
 
5 1% BSA-Azide solution 
 Bovine serum albumin  2.0g 
 Sodium azide   0.2g 
 PBS    to 200mL 
 
6 Antibody solutions in 1% BSA-azide (PBS in the case of dual staining) 
 Primary antibody  Anti-AEP, 1:300  
     Goat polyclonal anti-human, R&D (AF2199) 
     Anti-human CD68; undiluted   
     Mouse monoclonal PG-M1, Dako 
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 Secondary antibody  Biotinylated rabbit anti-goat, 1:250 
     (Vector laboratories, BA-5000) 
      
 Fluorescent secondary  TRITC-conjugated rabbit anti-mouse IgG 
 antibodies   (Excitation 550nm/emission 570nm) 
     1:15, Dako R 0270 
 
Alexa Fluor 488 conjugated rabbit anti-goat IgG 
(Invitrogen)    
 
7 Avidin-biotin enzyme amplification solution (Vector laboratories) 
Avidin DH 20µL and Biotinylated HRP 20µL to 1mL PBS 
Freshly prepared, allow to stand (not > 30 minutes), then apply 
 
8 Diaminobenzidine (DAB) reagent (Kem-En-Tec Diagnostics A/S, Denmark)  
 DAB     1 tablet 
 Deionised water  10mL 
 3% hydrogen peroxide 100µL to 10mL DAB solution  
 Freshly prepared, incubate 15 minutes at room temperature before use 
 
9 DPX (Distyrene Plasticiser Xylene) mounting medium 
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Section 8.3 Selected Methods Outline  
• Mononuclear cell isolation from bone marrow/peripheral blood 
• Plasmid DNA isolation 
• RNA isolation (TRIzol isolation protocol) 
• Ethanol-ammonium acetate double precipitation for ultra-pure RNA yields 
• Preparation of whole-cell protein lysates 
• Stripping of protein immunoblot membranes 
• Cryopreservation and thawing of cells 
• Trypsin mobilisation of adherent cells 
• AEP immunohistochemistry work flow 
BONE MARROW / PERIPHERAL BLOOD MONONUCLEAR CELL ISOLATION 
Note  • Immediate processing 
• Interim hold at room temperature  
• Class II laminar flow hood 
• Sterile filter pipette tips 
• Phenol waste disposal 
• Biohazardous waste disposal 
Density separation medium 
(Lymphoprep, Axis Shield) 
• Sample diluted 1:1 with PBS, layered on 
density-separation medium (volume ratios 
of sample and separation medium, 1:2) 
• Centrifuge, 400g, room temperature, 25 
minutes, slow acceleration, no deceleration 
brake 
Mononuclear cells Mononuclear cell layer interphase identified 
and isolated; PBS wash (300g, room 
temperature, 10 minutes) to remove residual 
separation medium  
Cell count Resulting cell pellet resuspended in PBS; 
aliquot removed for haemocytometer cell 
count (by Trypan blue exclusion,  to 
additionally assess viability). Subsequent 
second wash step (300g, room temperature, 
10 minutes) 
Cell lysis and storage Based on mononuclear cell counts  
• If ≤ 10×106, cells lysed directly in TRIzol 
(complete lysis ensured by pulse vortex ) 
• If >10×106, TRIzol lysis of 10×106 cells;  
remainder cells in cryoprotectant for liquid 
nitrogen storage 
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PLASMID DNA ISOLATION (HIGH COPY NUMBER PLASMID) 
Small-scale isolation (Wizard Plus SV Miniprep kit, Promega)
Precaution • Dedicated cloning work station 
• Biohazardous waste disposal 
Bacterial cell pellet  2mL overnight liquid culture (12-14h), 10 000g, 
5 minutes, room temperature; decant 
supernatant 
Bacterial cell resuspension Cell resuspension solution, 250µL, mix well 
Cell lysis Cell lysis solution, 250µL, mix well (no vortex); 
incubate 1-5 minutes, room temperature  for 
solution clearance 
Endogenous endonuclease 
inactivation 
Alkaline protease solution, 10µL, mix well (no 
vortex), incubate room temperature, 1-5 
minutes (avoid exceeding 5 minutes)  
Precipitation of bacterial nuclear 
DNA and proteins 
• Neutralisation solution, 350µL, mix well by 
inversion (no vortex) 
• Centrifuge, 14 000g, 10 minutes, room 
temperature 
Column plasmid DNA binding Lysate (~850µL) to spin column in 2mL 
collecting tubes; centrifuge 15 000g 1 minute, 
room temperature 
Column wash • Column wash solution, 750µL; centrifuge at 
room temperature 15 000g, 1 minute  
• Discard flow-through; repeat column wash 
with 250µL wash solution and repeat 
centrifuge at 15 000g, 1 minute 
Plasmid DNA elution • Discard flow through, centrifuge spin 
column at 15 000g, 1 minute to collect 
residual wash solution  
• Spin column to fresh 1.5mL microcentrifuge 
tube, 75-100µL nuclease-free water, 
centrifuge 15 000g, room temperature, 1 
minute 
Quantitation Spectrophotometry; A260/280 should exceed 1.8 
 
Large-scale isolation (Maxiprep, endonuclease-free, Qiagen)
Precaution • Dedicated cloning work station 
• Biohazardous waste disposal 
• Check buffer P2 for SDS precipitation 
• Retain supernatant from isopropanol 
precipitation and ethanol wash until 
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plasmid DNA isolation confirmed 
Liquid bacterial culture Agitated culture (12-16 hours), 37°C, 5mL 
overnight starter inoculate in 100mL volume 
with appropriate selection antibiotic, 1L sterile 
Erlenmeyer flask 
Bacterial stocks Glycerol storage vials of transformed cells 
Bacterial cell harvest and lysis • Balanced volumes (weights) in 250mL 
plasmid centrifuge tubes 
• Pellet bacterial cells - centrifuge 6 000g, 15 
minutes, 4°C 
• Decant supernatant, resuspend cells in 
10mL buffer resuspension buffer P1 (with 
RNase A) 
• Add lysis buffer P2, mix well by inversion, 
incubate at room temperature (do not 
exceed 5 minutes) 
• Add neutralization buffer P3, mix well by 
inversion, incubate on ice, 20 minutes 
(LyseBlue to indicate adequacy of mixing) 
Bacterial lysate clarification • Centrifuge, ≥ 20 000g (15 000 rpm, 
Sorvall), 4°C, 30 minutes 
• Carefully isolate supernatant 
Plasmid DNA binding and wash • Equilibrate resin column (Qiagen-tip 500) 
by applying buffer QBT, 10mL; allow to flow 
through by gravity into Erlenmeyer flask 
• Apply supernatant to column (place a 
sterile gauze pad over mouth of column) 
and allow to flow through by gravity 
• Wash column twice with buffer QC, 30mL; 
allow flow-through by gravity 
Plasmid DNA elution • Resin column to 30mL plasmid centrifuge 
tubes 
• Buffer QF, 15mL, to elute bound DNA 
DNA precipitation • Isopropanol, 10.5mL (0.7 volume) to 
eluate, mix immediately, centrifuge (mark 
tube to indicate pellet deposit) ≥ 15 000g, 
4°C, 30 minutes 
• Identify precipitate, carefully aspirate 
supernatant; retain supernatant until 
satisfactory DNA isolation confirmed 
DNA pellet wash • Ethanol 70%, 1mL; transfer to 1.5mL 
microcentrifuge tube; centrifuge maximum 
speed, 4°C, 10 minutes 
• Carefully pipette-remove supernatant 
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Reconstitution Air-dry pellet (avoid over-drying) and 
resuspend in 100µL sterile Tris-EDTA buffer or 
deionised water (pipette-mix) 
Quantitation Spectrophotometry; A260/280 should exceed 1.8 
 
RNA ISOLATION (TRIZOL RNA ISOLATION PROTOCOL) 
Precaution • Class II laminar flow hood 
• Sterile filter pipette tips 
• Phenol waste disposal 
• Retain supernatant in all steps until 
satisfactory RNA isolation confirmed 
Phase separation • Chloroform 200µL to 1mL TRIzol lysate 
• Mix vigorously, 15 seconds; incubate at 
room temperature for 5 minutes 
• Centrifuge, 12 000g, 4°C, 15 minutes 
Aqueous phase isolation Carefully transfer upper aqueous phase to a 
fresh 1.5mL microcentrifuge, taking care not to 
disturb the interphase (volume 380-400µL) 
RNA precipitation • To the aqueous phase, add 500µL 
Isopropanol 
• Mix well and incubate, either at room 
temperature for 10 minutes or overnight 
(12-16 hours) at 4°C  
• Centrifuge, 10 000g, 4°C, 10 minutes 
• Identify streaky white RNA pellet (base and 
sides of tube) 
RNA wash • To pellet, add 1mL 75% ethanol 
• Centrifuge, 10 000g, 4°C, 10 minutes 
RNA pellet reconstitution • Air-dry RNA pellet until translucent; avoid 
overdrying 
• Dissolve pellet in DEPC-treated water 
(volume estimated based on pellet size, 
between 10-30µL); mix by pipetting 
• Set aside 2-5µL aliquot for 
spectrophotometric quantitation 
Quantitation A260/280 ratio should exceed 1.8 
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ETHANOL-AMMONIUM ACETATE DOUBLE PRECIPITATION OF RNA 
Objective Isolation of high-purity RNA post-TRIzol RNA 
extraction 
Precaution • Class II laminar flow hood, filter pipette tips 
• Retain supernatant in all steps until 
satisfactory RNA isolation confirmed 
RNA precipitation • To RNA isolate, add 0.5 volume 7.5M 
ammonium acetate and 2.5 volume 
absolute ethanol 
• Incubate, -20°C, overnight (12-16 hours) 
• Centrifuge, 16 000g, 4°C, 30 minutes 
RNA wash • Wash × 2, 80% chilled ethanol, 500µL 
• Centrifuge, 16 000g, 4°C, 10 minutes 
RNA reconstitution • Air-dry RNA pellet and dissolve pellet in 
appropriate volume of DEPC-treated water; 
mix by pipetting 
• Set aside 2-5µL aliquot for 
spectrophotometric quantitation  
Quantitation A260/280 ratio should exceed 1.8 
 
PREPARATION OF WHOLE-CELL PROTEIN LYSATES 
Precaution In Class II laminar flow hood; biohazardous 
waste disposal 
Cell pellet • Cell line or primary cell pellets in 1.5mL 
microcentrifuge tubes, washed twice with 
sterile PBS 
• Centrifuge setting/wash cycle: 300g, room 
temperature, 5 minutes  
Cell lysis • In NP-40 or citrate lysis buffer; 150-200µL 
for every 10 million cells 
• Incubate on ice, 15 minutes 
Clarification High-speed centrifugation (16 200g), 4°C, 15 
minutes; isolate supernatant  
Quantitation Five microliter aliquots set aside for 
quantitation of total protein content using a 
modified Lowry assay; the remainder stored as 
25-100µL  aliquots (-80°C) 
Immunoblotting  Volume equivalent to 25-30µg/10-15µL sample 
loading buffer (1×) / well. Boiled (95°C, 5 
minutes) before gel loading 
 
167 
Chapter 8 Section 3  Selected Methods Outline 
STRIPPING AND RE-PROBING OF PROTEIN IMMUNOBLOT MEMBRANES 
Note Membranes awaiting stripping may be placed 
in PBS for up to 3 weeks at 4°C  
Membrane stripping Place membrane in proprietary Restore 
stripping buffer (20mL/membrane), 30 
minutes, room temperature 
Wash  PBS, 2 washes, 5 minute / wash 
Blocking 5% (w/v) non-fat milk solution, 1 hour, room 
temperature 
Antibody probing As with standard immunoblotting 
 
CRYOPRESERVATION AND THAWING OF CELLS 
Cryopreservation of cells 
Note • In Class II laminar flow hood; biohazardous 
waste disposal 
• Cryofreezing container at room 
temperature, with fresh (< 5 freeze-thaw 
cycles) isopropanol 
• Thawed cryoprotectant solution, 
maintained chilled on ice 
Cell suspension Viable cells > 90%, early passage for cell lines 
(<10), known cell count, pelleted by 
centrifugation at 300g, room temperature, 5 
minutes; discard supernatant and disperse 
pellet in residual 
Cryoprotectant volume Estimate 1.0mL cryoprotectant for 10-30 
million cells / cryovial 
Adding cryoprotectant • Add along sides of tube, initially 1 drop 
every 10 seconds with continuous mixing; 
steadily accelerate drop rate after every 10 
drops until required volume dispensed 
• Dispense 1.0mL/cryovial 
Storage • In cryofreezing container, -80°C for 12-16 
hours 
• Subsequently, to liquid phase of liquid 
nitrogen vessel; record storage details 
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Thawing of cryopreserved cells 
Note • In Class II laminar flow hood; biohazardous 
waste disposal 
• Cryovial maintained on dry ice until time of 
rapid thaw 
• Risk of contamination during rapid thaw of 
cryovial in circulating water bath; ensure 
cryovial placed in water bath above level of 
O-ring and ethanol-spray (70%) outer walls 
of vial before opening  
Rapid thaw Water bath, 37°C, until tiny frozen residual 
Slow resuscitation • Transfer vial contents to a 15mL conical 
centrifuge tube 
• Add pre-warmed sterile complete growth 
medium in drops along sides of tube, while 
gently mixing. Add a drop every 10 
seconds and accelerate drop-rate after 
every 10 drops until 2.5mL; bring volume to 
10mL by dripping complete growth medium 
along sides of tube 
Washes   • Pellet cells by centrifugation (300g, room 
temperature, 5 minutes) 
• Pipette-aspirate supernatant and discard 
• Disperse pellet and resuspend in fresh 
complete growth medium, 10mL; re-pellet 
by centrifugation (300g, room temperature, 
5 minutes) 
Cell suspension Resuspend cell pellet in complete growth 
medium (10mL) following 2nd wash. Cells are 
now suitable for downstream applications 
(estimate cell counts and viability before use)  
or may be maintained in cell culture (10mL 
volume in a 25cm2 cell culture flask) 
 
TRYPSIN MOBILISATION OF ADHERENT CELLS 
Note Adherent cells mobilised at a cell confluence 
of ~75% 
Removal of spent medium • Pipette-aspirate and discard spent medium 
without disturbing adherent cell monolayer 
• Gently layer with warmed PBS 
(10mL/75cm2 flask); aspirate-discard to 
remove residual growth medium 
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Trypsin-EDTA treatment • Add 0.5% Trypsin-EDTA 
• 2-5 minutes, 37°C/5% CO2 
Neutralise Trypsin Add equivalent volume of complete growth 
medium to neutralise Trypsin activity (for 
motility assays, use DMEM with 1% FBS) 
Wash cells Pellet cells by centrifugation, 300g, room 
temperature, 5 minutes; pipette-discard 
supernatant and disperse cell pellet 
Resuspend cells Reconstitute cells in fresh growth medium 
(with or without FBS, as the case may be)  
 
IMMUNOHISTOCHEMISTRY WORK FLOW 
Deparaffinise and rehydrate 
sections 
• Melt wax (60°C, 20 minutes) 
• Xylene immersions (5 minutes × 2) 
• Immersion in serially decreasing dilutions 
of ethanol (100%, 80%, 50%, 5 minutes, × 
2 immersions / dilution) 
Heat-induced epitope retrieval Tissue sections pressure-heated to 125°C in 
Tris-EDTA buffer for 10 minutes, then rapidly 
cooled in tap water (2 minutes) 
Endogenous peroxidase and 
biotin quenching 
• Methanol-peroxidase, 10 minutes 
• Tap water wash 
• Avidin blocking solution, 20 minutes 
• PBS wash  
• Biotin blocking solution, 20 minutes 
• Tap water wash  
Primary antibody layer • 40 minutes, room temperature 
• 1-minute PBS-Tween washes × 2 
• Negative controls, PBS only 
Secondary antibody layer • 30 minutes, room temperature 
• 1-minute PBS-Tween washes × 2  
Detection amplification • Avidin-biotin complex, 20 minutes 
• 1-minute PBS-Tween washes × 2 
Substrate chromogen • DAB solution, 10 minutes, monitor 
browning 
• Tap water rinse 
Haematoxylin counterstain • Haematoxylin 5 minutes 
• 0.3% acid-alcohol differentiation 
• Running water, 5 minutes, for blueing 
Dehydration and mounting • Dehydration in increasing concentrations of 
ethanol, then Xylene 
• DPX mounting and automated 
coverslipping 
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Dual Immunohistofluorescence staining (AEP and CD68)
Deparaffinise and rehydrate 
sections 
Tissue sections deparaffinised in CitroClear (a 
limolene-based xylene substitute) and serially 
rehydrated in decreasing strength alcohols 
(100%, 50%, 30%); 2 immersions each, 3 
minutes per immersion 
Heat-induced antigen retrieval Slide sections in Tris-EDTA buffer, pressure-
heated to 125°C, 2 minutes, slow cool to 85°C, 
then rapid cool in running tap water 
Dual primary antibody staining Goat polyclonal anti-AEP (1:300) and mouse 
monoclonal anti-CD68 (PG-M1, undiluted) in 
PBS; 125µL/slide section, room temperature, 
45 minutes (covered) 
Washes PBS, 1 minute/wash × 2 
Secondary antibody staining Rabbit-derived secondaries; TRITC anti-
mouse and Alexa Fluor 488 anti-goat 
immunoglobulins; 45 minutes, covered, light-
protected, room temperature 
Washes PBS, 1 minute/wash × 2 
DAPI nuclear counterstain and 
mounting 
DAPI in fluorescent mounting medium 
(1:1000), 100µL/tissue section, coverslipped, 
in slide tray with aluminium foil wrap; 4°C 
storage until imaging 
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Section 8.4 Selected protocol worksheets 
 
FIRST STRAND CDNA SYNTHESIS 
Step 1: Prepare RNA solution at 500ng/µL in 0.2mL PCR tubes 
Sample ID Sample 
details 
RNA ng/µL Dilution 
factor 
Volume for 
500ng (µL) 
Water to 
10.5µL 
      
 
Add random primer 1.5µL (150ng) to each tube 
 
Step 2: 42°C, 5 minutes; samples immediately to ice 
 
Step 3: Prepare reverse transcriptase (RTase) master mix 
       1×  (No. of samples+2)×
 dNTP 2.5mM   10µL 
 RTase Buffer, 5×    6µL 
 M-MLV RTase 400U   2µL      
 Total    18µL 
Pulse-vortex to mix, spin to collect; dispense 18µL mastermix to each tube   
      
Step 4: 42°C for 60 minutes, 95°C for 5 minutes 
 
Step 5: Add RNase H 2µL (2U) to each tube; 42°C for 20 minutes 
 
Step 6: Prepare cDNA samples for 384-well plate loading  
  Dilute 10.5µL sample cDNA in 102.5µL sterile water; vortex to mix 
  Include 1 tube as ‘No Template’ control (NTC, 112.5µL water)  
 
RQ-PCR REACTION MIX  
Reaction mix for each transcript, estimated for ‘n’ samples on a 384-well plate 
      1×  [(n+2)*4]×   
RQ-PCR mastermix, 2×  5.0µL 
Taqman probe-primer mix, 20× 0.5µL     
Total     5.5µL 
 
Pulse-vortex, spin to collect, maintain at 4°C until loaded to plate 
 
PLATE LAYOUT FOR AUTOMATED PIPETTING OF RQ-PCR REACTION MIX 
For 2 transcripts and ‘n’ samples (n1…, including NTC) on a 384-well plate  
For each sample, 4.1µL cDNA loaded/well across rows 
For each transcript, 5.5µL RQ-PCR reaction mixes loaded/well along columns   
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AEP β2M Sample 
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 
       
 
LIPID TRANSFECTION OF ADHERENT CELLS 
Check cell confluence (~80% confluence, 0.5-2×105 cells in 1mL complete 
growth medium [12-well plate format]) 
 
For a 12-well plate 
Step 1: Plasmid solution at 100ng/µL  
     
Plasmid ng/µL  Volume for 5µg Water to 50µL 
    
    
 
Step 2: Prepare DNA-OptiMEM I mix 
For each plasmid DNA 
     1×  (No. of wells+2)×
DNA 100ng/µL  10µL 
 OptiMEM I   90µL      
 Total    100µL 
Pulse-vortex to mix, short spin to collect and stand at room temperature 
 
Step 3: Prepare Lipofectamine-OptiMEM I mix 
     1×  (No. of wells+2)×
 Lipofectamine 2000  4µL 
 OptiMEM 1   96µL      
 Total    100µL 
Pulse-vortex to mix, short spin to collect; stand at room temperature for 5 min 
 
Step 4: Prepare DNA-OptiMEM I/Lipofectamine-OptiMEM I mix 
For each plasmid DNA  
     1×  (No. of wells+1)×
 DNA-OptiMEM I   100µL 
 Lipid-OptiMEM I  100µL      
 Volume/well   200µL 
 
For untransfected control cells 
     1×  (No. of wells+1)×
 OptiMEM I only  100µL 
 Lipid-OptiMEM I  100µL      
 Volume/well   200µL 
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Pulse-vortex to mix, short spin to collect; stand at room temperature, 20 min 
Dispense 200µL of Step 4 mix to respective wells  
 
Confirm successful transfection after 48 hours. If required, replace growth 
medium after 24 hours.  
 
 
PROTEIN QUANTITATION ASSAY 
Step 1: Prepare BSA standards using the BSA stock solution (5mg/mL) 
Prepare a 50µL volume of each standard (except a 100µL volume for the 
100µg/mL standard to account for small-volume pipetting errors) 
 
Step 2: 
 
Standards 
ID 
BSA (µg/mL) Volume of BSA 
stock (µL) 
Volume of lysis 
buffer (µL) 
S1 0 0 50 
S2 100 2 98 
S3 200 2 48 
S4 400 4 46 
S5 800 8 42 
S6 1200 12 38 
S7 1600 16 34 
S8 2000 20 30 
  64µL total 386µL total 
 
 
 
Prepare appropriate dilutions (1 in 5 or 1 in 10) of test samples in lysis buffer 
 
Step 3: Dispense 5µL BSA standard in duplicate in a 96-well flat-bottomed plate 
(BD Falcon) followed by 2-5µL of test samples (X1…, duplicates if available) 
(plate layout below) 
 
S1 S1 X1 X1         
S2 S2 X2 X2         
S3 S3           
S4 S4           
S5 S5           
S6 S6           
S7 S7           
S8 S8           
 
Step 4: Reagent A’ 
Prepare Reagent A’ (To 1mL Biorad DC assay reagent A, add 20µL Reagent S; 
mix). Add 25µL to each well and mix (avoid frothing) 
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Step 5: Biorad DC assay reagent B  
Add 200µL to each well 
 
Step 6: Incubate for 15 minutes, covered, at room temperature 
 
Step 7: Read end-point absorbance at 690nm (650-750nm reading range); 
ensure nil air bubbles before reading 
 
Step 8: Estimate volume of whole-cell lysate required for immunoblotting 
experiments  
E.g.: For a whole cell lysate X required to load a well each in two gels,   
(a) First, calculate total protein content of whole cell lysate by reading off from the 
BSA standard curve after appropriate corrections for sample dilution.  
(b) Then for a 3mg/mL (as an example) total protein content, volume required for 
a well each in 2 gels at 25µg total protein/ 15µL/ well/gel  
Sample lysate Volume for 75µg 
total protein (µL) 
Volume of 5 ×  
loading buffer (µL) 
Volume of lysis 
buffer to 45µL 
X (3mg/mL) 25 9 11 
 
 
AEP ACTIVITY ASSAY  
Step 1: Prepare working dilutions of reagents 
1. Assay Reagent 
Prepare 10mL 1× assay reagent using deionised water 
Add 20µL 0.5M DTT (effectively, 1mM DTT) 
Add 10µL 10% CHAPS (effectively, 0.01% CHAPS) 
2. Prepare 7-NHMeC standards (S1 to S8) 
Dilute 5µL stock solution in 45µL DMSO for a 2mM 7-NHMec solution 
25µL 2mM 7-NHMec + 175µL assay buffer = 250µM 7-NHMeC, 200µL 
S1 5µL 250µM 7-NHMeC + 495µL assay buffer = 2.5µM 7-NHMeC 
S2 5µL 250µM 7-AMC + 620µL assay buffer = 2.0µM 7-NHMeC 
S3 250µL S1 + 250µL assay buffer = 1.25µM 7-NHMeC 
S4 250µL S3 + 250µL assay buffer = 0.625µM 7-NHMeC 
S5 250µL S4 + 250µL assay buffer = 0.3125µM 7-NHMeC 
S6 250µL S5 + 250µL assay buffer = 0.15625µM 7-NHMeC 
S7 250µL S6 + 250µL assay buffer = 0.078125µM 7-NHMeC 
S8 250µL assay buffer only 
  
3. Prepare working dilution of AEP synthetic fluorogenic peptide substrate 
Add 10µL Z-Ala-Ala-Asn-NHMeC to 5mL deionised water (effectively, 20µM) 
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4. Prepare whole cell lysates (citrate lysis buffer) in assay reagent 
For each lysate, estimate for 5 wells at 20µg total protein/50µL assay 
reagent/well 
 
ID Sample Protein µg/µL Volume for 
100µg (µL) 
Assay buffer to 
250µL 
     
     
  
5. The AEP inhibitor MV026630 (AEPi) 
Prepare a 1mM AEPi solution in assay reagent (1 in 10 dilution of stock) 
Prepare a 50µM AEPi solution in assay reagent from the 1mM working 
solution; volume estimated as [(no. of samples + 2) × 2] × 25µL 
 
Step 2: Add reagents to 96-well plate  
Order of adding reagents (plate layout below) 
• Add 25µL 50µM AEPi solution to wells (in e.g., A5-F5; A6-F6) 
• Add 25µL assay buffer to all other wells 
• Add 50µL lysates to wells in duplicates for each condition [in e.g., X1-X6 
without AEPi  and X1i-X6i with AEPi] 
• Add 50µL standards S1-S6 in duplicates to wells as below 
• To all wells, add 25µL substrate solution 
 
  1  2  3  4  5  6  7  8  9  10  11  12 
A  S1  S1  X1  X1  X1i  X1i             
B  S2  S2  X2  X2  X2i  X2i             
C  S3  S3  X3  X3  X3i  X3i             
D  S4  S4  X4  X4  X4i  X4i             
E  S5  S5  X5  X5  X5i  X5i             
F  S6  S6  X6  X6  X6i  X6i             
G  S7  S7                     
H  S8  S8                     
 
Step 3: Incubate (covered) at 37°C for 30 minutes.  
 
Step 4: Ensure nil air bubbles; ensure constant gain setting and read end-point 
fluorescence (excitation 360nm, emission 460nm)  
 
Step 5: Subtract averaged Xni well fluorescence readouts from readouts in Xn 
wells to derive activity-specific fluorescence  
 
Express activity as ‘fluorescent units/µg total protein/30 minutes’ 
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Section 8.5 Optimisation-validation exercises in experimental protocols 
• Estimation of AEP transcript expression (qRT-PCR) 
• Cathepsin B immunoblotting  
• Immunostaining controls 
• Immunohistochemistry controls 
• Enforced and inducible AEP-expressing HEK293 cells  
• Boyden chamber motility assays 
• Cell culture supernatants and AEP immunoblotting  
 
Estimation of AEP transcript expression (qRT-PCR) 
1. This was a two-step approach, i.e. reverse transcription, followed by real-time 
quantitation using on-demand TaqMan probe-primer reagents 
2. Relative normalized AEP transcript expression was determined using the 
comparative cycle threshold (Ct) method (2-∆∆Ct).  
3. Suitability of choice of β2-microglobulin (β2M) as reference transcript was 
established from global gene-expression microarray analyses of primary 
leukaemic cells (Table 8.1, Figure 8.1). Other candidate transcripts examined 
included β-glucuronidase (GUS), β-actin (ACTB), Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and Abelson murine leukaemia viral 
oncogene homolog-1 (ABL1). Of the candidates examined, expression of 
β2M was both physiological (i.e. near-normal distribution) and minimally 
variable (as determined by the coefficient of variation), making it an 
appropriate reference transcript.  
4. Validation of suitability of applying the 2-∆∆Ct method for relative normalised 
AEP transcript estimation was established by step-wise determination of the 
following parameters [1]  
• Dynamic linear amplification characteristics of AEP and β2M transcripts 
• Equivalence and acceptability of amplification efficiencies for both 
transcripts 
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• Appropriate working range of input RNA 
5. Amplification efficiencies of AEP and β2M transcripts were appropriately 
equivalent (AEP 1.03, β2M, 0.98; 384-well format) and dynamically linear 
over a wide range of input RNA (spanning a 64-fold dilution from 31.25ng to 
2.0µg), with a working range of 0.125-2.0µg input RNA as most suitable 
(difference in AEP and β2M transcript Ct values were best maintained over 
these dilutions) (Figure 8.2) 
6. As assay protocols were previously established on 96-well reaction plates, 
assessment of the equivalence of 96-well and 384-well assay formats was 
also performed; results were comparable (Tables 8.2 and 8.3)  
7. Assay precision was satisfactory; this was based on inter-assay estimation of 
normalised AEP transcript expression of the calibrator (HRC57 cell line) using 
RNA as starting material (Table 8.4) 
 
Cathepsin B immunoblotting 
1. Autoactivation of the inactive zymogen (44-46kDa, depending on 
glycosylation) to the mature 31-33kDa single-chain enzyme is triggered by 
increasing acidification of the maturing endosome; further transition to the 2-
chain form (24-27kDa heavy chain, 5kDa light chain,) is mediated by other 
lysosomal proteases (e.g. AEP) [2, 3] (Figure 8.3). 
2. The following antibodies to human Cathepsin B (CTSB) were investigated:  
a) three rabbit polyclonal antibody preparations, including two from Merck 
Biosciences (product codes 219408 and PC41) and one from Enzo Life 
Sciences (Biomol SA-361)  
b) two mouse monoclonal antibodies, including an IgG2a isotype preparation 
from Merck Biosciences (clone CA-10) and an IgG1 isotype preparation 
(clone 155714) from R&D Systems.  
3. All antibodies were tested for ability to detect CTSB in whole cell lysate  
immunoblots from known positive human cell line controls (K562 and HeLa 
cell lines). Selected antibodies were also examined for ability to detect 
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inactive and single-chain mature forms of purified recombinant protein 
(recombinant human CTSB activated in 2-(-N-morpholino)ethanesulphonic 
acid buffer, pH 5.0).  
4. Among the polyclonal preparations, Biomol SA-361 was the most satisfactory 
(Figure 8.4C). Detection bands were crisp and distinct. The antibody 
consistently detected the heavy-chain (H-chain) component of the 2-chain 
active protease in whole cell lysates. Sensitivity was retained over dilutions 
(1:5000 to 1:20 000) (Figure 8.4B) and was enhanced with use of an HRP-
conjugated secondary antibody from Dako.  Antibody incubation times were 
empirical. The antibody detected both precursor and single-chain mature 
forms of CTSB in an activated purified preparation but demonstrated greater 
affinity for the H-chain form in complex mixtures. (Figure 8.4A) 
5. Although the CA-10 clone was generated from an epitope in the H-chain 
sequence, the antibody preferentially detected single-chain active CTSB in 
whole cell lysates (Figure 8.4A). Initial assessment was hampered by an 
unsatisfactory HRP-conjugated secondary antibody; detection was greatly 
enhanced with use of a secondary preparation from Dako but opportunity to 
further evaluate was not available. The 155714 clone failed in tests on known 
positive cell line controls (data not shown) and was not assessed further.  
6. Results of CTSB immunoblotting in a panel of leukaemia cell line lysates 
indicated good agreement between the CA-10 monoclonal and Biomol SA-
361 polyclonal antibodies (Figure 8.5).  
7. Additional optimisation steps including evaluation of detection specificity (in 
transcript-depleted or gene-deleted samples) and correlation with enzyme 
activity were not performed.  
 
Cell immunostaining 
1. The following cell fixation protocols for AEP immunostaining were 
investigated on SD1 cytospin preparations (data not shown):  
a) 3.7% formalin, 15 minutes incubation at room temperature, followed by 
permeabilisation with 0.25% Triton X-100 in PBS 
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b) 100% chilled methanol, 10 minutes incubation at -20°C; no 
permeabilisation 
c) 1:1 methanol:ethanol, equal volumes of chilled methanol and acetone with 
interval chilled PBS washes, serial 10-minute incubations at -20°C; no 
permeabilisation 
Cellular features and subcellular architecture were best preserved with 
formalin-fixation. 
2. Negative staining controls were included in all cell AEP immunostaining 
experiments (Figure 8.6). This initially included controls for both primary and 
secondary antibodies at equivalent dilutions in 1% BSA. As primary antibody 
control, non-immune goat serum (pre-cleared of aggregates by syringe 
filtration and centrifugation) substituted the goat polyclonal anti-human AEP 
antibody. As secondary antibody control, 1% BSA substituted the fluorophore-
conjugated anti-goat secondary. Images of controls were captured using 
microscope camera settings identical to those of test samples. Both negative 
controls were satisfactory and subsequent experiments only included the 
secondary antibody control.   
3. Live cell labelling of acidic organelles was initially performed using a 100nM 
concentration of the LysoTracker Red DND-99 (LyTR) probe. Incubation time 
and cell density were as advised by manufacturer. Although labelling was 
successful, signal intensities were weak and required extended exposures for 
image capture despite use of a sensitive low-light imaging system. Probe 
labelling concentration was increased to 500nM with resulting improvement in 
signal intensity and no apparent non-specific labelling.   
4. Live cell labelling of mature AEP using the fluorophore-tagged activity binding 
probe was performed as advised by Dr. Matthew Bogyo’s lab (Stanford 
University, CA, USA). DMSO vehicle concentrations in live culture did not 
exceed the recommended 0.1% (v/v).  Probe specificity was established by 
examining labelling in SD1 cells pre-incubated with the cell-permeable AEP 
inhibitor (AEPi), MV026630 (using an established non-lethal dose of 100µM, 
12 hours, 37°C; Figure 8.7). Further evaluation of probe specificity, including 
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intracellular labelling in stable AEP transcript-depleted SD1 cells and in cells 
transduced with catalytically-inactive AEP, was precluded by limited probe 
availability. The Bogyo lab has recently reported on the labelling performance 
of the probe (Chapter 3, [2]). 
5. Labelling specificity of AEP antibody and activity-binding probe was 
additionally confirmed by fixed cytospin staining of the AEP non-expressing 
ALL cell lines REH and SupB15 (Figures 8.8 and 8.9) 
6. Only a secondary antibody negative control was assessed when staining for 
LAMP1 with the mouse HA-43 monoclonal antibody.  
 
AEP Immunohistochemistry 
The following components of the experimental protocol were evaluated and 
optimised: 
1. Identification of positive staining controls  
These included formalin-fixed paraffin sections of colorectal adenocarcinoma 
and the HRC57 cell line. Agarose moulds of HRC57 were created by 
resuspending cell pellets (2 × 106 cells) in 1-2 drops of cooled ultra-pure low 
melting point agarose (fluid at 37°C, setting temperature <25°C; Invitrogen) in 
1.5mL microfuge tubes; post-set, cell moulds were loosened by tapping the 
base of microfuge tubes and submitted for formalin fixation and paraffin 
embedding (Experimental Pathology division, CRUK London Research 
Institute).  Positive controls were included in each staining run. 
2. Optimal antigen retrieval technique  
a) Heat-induced antigen retrieval of de-paraffinised tissue sections in Tris-
EDTA was the optimal epitope unmasking technique for AEP tissue 
immunostaining. 
b) Also examined were heat-induced antigen retrieval in Citrate buffer and 
proteolytic enzyme antigen retrieval using Pronase (pre-warmed [37°C] 
de-paraffinised tissue sections were incubated in a Coplin jar with Pronase 
[1mg/mL in PBS; Sigma-Aldrich] for 15 minutes at 37°C)  
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3. Minimisation of endogenous tissue peroxidase and biotin activity  
Attempts to minimise irrelevant background tissue staining were performed 
immediately following antigen retrieval and included  
a) Quenching of endogenous peroxidase activity by immersion of tissue 
sections in hydrogen peroxide-methanol (0.3% hydrogen peroxide, 10 
minutes) and use of sodium azide in diluent solutions of primary and 
secondary antibodies 
b) Quenching of endogenous biotin activity using a proprietary avidin-biotin 
blocking solution 
4. Negative staining controls (Figure 8.10) 
Created for each sample in parallel with primary antibody layer; AEP antibody 
substituted by 1% BSA in primary layer (secondary antibody control) 
5. AEP antibody dilution 
A dilution of between 1:300 and 1:400 was established to be optimal 
6. Controls for AEP-CD68 dual tissue immunofluorescence labelling 
Single-fluorescence labelling controls and controls for antibody cross-
reactivity (primary-secondary antibody combinations for AEP with isotype-
secondary antibody combinations for CD68 and vice-versa) were not 
examined as sufficient tissue sections were not available 
 
Stable enforced and inducible AEP-expressing HEK 293 cells 
The following procedures were evaluated and optimised as part of this line of 
work: 
1. Optimal selection dose of G-418 sulphate for isolation and maintenance of 
enforced AEP-expressing HEK293 cells 
HEK293 cells were placed in 6-well plates (0.5×106 cells in 2mL complete 
DMEM / well) and incubated with a range of G-418 doses (0, 0.2, 0.4, 0.8, 1.0, 
1.2 mg/mL). G-418 selection was refreshed every 48-72 hours.  Viability was 
serially assessed by phase-contrast microscopy. Complete cell kill was 
observed at a G-418 dose of 0.8mg/mL (day 8-10) while viable cells were still 
observed at lower doses. An initial G-418 dose of 0.8mg/mL was therefore 
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used for positive selection of transfected cells. Once growth of transfected 
cells was established and enforced expression confirmed, selection was 
switched to a lower G-418 maintenance dose of 0.6mg/mL.   
2. Mifepristone (Mfp) dosing for optimal expression in inducible AEP-expressing 
HEK293 cells 
a) Stably transfected inducible-expressing cells (0.5×106 cells in 1mL 
complete DMEM, 12-well plate) were treated for 24 hours with different 
concentrations of Mifepristone (0.01-100nM). Cells were subsequently 
mobilised, pelleted, washed and lysed in NP-40 protein lysis buffer. AEP 
expression was examined by immunoblotting. Induction of expression was 
best observed with a 10nM dose of Mifepristone (Figure 8.11, upper 
panel). This was also the induction dose recommended by the 
manufacturer. 
b) Duration of induced AEP expression was determined by serially tracking 
expression in transfected cells treated with a 24-hour pulse of 10nM 
Mifepristone.  Cells were placed in 12-well plates (0.5×106 cells in 1mL 
complete DMEM). Post-treatment, growth medium was refreshed and 
cells were harvested at different time points (12, 24, 48, 72 and 96 hours). 
AEP expression was examined by immunoblotting. Expression was 
observed 24 hours following pulse treatment and was maintained for at 
least 72 hours (Figure 8.11, lower panel). 
c) Optimal duration of Mifepristone treatment for induction of AEP expression 
was not investigated. A 24-hour treatment was advised by the 
manufacturer. 
d) Some baseline AEP expression was observed in non-treated controls. 
This could potentially be a consequence of endogenous steroid hormones 
in foetal bovine serum (FBS) mimicking the inducing effect of Mifepristone. 
Assessment of impact of elimination of endogenous steroid hormones on 
baseline AEP expression, for instance by charcoal treatment of FBS, was 
not performed.    
3. Evaluation of variability of AEP expression in inducible-expressing cells 
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Flow cytometry was used in a single experiment to assess the variation in 
AEP expression in the stably transfected polyclonal population of inducible-
expressing HEK293 cells. Mifepristone-treated cells (2×105, passage 15) 
were fixed-permeabilised (Cytofix/Cytoperm reagent, BD) and incubated with 
anti-AEP primary (1:100 dilution, 2µg/mL) and Alexa Fluor 488-conjugated 
secondary (1:1000 dilution) antibodies with appropriate intervening wash 
steps (Perm/Wash buffer, BD). Negative controls included Mifepristone-
untreated cells and treated cells incubated with either non-immune goat 
serum or 1% BSA in PBS as primary antibody substitute. Fluorescence was 
acquired on the BD FACScan instrument (488nm laser, FL1 530/30 bandpass 
filter) and examined using the WinMidi analysis package.    
Despite polyclonality, intracellular AEP expression was closely clustered and 
was 1-2 logs higher than non-induced control (Figure 8.12). Negative controls 
were appropriate (not shown).  
4. Evaluation of variability and intracellular localisation of AEP expression in 
enforced AEP-overexpressing cells 
In a single experiment, AEP immunostaining was used to examine expression 
characteristics in enforced expressing and mock-transfected controls. Cells 
(1×105, pass 9) were cultured to sub-confluence in 35mm glass bottom dishes 
(ibidi GmbH) and stained in-situ. Negative primary and secondary antibody 
controls were included. As expected, expression was heterogenous in the 
over-expressing polyclonal population and included a mix of strong-, 
intermediate- and weak/non-expressing cells. Intracellular localisation was 
similarly variable, occurring as either peripheral or perinuclear aggregates, or 
in some cases, a combination of the two (Figure 8.13). 
5. Interval confirmation of overexpressing phenotype, including after cryostorage 
retrieval 
Interval assessment of AEP overexpression by immunoblotting and enzyme 
activity was performed through the course of experiments to monitor 
phenotype stability and detect cross-contamination between experimental and 
control cells.  
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6. Concentration of selection agents (Hygromycin and Zeocin) in the isolation 
and maintenance of inducible-expressing HEK293 cells were as 
recommended by manufacturer.  
7. Clonal isolation (e.g. by limiting dilution) of transfected HEK293 cells to 
establish low-, intermediate- and high-expressing clones, was not performed.  
 
Boyden chamber motility assays 
Experimental procedures were largely based on local expert advice. The 
following components of the experimental protocol were evaluated; 
1. Matrigel coating of inserts 
Boyden chamber assays of inducible-expressing HEK293 cells were 
performed using 8-micron pore inserts coated with Matrigel at varying 
dilutions (in serum-free DMEM). At dilutions of up to 1 in 10 (1mg/mL), 
Matrigel polymerises to form a surrogate basement membrane matrix while at 
higher dilutions, it merely forms a non-barrier protein membrane coat that 
perhaps facilitates cell adhesion and motility. At higher Matrigel dilutions (1 in 
20 upwards), lower chamber counts of Mifepristone-untreated cells assessed 
24 hours after insert loading, were fairly constant while results were variable 
for Mifepristone-treated cells (10nM, 24 hours) (Figure 8.14). Based on 
published work (Chapter 2, [24]), subsequent assays were performed using a 
Matrigel coating dilution of 1 in 50.   
2. Cell culture conditions pre-assay 
The following variables were assessed 
a) Cell passage  
Enforced- and inducible-expressing cells were passaged 48 hours prior to 
Boyden chamber assays. This ensured that cells were optimally sub-
confluent and could be mobilised without forming aggregates. Assays 
were only performed when cell viabilities (Trypan Blue exclusion staining) 
were near 100%. In inducible-expressing cells, Mifepristone (10nM) or 
vehicle control (ethanol, equivalent volume) was added to growth medium 
24 hours pre-assay.  
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b) Serum starvation to minimise background adhesion-motility signals 
Cells were serum-starved for 24 hours by replacement of complete growth 
medium with serum-free DMEM. Serum starvation altered cell phenotype, 
with aberrant morphology (cytoplasmic swelling on phase-contrast 
microscopy) and enhanced adhesion (i.e. difficult Trypsin-EDTA 
mobilisation of cell monolayers in culture flasks and dishes). Cells were 
therefore not serum-starved pre-assay. Shorter serum withdrawal times 
were not assessed. 
3. Loading cell counts in inserts were as recommended by manufacturer (1×105 
cells in 0.3m2 8-micron pore inserts). Inserts with greater pore diameters (e.g. 
12-micron) were not assessed.  
4. All Boyden chamber assays using matrigel-coated inserts were evaluated 
after 24 hours incubation. Extended incubation times were not investigated,  
 
AEP activity assay 
The fluorometric substrate cleavage assay was adapted from a published report 
[4] and from a protocol established in Dr. Colin Watts’ lab (Cell Biology and 
Immunology, University of Dundee). The following parameters were evaluated 
and optimised: 
1. Fluorescence standard  
In serial experiments, reference range of the 7-amino 4-methyl coumarin 
fluorescence standard was calibrated such that mean fluorescence generated 
by the positive control, SD1 whole cell lysate, fell within the middle of the 
linear standards dilution curve.  
2. Inhibition of substrate cleavage  
To enable detection of AEP-specific substrate cleavage in whole cell lysates, 
reactions were performed with and without the addition of a selective AEP 
inhibitor (AEPi, MV026630; [5]). Optimal AEPi concentration was initially 
assessed in SD1 control lysates and was established at 50µM.  
3. Assay performance was monitored by including SD1 as control lysate in 
experiment runs.  
186 
Chapter 8 Section 5   Optimisation-Validation 
AEP in cell supernatants 
Appropriate RPMI growth medium requirements for investigation of AEP in cell-
free supernatants were evaluated. AEP immunoblotting of complete growth 
medium alone consistently revealed a 56kDa protein band, similar to that seen 
with pre proAEP (Figure 8.15). The confounding protein band was detected 
across all dilutions of foetal bovine serum (FBS) and was observed even after 
microvesicle depletion of FBS by ultracentrifugation (data not shown) but was not 
detected in serum-free RPMI. Thus, experiments investigating AEP expression in 
cell supernatants were performed by culturing cells in serum-free RPMI. To 
control for passive extracellular protein leak as a result of cell death, cell viability 
was assessed (Trypan blue exclusion) and ascertained to be near 100% in 
experiments.   
 
Experimental protocols adopted en bloc  
The following experimental procedures were adopted largely unmodified based 
on either well-established local practice or robust manufacturer protocols; 
additional comments are appended  
1. Protein quantitation and immunoblotting 
The goat polyclonal anti-human AEP antibody (R&D) has been evaluated 
against non-commercial mouse monoclonal antibodies (clones 6E3 and 11B7, 
Dr. Colin Watts) in whole cell lysates and in purified recombinant protein 
preparations (not shown). When combined with an HRP-conjugated donkey 
secondary from Santa Cruz, the optimal working dilution of the polyclonal 
antibody was 1:2500 (80ng/mL) with incubation times of 2 hours (room 
temperature) or 12-16 hours (4°C). Antibody specificity has subsequently 
been demonstrated in immunoblotting experiments of lysates from transcript-
deplete and enforced-expressing cells as well as in monoclonal antibody 
immunoprecipitates of cell lysates.  A protein-expressing positive control was 
included in all immunoblotting experiments.  
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2. Mononuclear cell isolation in clinical samples 
Bone marrow samples typically had in excess of 90% lymphoblasts at 
diagnosis and additional blast enrichment was not performed. Lymphoblast 
proportion in mononuclear cell isolates was not assessed post-processing. 
Almost all primary samples used in experiments were processed within less 
than 24 hours of collection. Sample integrity was indirectly estimated by 
examining relative transcript expression of the housekeeping β2M gene.  
3. RNA isolation 
RNA was isolated from banked samples, aliquots of which were previously 
used for RNA extraction towards microarray experiments. The satisfactory 
quality of RNA in microarray experiments serves as a surrogate estimate of 
sample integrity. 
4. Plasmid cloning  
Most procedures were based on robust manufacturer protocols. 
5. Lipid-based transfection 
Procedure was essentially based on manufacturer protocol.  
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8.6 Statistics 
Groups were compared using two-sided paired or unpaired t tests (2 groups) or 
by analysis of variance (more than 2 groups). Box-plot displays were used to 
better represent data dispersion. Linear association between continuous 
variables was investigated using the Pearson’s product moment correlation. The 
statistical significance threshold for single comparisons was 0.05.  Analyses were 
performed using the SPSS analysis package and the MS-Excel software.  
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Section 8.7 Catalogue of Product Suppliers 
   
Abcam Plc 
(www.abcam.com) 
Cambridge Science Park 
Cambridge, UK 
Applied Biosystems 
(www3.appliedbiosystems.com) 
Applied Biosystems 
Lingley House, Birchwood Boulevard 
Warrington, UK 
Anachem Ltd 
(www.anachem.co.uk) 
Anachem Ltd., 
Anachem House, Charles Street, Luton, 
Bedfordshire, UK 
Appleton Woods  
(www.appletonwoods.co.uk) 
Appleton Woods Ltd. 
Lindon House, Heeley Road, Selly Oak 
Birmingham, UK 
Affymetrix  
(www.affymetrix.com) 
Affymetrix UK Ltd. 
Voyager, Mercury Park, 
Wycombe Lane, Wooburn Green 
High Wycombe, UK 
Axis-Shield UK 
(www.axis-shielduk.com) 
Axis-Shield UK 
Ouse Road, Bicton Industrial Park 
Cambridgeshire 
Bachem  
(www.bachem.com) 
Bachem Distribution Services GmbH 
Hegenheimer Strasse, Weil am Rhein, Germany 
Beckman Coulter (UK) 
(www.beckmancoulter.co.uk) 
Beckman Coulter (UK) Ltd 
Oakley Court, Kingsmead Business Park 
London Road, High Wycombe 
BD Biosciences 
(www.bdeurope.com) 
BD Becton Dickinson UK Ltd. 
The Danby Building, Edmund Halley Road 
Oxford Science Park, Oxford, UK 
Bio-Rad Laboratories 
(www3.bio-rad.com) 
Bio-Rad Laboratories Ltd. 
Bio-Rad House, Maxted Road 
Hemel Hempstead, Hertfordshire, UK 
  
190 
Chapter 8 Section 7  Life Science Product Suppliers 
Carl Zeiss UK 
(www.zeiss.co.uk) 
Carl Zeiss Ltd. 
Woodfield Road, Welwyn Garden City 
Hertfordshire, UK 
Corning 
(www.corning.com/lifesciences) 
Corning B.V. Life Sciences 
Fogostraat , Amsterdam, The Netherlands 
Dako UK 
(www.dako.co.uk) 
Dako UK Ltd. 
Cambridge House, St. Thomas Place, 
Ely, Cambridgeshire, UK 
DNAStar 
(www.dnastar.com) 
DNASTAR, Inc. 
Regent Street, Madison, WI 53705, USA 
Enzo Life Sciences 
(www.enzolifesciences.com) 
Enzo Life Sciences (UK) Ltd. 
Palatine House, Matford Court 
Exeter, UK 
Eppendorf 
(www.eppendorf.co.uk) 
Eppendorf UK Ltd. 
Endurance House, Chivers Way 
Histon, Cambridge, UK 
Fisher Scientific 
(www.fisher.co.uk) 
Fisher Scientific UK Ltd 
Bishop Meadow Road, Loughborough, 
Leicestershire, UK 
GE Healthcare Life Sciences 
(www6.gelifesciences.com) 
GE Healthcare Life Sciences 
Amersham Place, Little Chalfont 
Buckinghamshire, UK 
Integrated Biodiagnostics 
(www.ibidi.de) 
ibidi GmbH 
Am Klopferspitz 
Martinsried (München), Germany 
Invitrogen 
(www.invitrogen.com) 
Invitrogen Ltd 
Fountain Drive, Inchinnan Business Park 
Paisley, UK 
Laboratory Sales UK  
(www.ls-uk.com) 
Laboratory Sales (UK) Ltd. 
Transpennine Trading Estate 
Rochdale , UK 
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Merck4Biosciences 
(www.merck-chemicals.co.uk) 
Merck Chemicals Ltd. 
Boulevard Industrial Park, Padge Road,  
Beeston, Nottingham, UK 
Millipore 
(www.millipore.com) 
Millipore (U.K.) Ltd. 
Croxley Green Business Park 
Watford, UK 
Molecular Devices 
(www.moleculardevices.com) 
Molecular Devices 
Sunnyvale, CA, USA 
National Diagnostics 
(www.nationaldiagnostics.com) 
Distributed by Fisher Scientific UK 
New England Biolabs 
(www.neb.com) 
New England Biolabs (UK) Ltd. 
Knowl Piece, Wilbury Way 
Hitchin, Herts. UK 
Nikon Instruments Europe 
(www.nikoninstruments.eu) 
Nikon UK Ltd. 
Richmond Road, Kingston Upon Thames 
Surrey, UK 
Nunc-Nalgene products 
(www.nuncbrand.com) 
Part of ThermoFisher Scientific 
Olympus UK  
(www.olympus.co.uk) 
Olympus UK Ltd 
KeyMed House, Stock Road 
Southend-on-Sea, Essex, UK 
PAA Laboratories 
(www.paa.com) 
PAA Laboratories Ltd. 
Termare Close, Houndstone Business Park 
Yeovil, Somerset, UK 
Pierce Biotechnology 
(www.piercenet.com) 
Part of Thermo Fisher Scientific UK 
Promega 
(www.promega.com) 
 
Promega UK 
Delta House, Southampton Science Park 
Southampton, UK 
Qiagen 
(www1.qiagen.com) 
 
Qiagen House 
Fleming Way, Crawley 
West Sussex, UK 
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R&D Systems 
(www.rndsystems.com) 
  
R&D Systems Europe Ltd. 
Barton Lane, Abingdon Science Park 
Abingdon, UK 
Roche Applied Science 
(www.roche-applied-
science.com) 
Roche Diagnostics Ltd. 
Charles Avenue,  
Burgess Hill, UK 
Santa Cruz Biotechnology 
(www.scbt.com) 
Santa Cruz Biotechnology Inc. 
Heidelberg, Germany 
Sera Laboratories 
International 
(www.seralab.co.uk) 
Sera Laboratories International Ltd 
Bolney Grange Business Park 
Haywards Heath, West Sussex, UK 
Sigma-Aldrich 
(www.sigmaaldrich.com) 
Sigma-Aldrich Company Ltd. 
Dorset, UK 
Scientific Laboratory 
Supplies 
(www.scientificlabs.co.uk) 
SLS Ltd. 
Wilford Industrial Estate 
Ruddington Lane, Wilford, Nottingham, UK 
Starlab 
(www.starlab.co.uk) 
Starlab UK Ltd 
Tanners Drive, Blakelands 
Milton Keynes, UK 
VWR 
(uk.vwr.com) 
VWR International Ltd. 
The Birches, Willard Way,  
Imberhorne Industrial Estate 
East Grinstead, West Sussex, UK 
Vector Labs 
(www.vectorlabs.com) 
Vector Laboratories (UK) Ltd.  
 Accent Park, Bakewell Road 
 Orton Southgate, Peterborough, UK 
Wolf Laboratories 
(www.wolflabs.co.uk) 
Wolf Laboratories Ltd.  
Colenso House, Deans Lane,  
Pocklington, York, UK 
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Figure 8.1 β2M expression is near-normally distributed in childhood acute 
leukaemia  
Histograms with overlaid distribution curves of microarray expression of candidate 
reference genes in primary childhood leukaemia samples  
ACTB, β actin; GUS, β glucuronidase; ABL1, Abelson murine leukaemia viral oncogene 
homolog 1, GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; values represent 
relative normalised mean fluorescent intensities on the Affymetrix HG-U133A gene 
expression array platform, analysed using the  Genespring 7.3.1 software package 
(Table 8.1) 
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Figure 8.2 Amplification characteristics of AEP and β2M transcripts are similar.  
(A) Estimation of amplification efficiencies and dynamic linear range of AEP and β2M transcripts in the HRC57 cell line, using both 
96- and 384-well Taqman reaction formats (B) Normalised AEP transcript expression (the difference between AEP and β2M Ct 
values or Delta Ct) was best maintained over a 16-fold input RNA dilution of 0.125 μg to 2.0μg (Tables 8.2, 8.3) 
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Figure 8.3 Schematic representation of maturation sequence of human CTSB 
Progressive acidification in the maturing endosome generates a single-chain mature 
form through autoactivation. Additional cleavage by extrinsic proteases yields a two-
chain form. Variability in molecular weights reflects glycosylation status. 
 
 
 
 
 
 
 
Figure 8.4 Evaluation of candidate anti-human CTSB antibodies for 
immunoblotting 
Both the Biomol SA-361 rabbit (Rb) polyclonal and CA-10 mouse monoclonal antibodies 
(ab) detect precursor and single-chain mature forms in activated purified recombinant (rh) 
preparations (A). Biomol SA-361 has preferential affinity for the heavy chain (H-chain) 
form in whole cell lysates (A), is sensitive over a range of dilutions (B) and unlike other 
candidate polyclonal antibodies (C), is associated with crisp detection bands.  
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Figure 8.5 Concordance in polyclonal and monoclonal CTSB immunoblots 
Good agreement in results of CTSB immunoblotting in a panel of human leukaemia cell 
line whole cell lysates using the monoclonal CA-10 and polyclonal Biomol SA-361 
antibodies; sole discordance was observed in the RPMI-8402 T-lineage leukaemia cell 
line (detection of inactive protein only with CA-10; detection of active H-chain form with 
Biomol SA-361)     
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Figure 8.6 Satisfactory negative AEP immunostaining antibody controls 
Representative microscopic images of SD1 cytospins. Upper panel: LysoTracker Red 
(LyTR)-labelled SD1 cells counterstained with DAPI (nucleus); non-immune goat serum 
replaced polyclonal goat-derived anti-human AEP as primary antibody control; Lower 
panel: SD1 cells labelled with DAPI; 1% BSA in PBS replaced anti-AEP as control for 
secondary antibody  
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Figure 8.7 The AEP activity-binding probe is relatively specific 
Live-cell labelling of AEP with activity-binding probe (ABP) in SD1 cells pre-incubated with a cell-permeable AEP inhibitor (MV026630, 
100μM, 12 hours, 37°C).  SD1 cytospin preparations were counterstained with the DAPI nuclear stain before imaging. Scale bars 50μ, 
10×; 10μ, 40×; Axiovert 200M Lowlight system, Metamorph imaging software 
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Figure 8.8 Fluorescent antibody labelling is not observed in the non AEP-
expressing cell lines, REH and SupB15 
Immunofluorescence staining of formalin-fixed cytospins. The non AEP-expressing 
progenitor-B ALL cell lines, SupB15 and REH, were labelled with anti-AEP primary (goat 
polyclonal, R&D) and Alexa Fluor 488-tagged rabbit anti-goat IgG secondary antibodies. 
In SD1-negative control samples, 1% BSA replaced the primary antibody layer and 
served as secondary antibody control. As expected, green fluorescent labelling was 
absent in all three samples. Images were acquired using an Olympus BX51 microscope 
equipped with a Photometrics CoolSnap HQ CCD camera operated by the Metamorph 
advanced imaging software. Scale bar, 10μ; DAPI nuclear counterstain. 
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Figure 8.9 The AEP non-expressing leukaemic cell lines, REH and SupB15, are 
not labelled by an AEP activity-based probe  
DAPI-counterstained, formalin-fixed cytospins of REH (upper panel) and SupB15 (lower 
panel) cells (2×105) labelled live with a BODIPY (λex/em 530/580)-tagged AEP activity-
based probe (1μM, 2 hours, 37°C; orange-red fluorescence); merged images are shown. 
Acquired using an Olympus BX51 microscope equipped with a Photometrics CoolSnap 
HQ CCD camera operated by the Metamorph advanced imaging software.  
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Figure 8.10 AEP Immunohistochemistry staining controls 
Representative images of parallel positive (A) and negative (B) staining controls of colon 
adenocarcinoma tissue sections; higher magnification images of colon carcinoma (C) 
and HRC57 (D) positive staining controls  
Images were acquired using the Olympus BX51 microscope equipped with a cooled 
CCD camera operated by the Olympus Soft Imaging System package (analySIS) 
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Figure 8.11 Mifepristone dose-finding and AEP expression kinetics in inducible-
expressing HEK293 cells 
Upper panel Immunoblot of AEP expression in AEP293GS treated for 24 hours with an 
ascending range of Mifepristone (Mfp) concentrations; an induction dose of  10nM was 
optimal. Lower panel Immunoblot of AEP expression in AEP293GS cells at different 
timepoints following a 24-hour induction pulse of 10nM Mfp; AEP expression was 
established 24 hours following induction and was maintained for at least another 48 
hours. Untr, untreated  
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Figure 8.12 Relative homogenous AEP expression in inducible-expressing 
HEK293 cells 
Flow cytometry dot-plot (forward scatter v fluorescence) and histogram (fluorescence v 
cell count) representations of intracellular AEP expression in Mifepristone-treated and 
untreated inducible-expressing HEK293 cells (AEP.293GS). Following Mifepristone 
induction (24-hour, 10nM), intracellular AEP expression in AEP.293GS cells was 
relatively uniformly clustered at 1-2 logs higher than baseline.  
FSC-H, forward scatter parameter; FL1-H, λ530/30 fluorescent emission filter 
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Figure 8.13 Heterogeneous AEP expression in polyclonal enforced-expressing 
HEK293 cells 
AEP immunostaining in enforced-expressing (AEP.293) and mock-transfected (EV.293) 
HEK293 cells. As expected, AEP expression in polyclonal AEP.293 cells is 
heterogeneous with a mix of strongly-expressing and non-expressing cells. Intracellular 
expression is either peripherally localised (100×, middle panel) or perinuclearly clustered 
(100×, lower) and in other cases, a combination of the two (100×/Optovar 1.5, lower). 
Images were acquired using an Axiovert 200M Lowlight microscope equipped with a 
Photometrics CoolSnap HQ CCD camera operated by the Metamorph advanced imaging 
software.  
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Figure 8.14 Motility of inducible-expressing HEK293 cells in Boyden chamber assays was better observed at higher 
Matrigel dilutions  
Lower chamber cell counts (cells/mL, 24-hour assays) across a range of Matrigel coating dilutions. Motility of Mifepristone (Mfp) 
untreated inducible-expressing cells was relatively constant at higher Matrigel dilutions (1 in 20 upwards) while results were variable 
with Mfp-treated cells. Plus error bars, standard deviation of replicate counts; summary of 2 experiments 
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Figure 8.15 A confounding 56kDa protein band is consistently observed in 
serum-supplemented growth medium 
Immunoblotting for AEP in whole cell lysates and cell-free supernatants of leukaemic cell 
lines (SD1, REH, SupB15). A 56kDa protein band is consistently detected in cell-free 
supernatants. Note that this band is also observed in cell-free complete growth medium 
(lane labeled ʻONLYʼ, RPMI with 2% FBS in this experiment) but not in cell-free serum-
unsupplemented RPMI. Also note the trace detection of β-actin in SD1 supernatant; this 
was a consistent finding in SD1 supernatant isolates despite rigorous measures to 
ensure cell viability (~100% at time of centrifugation) and harvest of cell-free solution.  
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Table 8.1 Microarray expression (normalised intensity values) of candidate 
reference transcripts (n=120).  
β2M, Beta-2 microglobulin; GUS, β glucuronidase; ABL1, Abelson murine leukaemia 
viral oncogene homolog 1; GAPDH, glyceraldehydes-3-phosphate dehydrogenase 
ACTB, β actin 
Cytogenetic 
subtype 
β2M 
NM_004048 
GUS 
NM_000181 
ABL1 
NM_005157 
GAPDH 
Averaged 
ACTB 
NM_001101 
Progenitor B-ALL      
TCF3-PBX1      
ID_1 77.42 4.738 3.905 122.05 178.9 
ID_94 79.02 4.51 3.251 111.35 187.3 
ETV6-RUNX1      
ID_4 88.65 3.364 2.074 100.66 153.4 
ID_5 88.94 3.398 2.352 66.625 171.6 
ID_15 117.5 3.785 2.955 75.305 165.3 
ID_16 108.6 2.419 2.314 68.91 169.4 
ID_18 81.16 6.152 2.643 77.48 162.9 
ID_28 100.2 6.023 4.729 129.8 176.7 
ID_40 69.73 6.454 4.387 128.3 134.1 
ID_45 114.7 7.677 4.225 130.25 220 
ID_ 48 94.76 7.682 2.796 139.1 191.8 
ID_55 92.51 4.875 3.715 142.85 178.6 
ID_62 78.83 4.113 3.969 102.88 157.4 
ID_64 99.55 5.499 2.641 112.97 166.9 
ID_65 82.97 6.519 4.586 126.6 162 
ID_69 48.86 8.665 4.392 103.115 173.9 
ID_75 60.37 8.815 3.393 122.41 167.8 
ID_89 99.27 4.759 2.322 104.845 177.9 
ID_103 79.9 6.889 2.992 121.6 158.5 
High Hyperdiploidy       
ID_0 107.1 4.868 4.09 114.03 161.7 
ID_19 81.27 4.799 4.073 85.29 207.1 
ID_23 71.71 5.945 4.558 123 152.7 
ID_24 102.7 5.781 3.523 127.6 238.1 
ID_27 111.5 4.263 2.547 130.7 152 
ID_30 94.27 4.117 3.38 109.785 153 
ID_35 66.68 3.773 4.171 116.575 171.5 
ID_38 71.05 5.447 2.586 121.45 141.7 
ID_52 104.9 6.796 2.145 115.335 190.1 
ID_53 99.91 5.307 3.695 123.95 130.6 
ID_54 100.2 4.32 4.073 127.45 113.1 
ID_63 71.7 3.552 3.26 107.405 152.3 
ID_66 94.86 6.465 2.665 112.605 143.8 
ID_76 75.61 7.024 3.011 103.595 176.3 
ID_78 71.82 5.072 3.01 122.3 109.3 
ID_80 86.04 5.553 3.219 125.75 147.8 
ID_82 73.61 6.374 4.82 124.4 147.2 
ID_83 73.03 6.799 5.048 120.5 123.9 
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Subtype β2m GUS ABL1 GAPDH ACTB  
ID_84 75.32 3.932 4.279 99.865 201 
ID_85 91.13 4.171 2.523 123.9 155.6 
ID_90 87.7 4.132 3.864 144 132.2 
ID_95 85.14 6.493 3.813 134.15 175.9 
ID_96 100.5 3.95 2.098 124.85 149.9 
Normal Karyotype      
ID_10 77.1 6.675 6.742 126.9 166.1 
ID_34 101.9 3.912 5.316 33.77 159.7 
ID_39 87.01 11.18 3.065 104.675 177.1 
ID_57 74.56 6.681 4.812 147.45 181.9 
ID_59 85.39 3.966 3.739 93.27 129.6 
ID_79 95.76 9.808 3.121 93.555 188.9 
ID_113 77.73 8.683 2.138 119.05 184.1 
MLL rearranged      
ID_87 69.34 6.733 4.604 114.85 151.4 
ID_106 63.07 6.611 2.84 106.855 144 
ID_114 54.1 5.569 2.077 132.7 124.7 
ID_116 71.9 9.137 3.834 128.65 191.2 
BCR-ABL1      
ID_70 101.8 6.572 8.105 115.485 205 
ID_88 58.39 7.586 7.16 109.95 171.2 
ID_91 81.9 7.579 10.75 64.325 152.6 
ID_98 99.05 7.016 7.265 121.35 187.4 
ID_109 118.6 5.379 3.379 139.7 116 
iAMP21      
ID_56 110.3 5.845 3.996 116.35 115.4 
ID_81 98.17 14.3 4.725 108.165 156.8 
ID_99 38.89 5.963 2.328 143.35 61.69 
ID_100 42.06 6.484 2.575 159.85 128 
ID_101 75.55 5.754 1.874 100.295 116.8 
ID_107 60.67 9.056 3.07 111.245 103.3 
ID_108 68.41 5.975 2.836 117.7 110.7 
RUNX1 multiple copies 
ID_9 72.11 5.089 2.814 128.225 150.2 
ID_13 91.27 4.172 2.643 109.215 161.2 
ID_61 120.2 10.13 2.599 130.4 225.6 
ID_72 100.5 6.029 5.048 109.285 190.4 
ID_104 82.2 11.1 1.706 113.62 125.2 
Hypodiploidy      
ID_68 108.9 9.921 4.978 114.26 152 
ID_111 69.92 6.035 2.887 130.5 132.4 
ID_115 99.89 8.735 2.642 180.4 175.6 
Miscellaneous      
ID_2 90.81 3.35 4.305 134.1 198.8 
ID_17 94.61 5.363 7.519 108.325 210.3 
ID_20 85.97 6.336 3.142 119.715 177.8 
ID_22 80.68 5.816 3.232 126.85 167.4 
ID_42 72.84 2.106 3.457 90.385 158.2 
ID_50 85.34 6.255 4.792 97.415 183.1 
ID_60 67.49 6.321 3.155 104.085 127.5 
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Subtype β2m GUS ABL1 GAPDH ACTB  
ID_93 59.59 4.887 3.842 92.805 215.9 
ID_97 135.1 3.965 2.763 62.87 199.2 
ID_119 71.93 10.31 5.73 124.75 179.4 
Progenitor T-ALL      
ID_8 53.9 2.45 1.815 135.5 172.2 
ID_25 89.09 4.435 2.608 91.815 205 
ID_37 87.42 4.463 2.767 113.555 176.8 
ID_44 84.84 3.025 3.232 141.25 200.7 
ID_46 65.12 10.81 3.048 189.2 199.7 
ID_51 82.09 3.74 4.163 131.6 164.6 
ID_71 56.73 4.075 6.04 132.85 172.9 
ID_73 130.1 3.89 3.365 101.015 233.3 
ID_74 71.7 5.709 3.174 105.59 169.4 
ID_105 75.99 4.188 3.392 144.95 204.6 
ID_118 58.44 5.629 3.676 163.8 176.7 
Acute Myeloid Leukaemia 
ID_3 95 11.58 3.208 142.4 252.2 
ID_6 59.64 10.37 2.609 158.65 167.4 
ID_7 66.34 19.18 3.625 99.435 138.3 
ID_11 83.97 10.42 5.713 123.7 159.5 
ID_12 89.37 4.254 2.688 102.295 191.9 
ID_14 77.09 8.887 2.937 123.5 167.3 
ID_21 64.44 10.77 2.544 106.035 181.8 
ID_26 86.85 9.119 3.446 120.85 202.6 
ID_29 75.47 10.65 2.765 171.25 201.3 
ID_31 62.57 2.984 1.108 107.745 147.8 
ID_32 63 6.322 4.416 84.41 171 
ID_33 108.4 9.412 3.45 136.6 180 
ID_36 72.87 5.888 3.429 129.8 201 
ID_41 72.89 13.78 3.048 174.55 193.1 
ID_43 60.78 9.584 5.391 149.05 200.4 
ID_47 97.84 4.455 4.768 141.7 231.9 
ID_49 43.06 14.55 3.133 187.7 199.9 
ID_58 47.43 12.34 2.457 134.15 207.5 
ID_67 56.39 11.01 2.366 140.65 188.3 
ID_77 62.32 6.297 3.556 98.12 124.9 
ID_86 47.95 12.48 3.946 110.275 187.2 
ID_92 53.79 9.559 3.49 148.5 203.9 
ID_102 84.02 10.32 2.592 165.15 223.5 
ID_110 48.69 8.26 2.059 126.9 107 
ID_112 85.85 17.05 2.512 169.3 166.6 
ID_117 47.09 6.932 3.832 136.6 105.3 
Mean 81.09 6.80 3.62 120.44 168.44 
SD 19.32 3.06 1.40 25.09 32.51 
Median 80.92 6.09 3.31 121.53 170.2 
CV 23.82% 44.93% 38.58% 20.83% 19.30% 
Lower 95% CI 43.22 0.81 0.88 71.26 104.73 
Upper 95% CI 118.95 12.80 6.35 169.61 232.15 
Minimum 38.89 2.106 1.108 33.77 61.69 
Maximum 135.1 19.18 10.75 189.2 252.2 
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Table 8.2 Raw Ct values of AEP and β2m transcripts across a 64-fold dilution (0.03125-2μg) of input HRC57 cell line RNA  
 
HRC57 RNA AEP Ct  β2M Ct AEP- β2M ΔCt 
quantity 
(μg)  
96-well 
replicates 
Average 
(CV%) 
384-well 
replicates 
Average 
(CV%) 
96-well 
replicates 
Average 
(CV%) 
384-well 
replicates 
Average 
(CV%) 
96-well 
assay 
384-well 
assay 
Nil Template  ⎯  ⎯ ⎯ ⎯  ⎯  ⎯ ⎯ 
 ⎯  ⎯ ⎯ ⎯  ⎯    
 ⎯  ⎯  ⎯  ⎯    
HRC57  22.766 22.720 22.810 22.94 18.045 17.92 18.654 18.64 4.80 4.29 
2μg  22.696 0.17% 23.139 0.77% 17.892 0.65% 18.605 0.19%   
 22.700  22.865  17.816  18.673    
HRC57       23.155 23.096 23.487 23.55 18.521 18.44 19.010 19.24 4.66 4.31 
1μg 22.981 0.43% 23.648 0.37% 18.442 0.48% 19.357 1.02%   
 23.150  23.515  18.346  19.345    
HRC57  24.239 24.136 24.347 24.28 19.601 19.58 20.277 20.07 4.55 4.21 
0.5μg  23.916 0.79% 24.231 0.24% 19.575 0.09% 20.014 0.92%   
 24.255  24.270  19.570  19.923    
HRC57  24.979 24.959 25.439 25.48 20.571 20.53 21.257 21.32 4.43 4.16 
0.250μg  25.037 0.36% 25.503 0.13% 20.424 0.44% 21.522 0.84%   
 24.861  25.483  20.588  21.178    
HRC57  25.838 25.977 26.236 26.29 21.479 21.47 22.149 22.16 4.51 4.13 
0.125μg 26.143 0.59% 26.485 0.67% 21.670 0.97% 22.254 0.40%   
 25.952  26.142  21.256  22.079    
HRC57  27.195 27.094 27.645 27.51 22.608 22.64 23.565 23.47 4.46 4.04 
0.0625μg 26.910 0.59% 27.659 0.90% 22.751 0.46% 23.332 0.52%   
 27.177  27.224  22.548  23.519    
HRC57  27.608 27.867 28.554 28.76 23.564 23.49 24.614 24.61 4.38 4.15 
0.03125μg 28.036 0.82% 28.937 0.67% 23.548 0.53% 24.703 0.41%   
 27.957  28.776  23.342  24.500    
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Table 8.3 TaqMan assay estimation of dynamic linear range of AEP, β2m and GAPDH transcript expression (Ct) in the HRC57 cell line 
(calibrator) using both 96-well and 384-well reaction formats. 
 
 
 
 
 
 
 
 
Table 8.4 Estimation of TaqMan inter-assay precision (HRC57 RNA, 384-well format); CV = coefficient of variation 
 
 
Input RNA 
(μg) 
Log input 
RNA  
AEP Ct  β2M Ct  GAPDH Ct  
  96-well 384-well 96-well 384-well 96-well 384-well 
2 0.30103 22.72 22.94 17.92 18.64 18.97 19.08 
1 0 23.10 23.55 18.44 19.24 19.83 19.79 
0.5 -0.30103 24.14 24.28 19.58 20.07 20.65 20.57 
0.25 -0.60206 24.96 25.47 20.53 21.32 22.04 22.27 
0.125 -0.90309 25.98 26.29 21.47 22.16 23.35 23.11 
0.0625 -1.20412 27.09 27.51 22.64 23.47 — — 
0.03125 -1.50515 27.87 28.76 23.48 24.61 26.78 26.85 
HRC57 RNA AEP Ct Mean (CV) β2M Ct Mean (CV) AEP-β2M ΔCt 
Assay 1 22.77 22.78 17.78 17.86 4.91 
 22.76 (0.06%) 17.96 (0.49%)  
 22.79  17.85   
Assay 2 22.73 22.69 17.91 17.94 4.76 
 22.47 (0.92%) 17.97 (0.16%)  
 22.88  17.94   
Assay 3 23.58 23.61 18.96 19.00 4.61 
 23.54 (0.34%) 18.91 (0.58%)  
 23.70  19.12   
Assay 4 23.19 23.3 18.75 18.6 4.7 
 23.36 (0.4%) 18.40 (1.0%)  
 23.27  18.53   
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Supplementary Table S3.1 Details of patient samples assayed for AEP expression by qRT-PCR. UPN numbers represent 
samples examined for AEP protein expression and ASNase digestion.  
 
Subtype Patient 
initials 
Sample 
ID 
UPN Cytogenetics  
Progenitor-B ALL 
ETV6-RUNX1 
MMi 42  46, XX; interphase FISH, ETV6-RUNX1 fusion with loss of wt ETV6 
 EHi 45  Detailed karyotype not available; interphase FISH, ETV6-RUNX1 
fusion 
 SBi 77  Interphase FISH, ETV6-RUNX1 fusion  
 ARa 87  46, XX (20 metaphases); interphase FISH, variant ETV6-RUNX1 
fusion 
 JBut 130 1 46, XY; interphase FISH, ETV6-RUNX1 
 JMG 138  46, XY; interphase FISH, ETV6-RUNX1 
 SKh 153  46,XY, dup(7)(p15p22), t(12;19)(q13;p13); interphase FISH, ETV6-
RUNX1, additional RUNX1 copies in 36% cells (of 200)  
 DBa 188  47, XY, ?add(2)(p23), add(3)(q34), dup(5)(q31q35), 
del(7)(p1), ?add(7)(q32), del(10)(q24.1q24.3), add(12)(p13), 
t(12;21)(p13;q22), add(20)(q13), +(21)/ 47, idem, del(12)(p11.2); 
interphase FISH, ETV6-RUNX1 
 GKe 215  46, XX, t(12:21)(p13;q22), del(14)(q23?)/ interphase FISH, ETV6-
RUNX1 fusion  
 AmZu F2508  49, X, -Y, +5, add(6)(p25), del(6)(q11-12q23), +del(6)(q11-12q23), 
+8, ins(9;?)(p13;/), der(9)del(9)(q22q33)ins(9;?)(p13;?), add(11)(p15), 
-12, t(12;21)(p13;q22), +der(21)t(12;21)(p13;q22), +mar1/ 50, idem, 
+19/ 50X, -Y, +5, del(6)(q11-12q23), +del(6)(q11-12q23), +?7, +8, 
ins(9;?)(p13;?), der(9)del(9)(q22q33)ins(9;?)((p13;?), add(11)(p15), -
12, t(12;21)(p13;q22), -18, +der(21)t(12;21)(p13;q22), +mar1, +mar2/ 
46, XY; interphase FISH, ETV6-RUNX1, 2 fusions 
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initials 
Sample 
ID 
UPN Cytogenetics  
ETV6-RUNX1 OSa F2760  46, XY, t(3;12;21)(q2; p13; q21); interphase FISH, ETV6-RUNX1 
fusion, loss of wt ETV6 allele 
 OMi F3175  46, XY, t(12;13)(p13;q12), ?t(12;21)(p13;q22)/46, XY, 
t(3;17)(p21;q25), ?t(12;21)(p13;q22), ?del(11)(q2?q22) 
 KTh F6336  Failed G-banded karyotype; interphase FISH, ETV6-RUNX1 fusion 
 OM F6410  47, XY, t(2;7)(P21;q34), add(4)(q31), add(4)(q31), add(9)(q32), 
add(10)(p11.2), der(12)t(12;21)(p13;q22)?add(12)(p11.2), 
add(12)(p11.2), t(13;21)(q10;q10), add(16)(p11.2), add(19)(q13), 
der(21)t(12;21)(p13;q22), +der(21)t(12;21)(p13;q22); interphase 
FISH, ETV6-RUNX1 with loss of wt ETV6 
 AZ F7255  48, XY, del(6)(q11-12q23), +del(6)(q11-12q23), +8, 
der(9)ins(9;?)(p13;?)del(9)(q22q33), add(11)(p15), 
der(12)t(9;12)(?;p1?)del(12)(q12q21), der(21)t(12;21)(?;q22)/48, 
idem, _Y, +der(21)t(12;21)(?;q22)/46, XY; interphase FISH, ETV6-
RUNX1 fusion 
 MMu F7556  47, XY, add(2)(q1), add(5)(q11.2), der(6)(t(6;7)(q22;p13), 
der(7)add(7)(p1)del(7)(q32q36), -9, add(9)(p2), del(12)(p11.2p13), -
13, del(14)(q24q32), -15, +?21, +der(?)t(5;?)(q1:?), 
+der(?)t(9;?)(q1,?), +mar; interphase FISH, two copies of ETV6-
RUNX1 fusion 
Progenitor B ALL 
High Hyperdiploidy 
SIA 15  57, XY, +X, +4, +6, +10, +14, +15, +17, +18, +21, +21, mar 
 EBr 54  57, XX, +X, +X, +der(1)t(1;?), +4, +6, +10, +14, +17, +18, +21, +21/ 
46,XX; interphase FISH negative for sentinel rearrangements 
 AVe 59  54 XY, +X, ins(1;?)(q2;?), +6, del(6)(q1q2), +10, +18, +18, +21, +21, 
+mar; interphase FISH negative for sentinel rearrangements 
 JWi 71 2 57, XY, +X, +4, +4, +6, +9, +10, +14, +17, +18, +21, +21; interphase 
FISH negative for sentinel rearrangements 
SUPPLEMENTAL Chapter 3 
262 
Subtype Patient 
initials 
Sample 
ID 
UPN Cytogenetics  
High Hyperdiploidy EWi 75  59, XX, +X, +2, +4, +6, +8, +9, +10, +12, +17, +?18, +21, +21, +21; 
interphase FISH negative for sentinel rearrangements 
 ACh 106  57, XX, +X, +4, +6, +10, +14, +14, +17, +18, +21, +21, +mar; 
interphase FISH negative for sentinel rearrangements 
 FRo 111  56, XX, +X, dup(1)(q21q42), +4, +6, +10, +14, +17, +18, +21, +2mar/ 46
XX; interphase FISH negative for sentinel rearrangements 
 ZCh 131  54-59, XY, +9, +?11, +14, +14, +?17, +?20, +21, +21, +21, +?22, 
+mar1,+mar2; interphase FISH negative for sentinel rearrangements 
 AMi 169  55, XX, +X, +4, +6, +10, +14, +14, +17, +21, +21/46, XX; interphase 
FISH negative for sentinel rearrangements 
 JMa 173  55, XY, +X, +4, +14, +14, +17, +18, +21, +21/46, XY; interphase 
FISH negative for sentinel rearrangements 
 ASa 191  55, XX, +X, +4, +6, +8, +10. +14, +18, +19, ?del(20)(q1?), +21; 
interphase FISH negative for sentinel rearrangements 
 BBl 203  57, XY, +X, +4, +5, +9, +10, +14, +17, +?add(18)(q?11.2), +21c, 
+mar/ 58, idem, +21/ 59, idem, +11, +21/ 47, XY, +21c; interphase 
FISH negative for sentinel rearrangements 
 NKa F5511  3 56, XY, +X, +4, +5, +6, +8, +14, +17, +18, +21, +21/ 46, XY; 
interphase FISH negative for sentinel rearrangements 
Progenitor-B ALL SDa 99 4 46, XX, der(19)t(1;19)(q23;p13)/ 50, idem, +5, +8, +8, +14 
TCF3-PBX1 NAY 199  46, XX, t(1;19),(q23:p13)/ 44, XX, idem, +8, +8/ 48, XX, -1, +8, 
der(19) ,t(1:19)(q23;p13), +mar1, +mar2(1)/ 46, XX  
 LNi  278 6 46, XX, der(19)t(1;19)(q23;p13)/46, XX 
 MMa F8141 5 46, XY, t(1:19)(q23;p13)/45, idem, -Y, del(9)(p13-21p24)/46, XY 
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TCF3-PBX1 JAK F9460  47, XX, t(1;19)(q23;p13), i(7)(q10), der(13)t(1;13)(q12;p11.2), 
i(21)(q10), +mar 
Progenitor-B ALL 
Normal Karyotype  
— 25  Detailed karyotype not available; interphase FISH negative for 
sentinel rearrangements; no hidden hyperdiploidy on Multiprobe-I 
testing 
 CGe 36  Failed G-banded karyotype; interphase FISH negative for sentinel 
rearrangements; no hidden hyperdiploidy on Multiprobe-I testing 
 ASh 43  46, XY/ minor subclone - 47, XY, +2, add(10)(q24) 
 AMo 69 11 46, XX; interphase FISH negative for sentinel rearrangements 
 CSw 118  46, XY; interphase FISH negative for sentinel rearrangements 
 AMu 160  46, XX; interphaseFISH: 12p deletion, negative for sentinel fusions 
Progenitor-B ALL 
Miscellaneous 
JHa 17  46, XY, i(9)(q10); interphase FISH negative for sentinel 
rearrangements 
 ACh 52  46, XY, -1, -2, del(2)(p1p2), -4, -5, der(7)t(1;7)(p13;q2), 
der(9)t(4;9)(q1;p1), -10, -15, +21, +der(?)t(5;?)(q1;?), +4mar; 
interphase FISH negative for sentinel rearrangements 
 JKe  198  46,XY,  i(17)(q10)(2)/ 46, XY, idem, ?dup(7)(p?21), 
del(13)(q?14,q?22)/ 46, XY, idem, ?dup(7)(p?21), del(13)(q?14q?22), 
+mar1, +mar2/ 46,XY; interphase FISH negative for sentinel 
rearrangements 
 KFr 204  46, XX, ?del(9)(p?)/ 46,XX, del 9p21; interphase FISH, loss of one 
p16 allele (9p21 locus), negative for sentinel rearrangements  
 LFe 301 12 46, XX, t(1:9)(q21;p21), ?add(5)(q3); interphase FISH negative for 
sentinel rearrangements 
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ID 
UPN Cytogenetics  
Progenitor-B ALL 
Hypodiploidy 
ATu 134 7 26, X, +Y, +14, +21/ 26, idem, -14, +mar/ 52, idemx2/ 52, idemx2, -
14, -14, +mar, +mar/ 46, XY 
 RSm 245  37, XY, -2, -3, -4, -7, del(9)(q1~q2q34), -12, -13, 
der(13)t(13;13)(q34;q12), -15, -16, -17 
 AMo 252  26, X, +14, +18, +21/ 46, XY / 52, idem x 2 
Progenitor-B ALL 
BCR-ABL1 
NAu 140  46, XY, t(9;22)(q34;q11)/ 45, idem, der(7)t(7;9)(p1?;q1?), -9/ 46, 
idem, der(7)t(7;9)(p1?;q1?), -9, +der(22)t(9;22)(q34;q11); interphase 
FISH, BCR-ABL1, deletion of MML (21%), deletion of IgH (26%), 
deletion of p16 (19%) 
 AhZu 184  53, XY, +21, t(9;22)(q34;q11.2); interphase, FISH BCR-ABL1 fusion 
 RHu  193  49, XY, t(9;22)(q34; q11.2), +21 
 OMo 205  46, XY, der(9), del(9)(p13p24)t(9;22)(q34;q11.2), der(22)t(9;22) 
 SaB 258 8 49, XX, +8, t(9;22)(q34;q11.2), +der(22)t(9;22), +mar/ 46, XX 
 NAl F8122  46, XY, t(9;22)(q34;q11.2) 
 TD ALL2003-
4479 
 Detailed karyotype not available; interphase FISH, BCR-ABL1 fusion 
Progenitor-B ALL 
iAMP21 
IAy 110 9 46, XX, der(21)idic(21)(q?)iAMP21q/ 46, XX 
 EYe 170  46, XY, +mar; interphase FISH, iAMP21 
Progenitor-B ALL 
Multiple RUNX1 
copies 
KLa 29  46, XX, -21, +mar1/ 47, idem, +mar2/ 46, XX; interphase FISH, 6 
RUNX1 copies 
 CDa 123  46, XY/ 47, XY, ?del(6q), +mar; interphase FISH, 4 RUNX1 copies 
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Subtype Patient 
initials 
Sample 
ID 
UPN Cytogenetics  
Progenitor-B ALL 
Multiple RUNX1 
copies 
JBus F5481   49, XY, +X, -10, -11, add(12)(p11.2), +14, del(21)(q22q22)x2, +21, -
22, +2 mar/ 49, XY, +X, del(7)(p15p22), -10, -11, add(12)(p11.2), +14, 
del(21)(q22q22)x2, +21, -22, +2 mar/ 46, XY; interphase FISH, four 
RUNX1 copies 
Progenitor-B ALL 
MLL rearranged 
DBo F7901 10 46, XY, t(4;11)(q21;q23)/ 46, XY 
 TSe 183  46, XY, t(4;11)(q21;q23)/ 46,XY 
     
 GWi  237  46, XX, t(4;11)(q21;q23) 
Progenitor-T ALL KKn 28  46 XY; interphase FISH negative for sentinel rearrangements 
 CWO 57  46, XY, t(6;10)(q2?1/q?11), add(11)(q23), del(12)(p1?2)/ 46, XY; 
interphase FISH negative for sentinel rearrangements  
 DLi 73  46, XX; interphase FISH negative for sentinel rearrangements 
 LMe 86  46,XY,del(6)(q)(10); interphase FISH negative for sentinel 
rearrangements 
 JTa 96  46, XY; interphase FISH negative for sentinel rearrangements 
 PLe 141  Failed G-banded karyotype; interphase FISH negative for sentinel 
rearrangements; no hidden hyperdiploidy on Multiprobe-I testing 
 DDo 150  46, XY, t(1;17)(p13;q11), t(2;11)(q37;q23)/ 46, idem, 
del(8)(q1?1q1?3), add(9)(q34)/ 46, XY 
 BMi 152  46, XY, ?dup(2),(q3?q3?), ?dup(3)(q2?5q2?7), add(5)(p1?5), 
del(6)(q21q25), add(8)(p2?), del(12)(p11.2),add(17)(p11.2)(20); 
interphase FISH, 161/250(64%) loss of oneETV6 allele 
 ASo 3122  46, XY, add(11)(p1); interphase FISH, t(7;11)(q35; p13) 
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Subtype Patient 
initials 
Sample 
ID 
UPN Cytogenetics  
Acute Myeloid 
Leukaemia  
JNe 31  46, XY; interphase FISH negative for sentinel rearrangements 
 GCa 90  51, XX, +2, ?der(2)t(1;2)(q25;q3?), +10, +13, +15, +22; interphase 
FISH negative for sentinel rearrangements 
 Es 157  46, XY; interphase FISH negative for sentinel rearrangements 
 JMa 182  AML M7 (dry marrow tap, detailed karyotyping not available) 
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Supplementary Table S3.2 Details of adherent and other suspension cell lines used in experiments  
Cell line Lineage Genetic hallmark Full karyotype 
MHH-
CALL2 
Human precursor B 
leukaemia 
Hyperdiploidy Hyperdiploid, 13% polyploidy, modal number 50-52, XX, gain of 
chromosomes 8, 10, 18, 21 (tetrasomy) 
697 Human precursor B 
leukaemia 
TCF3-PBX1  Near diploid - 46(45-48) XY, t(1;19)(q23;p13), del(6)(q21) 
U266 Human multiple 
myeloma 
11q13 breakpoint  Complex hypodiploid, modal number 40-46, XY, loss of chromosome 8, 
10, 13, gain of chromosome 15, marker +3q27, +7q32, +8q24, +9q34, 
+10p14, +14p11, +17p11, +18p12, der(22)t(15;22)(q21;q13), 
t(1;11)(p33;q13), t(4;11)(q?21;q23) 
RPMI-8402 Human precursor T 
leukaemia 
SIL-TAL1                         
Also, LMO1-TCRD 
Hypotetraploid, modal number 79-91, XXX, loss of chromosomes X, 10, 
13, 14, 18, 20, gain of chromosome 3, 15, deletions (6)(q14q22)x2,  
duplication (4)(q13q23)x2, marker +15p13, t(11;14)(p15;q11)x2, sideline 
clone with der(1)t(1;9)(p35/36;q11), +13q34  
MV4:11 Human acute 
monocytic leukaemia 
MLL-AF4 48(46-48)XY, gains of chromosome 8, 18, 19, loss of chromosome 21, 
t(4;11)(q21;q23) 
HL60 Human acute 
myeloid leukaemia 
Nil specific  Hypotetraploid with hypodiploid sideline, modal number 82-88, XX, 
deletions of chromosome X, 8, 16, 17, gain of chromosomes 18, 22, 
markers +6q27x2, +18q21, ins(1;8)(p?31;q24hsr)x2, 
der(5)t(5;17)(q11;q11)x2, der(9)del(9)(p13)t(9;14)(q?22;q?22)x2, 
der(14)t(9;14)(q?22;q?22)x2, der(16)t(16;17)(q22;q22)x1-2,  - sideline 
with losses of chromosome 2, 5, 15, deletion (11)(q23.1q23.2)  
NB4 Human acute 
promyelocytic 
leukaemia 
PML-RARA Hypertriploid, modal number 71-81, XX, loss of chromosomes X, 19, gain 
of chromosomes 2, 6, 7, 11, 12, 13, 14, 17, 20, markers 
+14pder(8)t(8;?)(q24;?), der(11) from 3-way intrachromosomal 
rearrangements, der(12)t(12;?)(p11;?), t(15;17)(q22;q11-12.1), 
der(19)t(10;19)(q21.1;p13.3)x2  
THP-1 Human acute 
monocytic leukaemia 
MLL-AF9 Near-tetraploid, modal number 88-96, XY/XXY, loss of chromosomes Y, 
8, 13, 19, 22, gain of chromosomes 1, 3, 6, deletions 1q42.2, (6p21)x2-4, 
markers +1p11, +(12q24)x1-2, +(?18q21), isochromosome 2q, 
der(9)t(9;11)(p22;q23)i(9)(p10)x2, der(11)t(9;11)(p22;q23)x2, 
der(13)t(8;13)(p11;p12) 
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U937  Human acute
monocytic leukaemia 
CALM-AF10 Hypotriploid,  modal number 58-69, XXY, loss of chromosomes 2, 4, 6, 9, 
20, 21 gain of chromosome 7, markers +9p22, +16q22,  +19q13, 
isochromosome 11q, 12p, der(5)t(1;5)(p22;q35), t(1;12)(q21;p13), , 
t(10;11)(p14;q23), t(1;5)  
K562  Human Chronic
Myeloid Leukaemia 
in myelo-erythroid 
blast crisis 
BCR-ABL1, encoding 
the e13-a2 fusion 
transcript 
Hypotriploid, modal number 61-68, loss of chromosomes X, 3,13, 18, gain 
of chromosome 7, deletions (9)(p11/13), Xp22, markers 
der(14)t(14;?)(p11;?), der(17)t(17;?)(p11/13;?), 
der(?18)t(15;?18)(q21;?q12); t(9;22)(q34;q11) by FISH 
HEK293  Human embryonic
kidney fibroblasts  
Nil specific  Near-triploid, modal number 64-69, loss of chromosomes 10, 13, 16, 18, 
20, gain of chromosomes 1, 6, 21, 22, deletions 1p35, 6q11, inversions 
(1)(p35q43), markers +(?X)(p22), +(8)(q24), +(13)(p13), +(17)(qter), 
der(?)t(5;?)(q13;?), isochromosome(5p) 
PC3  Human prostate
carcinoma 
c-myc amplification Hypotetraploid, modal number 80-90, XX/XXX, loss of chromosomes Y, 
1, 2, 4, 5, 8, 10, 12, 13, 15, 16, 17, 18, 22, gain of chromosomes 3, 7, 14,  
deletion (1)(p34p35), (5)(p1?)x1-2, (9)(p21)x1-2, 17p11, marker +18-21, 
+1-2 double-minute, +1p?32, +3p1?, +3q13, +(3)(q21)x2, +9(p1?1), 
+9q34, +12q24, +13p11, +19p13 - sideline with 
der(3)add(3)(p2?5)add(3q2?), deletion (4)(q2?4q2?8), +7q11, +(8)(p1?) 
  
 
 
Supplementary Table S3.3 Real-time TaqMan assays: Fluorescent probe details (on-demand reagents from Applied Biosystems) 
 
Transcript Product code Target nucleotide sequence and location  
AEP Hs 00271599_m1 CAAAGTCCTGAAGAGTGGCCCCCAG 
Exon boundary 5 and 6 
79 bp amplicon 
β2M Hs 99999907_m1 TTAAGTGGGATCGAGACATGTAAGC 
Exon boundary 2 and 3 
75 bp amplicon 
Note: Primer sequence details are not available as are deemed proprietary (vide 
correspondence with Applied Biosystems UK [now part of Life Technologies 
Corporation]; Inquiry Reference 2-1839759341, dated 14/2/2011) 
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Supplementary Table S3.4 Raw Ct values of AEP and β2M transcripts in primary 
leukaemia samples 
Sample ID AEP Ct Mean/CV β2M Ct Mean/CV AEP-β2M 
Progenitor-B ALL       
ETV6-RUNX1      
 25.99 25.93 22.44 22.04 3.89 
AZ_F2508 25.95 0.3% 21.77 1.6%  
 25.86  21.91   
OS_F2760 29.68 29.46 23.48 23.42 6.05 
 29.33 0.7% 23.48 0.4%  
 29.38  23.30   
OM_F3175 29.55 29.79 20.83 23.45 6.34 
 29.96 0.7% 22.94 7.1%  
 29.87  23.97   
KT_F6336 26.17 26.53 22.48 22.47 4.07 
 26.68 1.2% 22.39 0.3%  
 26.75  22.53   
AZ_F7255 28.26 28.24 21.99 21.84 6.39 
 28.20 0.1% 21.82 0.6%  
 28.25  21.72   
12:21_42 25.62 25.59 19.16 19.19 6.40 
 25.55 4.9% 19.21 0.2%  
 27.84  19.20   
12:21_45 24.09 23.97 19.72 19.70 4.27 
 23.88 0.4% 19.65 0.2%  
 23.95  19.73   
12:21_77 24.30 24.29 19.31 19.29 5.00 
 24.28 0.1% 19.19 0.5%  
 24.29  19.36   
12:21_87 24.85 25.14 18.71 18.57 6.57 
 25.10 1.3% 18.54 0.7%  
 25.48  18.47   
12:21_130 23.86 24.1 19.69 19.5 4.6 
 24.24 0.8% 19.38 1.1%  
 24.12  19.28   
12:21_138 27.20 27.25 22.79 22.83 4.41 
 27.23 0.2% 22.85 0.2%  
 27.30  22.87   
12:21_153 25.17 25.0 19.70 19.9 5.0 
 24.83 0.7% 20.17 1.2%  
 24.89  19.97   
12:21_188 25.52 25.33 19.44 19.28 6.05 
 25.16 0.7% 19.17 0.7%  
 25.30  19.23   
12:21_215 24.96 25.0 20.24 20.2 4.8 
 24.94 0.1% 19.99 0.7%  
 24.96  20.25   
MMu_F7556 30.70 30.49 22.82 22.82 7.68 
 30.36 0.60% 22.79 0.1%  
 30.42  22.84   
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Sample ID AEP Ct Mean/CV β2M Ct Mean/CV AEP-β2M 
MM_F8141 27.59 27.54 21.54 21.50 6.04 
 27.47 0.22% 21.46 0.2%  
 27.55  21.49   
Hyperdiploidy      
NKa_F5511 25.23 25.24 21.75 21.72 3.53 
 25.16 0.4% 21.60 0.5%  
 25.34  21.80   
HHD_15 24.16 24.20 18.52 18.41 5.79 
 24.26 0.2% 18.38 0.6%  
 24.18  18.32   
HHD_54 25.41 25.48 19.96 19.72 5.76 
 25.50 0.2% 19.56 1.1%  
 25.53  19.64   
HHD_59 24.11 24.2 19.50 19.6 4.6 
 24.24 0.3% 19.53 0.5%  
 24.19  19.67   
HHD_71 26.21 26.23 21.39 21.26 4.97 
 26.26 0.1% 21.14 0.6%  
 26.22  21.25   
HHD_75 26.42 26.38 19.88 19.89 6.50 
 26.35 0.1% 19.90 0.04%  
 26.38  19.88   
HHD_106 23.61 23.60 19.10 19.11 4.49 
 23.56 0.1% 19.18 0.4%  
 23.63  19.04   
HHD_111 24.13 24.08 18.73 18.77 5.31 
 24.15 0.4% 18.77 0.2%  
 23.97  18.81   
HHD_131 24.23 24.22 18.96 19.01 5.21 
 24.29 0.3% 18.95 0.5%  
 24.15  19.12   
HHD_169 23.19 23.2 19.20 19.3 3.9 
 23.02 0.6% 19.37 0.5%  
 23.28  19.36   
HHD_173 23.00 22.9 19.85 19.9 3.0 
 22.83 0.4% 19.93 0.2%  
 22.96  19.95   
HHD_191 24.89 25.07 19.19 19.29 5.77 
 25.17 0.6% 19.23 0.8%  
 25.14  19.47   
HHD_203 28.14 28.1 21.92 22.9 5.2 
 28.20 0.5% 23.14 4.0%  
 27.95  23.71   
TCF3-PBX1      
1:19_JAK 27.84 27.96 22.62 22.85 5.12 
 28.12 0.5% 23.01 0.9%  
 27.94  22.91   
1:19_99 25.86 25.92 19.57 19.44 6.49 
 25.99 0.2% 19.55 1.1%  
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Sample ID AEP Ct Mean/CV β2M Ct Mean/CV AEP-β2M 
 25.92  19.19   
1:19_199 26.70 26.72 19.89 19.88 6.84 
 26.74 0.1% 19.94 0.3%  
 26.72  19.82   
1:19_278 27.01 27.1 19.96 20.0 7.0 
 27.00 0.4% 20.14 0.5%  
 27.21  19.99   
Pre B ALL-Other      
Other_17 25.18 25.20 17.23 17.23 7.97 
 25.19 0.10% 17.20 0.13%  
 25.22  17.24   
Other_52 22.68 22.64 19.54 19.51 3.13 
 22.68 0.3% 19.48 0.2%  
 22.56  19.52   
Other_198 26.95 26.9 21.18 21.1 5.8 
 26.92 0.4% 20.93 0.6%  
 26.73  21.07   
Other_204 25.53 26.1 19.01 20.3 5.8 
 26.46 1.9% 20.38 0.8%  
 26.30  20.14   
Other_301 23.81 23.7 18.93 18.9 4.8 
 23.63 0.6% 18.75 0.5%  
 23.52  18.90   
Normal Karyotype      
NK_25 26.93 27.03 18.72 18.62 8.41 
 26.96 0.53% 18.60 0.50%  
 27.19  18.53   
NK_43 27.77 27.66 18.38 18.50 9.16 
 27.49 0.5% 18.52 0.6%  
 27.72  18.60   
NK_69 26.30 26.4 20.10 20.7 5.7 
 26.58 0.7% 20.74 2.7%  
 26.24  21.23   
NK_118 26.36 26.53 19.10 19.08 7.44 
 26.59 0.5% 19.14 0.4%  
 26.63  19.01   
NK_160 24.63 24.6 19.75 20.0 4.6 
 24.70 0.6% 20.31 1.4%  
 24.42  19.93   
High-Risk Pre-B ALL      
JB_F5481  27.93 27.81 21.79 21.95 5.86 
 27.61 0.62% 22.10 0.7%  
 27.90  21.97   
DB_F7901 26.54 27.36 23.28 22.92 4.44 
 27.37 2.99% 22.74 1.4%  
 28.18  22.74   
NA_F8122 26.59 26.63 23.49 23.29 3.33 
 26.45 0.72% 22.93 1.4%  
 26.83  23.47   
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Sample ID AEP Ct Mean/CV β2M Ct Mean/CV AEP-β2M 
Ph+_140 24.53 24.58 18.60 18.61 5.96 
 24.64 0.2% 18.58 0.2%  
 24.57  18.66   
Ph+_184 24.47 24.46 19.85 19.77 4.69 
 24.42 0.1% 19.69 0.4%  
 24.49  19.77   
Ph+_193 22.92 22.83 19.18 19.03 3.80 
 22.68 0.60% 18.89 0.74%  
 22.90  19.02   
Ph+_205 26.27 26.28 19.52 19.61 6.67 
 26.25 0.11% 19.62 0.44%  
 26.31  19.69   
Ph+_258 26.40 26.32 19.05 18.94 7.38 
 26.25 0.3% 18.88 0.5%  
 26.30  18.89   
MLL_183 27.41 27.5 20.89 20.9 6.6 
 27.54 0.3% 21.01 0.3%  
 27.53  20.90   
MLL_237 27.70 28.1 20.81 20.9 7.1 
 28.26 1.1% 20.88 0.5%  
 28.19  21.03   
HypoD_134 28.41 28.1 19.85 19.9 8.2 
 27.96 1.0% 19.75 0.5%  
 27.93  19.97   
HypoD_245 23.11 23.2 20.00 19.9 3.2 
 23.15 0.3% 19.84 0.4%  
 23.25  19.98   
HypoD_252 23.44 23.4 20.02 20.0 3.4 
 23.39 0.3% 19.89 0.8%  
 23.52  20.22   
iAMP21_110 23.57 23.6 20.17 20.4 3.2 
 23.56 0.1% 20.51 0.9%  
 23.60  20.42   
iAMP21_170 23.80 23.8 21.39 21.0 2.8 
 23.93 0.6% 20.88 1.6%  
 23.65  20.77   
RUNX1amp_29 23.88 24.0 21.24 21.2 2.8 
 24.01 0.6% 21.26 0.1%  
 24.18  21.23   
RUNX1amp_123 24.73 24.7 20.05 19.9 4.8 
 24.67 0.3% 19.95 0.6%  
 24.80  19.82   
Progenitor T ALL      
T_28 26.65 26.63 20.00 20.03 6.60 
 26.58 0.2% 20.14 0.5%  
 26.66  19.95   
T_57 23.90 23.8 19.41 19.6 4.2 
 23.57 0.7% 19.56 0.8%  
 23.79  19.72   
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Sample ID AEP Ct Mean/CV β2M Ct Mean/CV AEP-β2M 
T_73 28.38 28.27 18.68 18.90 9.37 
 28.22 0.3% 18.62 2.3%  
 28.21  19.41   
T_86 28.35 28.59 18.92 19.11 9.48 
 28.77 0.7% 19.18 0.9%  
 28.64  19.23   
T_96 25.48 25.48 19.84 19.72 5.76 
 25.44 0.1% 19.43 1.3%  
 25.51  19.89   
T_141 24.95 24.9 20.83 20.8 4.1 
 24.86 0.3% 20.75 0.2%  
 24.99  20.82   
T_152 24.53 25.1 15.18 19.7 5.4 
 25.38 2.0% 19.86 1.1%  
 25.40  19.56   
T_150 25.52 25.6 20.93 19.4 6.2 
 25.71 0.4% 19.44 0.01%  
 25.60  19.44   
T_3122 28.70 28.8 22.19 22.2 6.6 
 28.74 0.4% 22.36 0.8%  
 28.94  22.03   
Acute Myeloid 
Leukaemia 
     
AML_90 28.26 28.24 18.43 18.53 9.71 
 27.98 0.9% 18.57 0.5%  
 28.49  18.60   
AML_157 28.67 28.59 19.54 19.46 9.13 
 28.51 0.3% 19.35 0.5%  
 28.59  19.50   
AML_182 25.79 25.73 19.16 18.98 6.75 
 25.54 0.6% 18.86 0.9%  
 25.85  18.90   
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Supplementary Table S3.5 Relative AEP transcript expression and enzyme activity 
in lymphoid and myeloid cell lines. Note discrepancy in AEP transcript expression 
and activity in the RPMI-8402 and K562 cell lines (shaded gray) 
 
Cell line Relative* normalised AEP RNA expression 
Relative* AEP 
enzyme activity 
HRC57 1.0000 1.0000 
SD1 1.6196 1.1005 
SupB15 0.0183 0.0185 
REH 0.1914 0.0021 
697 0.0018 BLD 
MHH-CALL2 0.0086 ⎯ 
U266 0.9480 1.5345 
RPMI-8402 2.4144 0.1834 
MV4;11 0.0024 0.0012 
HL60 0.0542 BLD 
NB4 BLD ⎯ 
THP1 0.0052 ⎯  
U937 0.0002 ⎯ 
K562 0.9324 0.0120 
 
BLD, below limit of detection *Relative to the HRC57 cell line 
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Supplementary Table S4.1 Summary of Boyden chamber motility assays in inducible AEP-expressing HEK293 cells.  
Lower chamber cell counts (cells/mL) 24 hours after seeding of 8-micron pore Matrigel-coated inserts (1:50 dilution) loaded with 1×105 cells. AEP.293GS: HEK293 cells stably transfected 
with the mifepristone (Mfp)-inducible AEP-expressing dual-plasmid GeneSwitch constructs.  Mfp-treated: AEP293.GS cells pulsed with mifepristone (10nM) 24 hours prior to assay. 
Untreated (Mfp-untreated) and ethanol-treated (Vehicle control) AEP.293GS cells served as controls. Experiments 4a and 4b refer to invasion assays performed in two separate plates on 
the same day.  
 
Lower chamber cell counts (cells/mL) 
AEP293  EV293 PC3 
Expt 1 700 540 1560 
    
   
740 800 1800
1040 2640
Expt 2 420 240 1400 
    
   
   
   
   
500 500 1520
700 540 1520
740 600 1560
820 660 1560
860 660 1580
Expt 3 649 1272 ⎯ 
    
   
   
519 1160
960 1168
908
Table 
Summary of Boyden chamber motility assays in enforced AEP-expressing HEK293 
cells 
Lower chamber cell counts (cells/mL) 24 hours after seeding uncoated 8-micron pore inserts 
with 1×105 cells. AEP.293, Enforced AEP-expressing HEK293 cells; EV.293: Mock transfected 
isogenic controls; PC3: human prostate adenocarcinoma cell line as positive control 
 AEP.293 GS cells (cells/mL) 
 Mfp-treated  Mfp-untreated Vehicle control 
Experiment 1 160 20 ⎯ 
    
    
    
    
    
100 40
100 100
60 100
200 220
280 80
Experiment 2 180 80 ⎯ 
    
    
    
    
    
120 20
140 20
220 120
60 100
120 240
Experiment 3 80 80 100 
    
    
  
  
  
80 40 40
100 80 40
80 ⎯ ⎯ 
120 ⎯ ⎯ 
80 ⎯ ⎯ 
Experiment 4a 190 294 415 
    
    
  
  
  
138 156 138
398 121 138
242 ⎯ ⎯ 
346 ⎯ ⎯ 
208 ⎯ ⎯ 
Experiment 4b 208 208 156 
    
    
  
  
  
225 69 68
35 346 173
52 ⎯ ⎯ 
242 ⎯ ⎯ 
761 ⎯ ⎯ 
Experiment 5 383 17 ⎯ 
    
    
    
  
  
156 35
190 52
138 17
121 ⎯  
86 ⎯  
 
 
275 
SUPPLEMENTAL Chapter 4 
Supplementary Table S4.2 Parallel proliferation and migration studies on enforced 
AEP-expressing HEK293 cells.  
Serial cell counts of stably transfected AEP-expressing (AEP.293) and mock-transfected 
(EV.293) HEK293 cells seeded in parallel in 6-well plates and in 24-well Boyden 
chamber assays using 8-micron pore uncoated inserts). 
 
 
 AEP.293 EV.293  
Hours after 
seeding 
Cells/mL Migration 
(Cells/mL) 
Cells/mL Migration 
(Cells/mL) 
12h 1500000 740 1500000 1800 
 1497000 920 1548000 1120 
 1365000 980 1302000 1820 
24h 1300000 960 1199000 1140 
 940800 860 980000 1420 
 1212000 800 861600 2020 
60h 1570000 1320 1887000 1680 
 1608000 1080 1992000 1700 
 2006000 1740 2184000 1760 
80h 1750000 1660 2311000 2000 
 1523000 1100 2258000 1400 
 3397000 1740 2230000 2200 
100h 3151000 1140 2342000 1780 
 3235000 1260 2231000 1920 
 2587000 1220 2000000 1760 
135h ⎯ 2880 ⎯ 2280 
 2120 1680 
 1800 2620 
The italicised value is probably an erroneous readout. 
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Supplementary Figure S5.1 Both AEP and CTSB cleave to inactivate ASNase 
Residual ASNase activity estimated 3 hours after incubation with purified recombinant 
human AEP or CTSB (lower panel). ASNase activity was assessed using a proprietary 
chromogen substrate-cleavage assay kit (Medac Asparaginase Activity Test; schematic, 
upper panel) [70]. 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S5.2 In non AEP-expressing REH cells, a papain family 
cathepsin degrades ASNase  
ASNase immunoblot of digests of ASNase (2μg) incubated (12-16 hours) with REH 
whole cell lysates pretreated with the AEP inhibitor MV026630 (AEPi), a protease 
inhibitor cocktail (PIC) or its individual components, leupeptin, pepstatin, AEBSF, 
bestatin and aprotinin. Lysate pretreatment with PIC or leupeptin alone prevented 
ASNase degradation.  
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Supplementary Figure S5.3 Singly or in combination, Cathepsin B and AEP alone in primary lymphoblasts cleave 
ASNase  
ASNase immunoblots following 24-hour incubation of ASNase (2-4μg) with whole cell lysates of primary lymphoblasts (UPN1-12) in 
acid citrate digestion buffer. The profile of ASNase cleavage inhibition is directly determined by blast expression of CTSB and AEP 
(inset, summary table of AEP and CTSB immunoblot expression) 
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Supplementary Table S6.1 Method outline for continuous coupled spectrophotometry estimation of glutaminase activity 
of native and variant ASNase recombinants (method adapted from various sources; reagents from Sigma-Aldrich) 
 
Reaction  Reaction components Assay condition  Reaction product 
Reaction Step 1    
Test sample (0.5 mg/mL) + L-
Glutamine (final, 20mM); no 
sample blank included 
Sodium acetate pH 5.0 1 mL, microfuge format; 37°C, 
60min  
Hydrolysis of L-Glutamine to 
L-Glutamate (and ammonia)  
Reaction Step 2    
Aliquot from Reaction step 1 + L-
Glutamate dehydrogenase (L-
GDH) 
Tris-EDTA pH 9.0; hydrazine hydrate to 
scavenge α-ketoglutarate and maintain 
unidirectionality of reaction; adenine 
diphosphate to stabilise L-GDH 
48-well format, 500μL volume; 
room temperature, 40 minutes.  
Baseline absorbance 
measured pre- L-GDH 
Redox reaction to generate α-
ketoglutarate and β-NAD 
Reaction standard    
Ten-point L-Glutamate standard  
0-500μM 
As above As above As above 
Readout    
β-NAD, absorbance at 340nm  Minute-by-minute reading until 
plateau (20 minutes) 
 
Optimisation steps    
L-Glutamine concentration  Final concentration range from 2 to 
50mM 
L-Glutamine 20mM optimal  
Volume from Reaction Step 1 to 
be used in Reaction Step 2 
15 to 250μL volumes To ensure absorbance within middle part of L-Glutamate 
standard curve  
E. coli L-Glutaminase enzyme as 
positive test control 
Activity range from 20-200mU  Strength adjusted to linear part of standard curve, 100mU 
optimal 
Estimation of glutaminase 
activity of test sample (U/mg) 
Calculated from the following variables: blank-corrected increase in absorbance (β-NAD generation), 
reaction volume in Step 1 (1mL); reaction volume from Step 1 used in Step 2; test sample quantity (0.5 
mg); assay time (60 minutes) and molar absorption coefficient of β-NAD (6.22) 
  
 
 
 
 
 
 
 
Appendix A–D 
  
 
 
APPENDIX 
Appendix A 
Culture Characteristics of B-lineage leukaemic and lymphoblastoid cell lines 
     
     Features SD1 SupB15 REH HRC57
Type B cell precursor ALL B cell precursor ALL B cell precursor ALL Mature normal B 
lymphoblastoid  
Genetic subtype BCR-ABL1, p190  BCR-ABL1, p190  ETV6-RUNX1 Normal  
Origin Woman with Ph+ ALL, 
peripheral blood at diagnosis  
9-year boy with Ph+ALL, bone 
marrow at second relapse 
15-year North African girl, ETV6-
RUNX1 ALL, peripheral blood, 
first relapse 
Not available 
Karyotype Near-tetraploid clone with two 
balanced Ph+ translocations  
Pseudodiploid karyotype 
46XY, t(9;22)(q34;q11), 
der(1)t(1;1)(p11;q31), 
add(3)(q2?7), 
der(4)t(1;4)(p11;q35), , 
add(10)(q25), 
?del(14)(q23q31), 
der(16)t(9;16)(q11;p13)  
45-47X, -X, del (3)(p21p22), 
t(4:12;21;16)(q32;p13;q22;q24), 
inv(12)(p13q22), 
t(5;12)(q31;p1?2), 
+der(16)t(4;12;21;16), +21[cp10]; 
ETV6-RUNX1 fusion by FISH, 2 
additional ETV6 signals 
Diploid  
Growth medium RPMI 1640, 10% FBS RPMI 1640, 10% FBS RPMI 1640, 10% FBS RPMI 1640, 10% FBS 
Morphology in culture Highly pleomorphic, loosely 
clumping ovoid cells 
associated with microvesicles 
in culture 
Uniform single round cells, 
loosely adherent to base of 
culture flask 
Uniform small single round cells, 
small loose clumps when 
overgrown 
Pleomorphic loosely 
clumping ovoid cells 
Doubling time 28-32 hours 60-72 hours 60-72 hours 24-48 hours 
Seeding and passage 
cell density 
1⋅106 cells/mL 1×106 cells/mL  1×106 cells/mL at seeding, 2×106 
/mL at passage 
1×106 cells/mL 
EBV transformation Yes No  No Yes 
Cryopreservation RPMI 1640, 10% DMSO, 20% 
FBS at 10-20×106 
cells/cryovial 
RPMI 1640, 10% DMSO, 20% 
FBS at 10-20×106 
cells/cryovial 
RPMI 1640, 10% DMSO, 20% 
FBS at 10-20×106 cells/cryovial 
RPMI 1640, 10% DMSO, 
20% FBS at 10-20×106 
cells/cryovial 
Mycoplasma Negative (monthly tests) Negative (monthly tests) Negative (monthly tests) Negative (monthly tests) 
Source CRUK Central Cell Services DSMZ (German collection of 
cell cultures) 
CRUK Central Cell Services CRUK Central Cell 
Services 
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AEP transcript nucleotide sequence NCBI accession RefSeq 
NM_005606.5 
The 2040-nucleotide (nt) transcript corresponds to location 93170154-93215012 on 
the minus strand of the genomic AEP sequence (NC_000014.8) and is one of eleven 
(well annotated, 7) alternative transcripts, all of which encode the same protein. 
Alternating font colours demarcate exons (n=14). Underlined nucleotide sequences 
indicate forward (continuous line) and reverse (dashed line) sequencing primers. 
Boxed sequences enclose the coding segment (1302 nt). The grey-highlighted 
nucleotide sequence refers to the exon-spanning (exon boundaries 5 and 6) target 
sequence for the FRET-labelled AEP Taqman probe. Yellow highlights indicate 
nucleotides with known non-synonymous coding polymorphisms.  
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1 gcacagtggc ccttaagcga ggagcggcgg cgcccgcagc aatcacagca gtgccgacgt
 
61 cgtgggtgtt tggtgtgagg ctgcgagccg ccgcgagttc tcacggtccc gccggcgcca  
 
121 ccaccgcggt cactcaccgc cgccgccgcc accactgcca ccacggtcgc ctgccacagg 
 
181  tgtctgcaat tgaactccaa ggtgcagaat ggtttggaaa gtagctgtat tcctcagtgt 
 
241 ggccctgggc attggtgccg ttcctataga tgatcctgaa gatggaggca agcactgggt  
 
301 ggtgatcgtg gcaggttcaa atggctggta taattatagg caccaggcag acgcgtgcca  
 
361 tgcctaccag atcattcacc gcaatgggat tcctgacgaa cagatcgttg tgatgatgta  
 
421 cgatgacatt gcttactctg aagacaatcc cactccagga attgtgatca acaggcccaa 
 
481 tggcacagat gtctatcagg gagtcccgaa ggactacact ggagaggatg ttaccccaca 
 
541 aaatttcctt gctgtgttga gaggcgatgc agaagcagtg aagggcatag gatccggcaa  
 
601 agtcctgaag agtggccccc aggatcacgt gttcatttac ttcactgacc atggatctac 
 
661 tggaatactg gtttttccca atgaagatct tcatgtaaag gacctgaatg agaccatcca 
 
721 ttacatgtac aaacacaaaa tgtaccgaaa gatggtgttc tacattgaag cctgtgagtc 
 
781 tgggtccatg atgaaccacc tgccggataa catcaatgtt tatgcaacta ctgctgccaa  
 
841 ccccagagag tcgtcctacg cctgttacta tgatgagaag aggtccacgt acctggggga 
 
901 ctggtacagc gtcaactgga tggaagattc ggacgtggaa gatctgacta aagagaccct 
 
961 gcacaagcag taccacctgg taaaatcgca caccaacacc agccacgtca tgcagtatgg  
 
1021 aaacaaaaca atctccacca tgaaagtgat gcagtttcag ggtatgaaac gcaaagccag 
 
1081 ttctcccgtc cccctacctc cagtcacaca ccttgacctc acccccagcc ctgatgtgcc  
 
1141 tctcaccatc atgaaaagga aactgatgaa caccaatgat ctggaggagt ccaggcagct 
 
1201 cacggaggag atccagcggc atctggatgc caggcacctc attgagaagt cagtgcgtaa  
 
1261 gatcgtctcc ttgctggcag cgtccgaggc tgaggtggag cagctcctgt ccgagagagc  
 
1321 cccgctcacg gggcacagct gctacccaga ggccctgctg cacttccgga cccactgctt  
 
1381 caactggcac tcccccacgt acgagtatgc gttgagacat ttgtacgtgc tggtcaacct 
 
1441 ttgtgagaag ccgtatccgc ttcacaggat aaaattgtcc atggaccacg tgtgccttgg  
 
1501 tcactactga agagctgcct cctggaagct tttccaagtg tgagcgcccc accgactgtg  
 
1561 tgctgatcag agactggaga ggtggagtga gaagtctccg ctgctcgggc cctcctgggg  
 
1621 agcccccgct ccagggctcg ctccaggacc ttcttcacaa gatgacttgc tcgctgttac 
 
1681 ctgcttcccc agtcttttct gaaaaactac aaattagggt gggaaaagct ctgtattgag  
 
1741 aagggtcata tttgctttct aggaggtttg ttgttttgcc tgttagtttt gaggagcagg  
 
1801 aagctcatgg gggcttctgt agcccctctc aaaaggagtc tttattctga gaatttgaag  
 
1861 ctgaaacctc tttaaatctt cagaatgatt ttattgaaga gggccgcaag ccccaaatgg 
 
1921 aaaactgttt ttagaaaata tgatgatttt tgattgcttt tgtatttaat tctgcaggtg  
 
1981 ttcaagtctt aaaaaataaa gatttataac agaacccaaa aaaaaaaaaa aaaaaaaaaa 
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Appendix C 
 
AEP prepropeptide amino acid sequence (433 amino acids, 
UniProtKB/Swiss-Prot accession Q99538) 
The highlighted sequences represent the sequentially cleaved N- and C-terminal 
segments in the maturing peptide.  The 1-17 amino acid signal peptide sequence 
resides within the N-terminal cleaved segment. The H148 and C189 residues 
(underlined, in red boldface) define the His-Cys catalytic dyad within the His-Gly-
spacer-Ala-Cys catalytic motif. Yellow highlights indicate polymorphic amino acid 
residues.  
 
 
                      
 
 
1 MVWKVAVFLS VALGIGAVPI DDPEDGGKHW VVIVAGSNGW YNYRHQADAC  
                      
51 HAYQIIHRNG IPDEQIVVMM YDDIAYSEDN PTPGIVINRP NGTDVYQGVP  
 
101 KDYTGEDVTP QNFLAVLRGD AEAVKGIGSG KVLKSGPQDH VFIYFTDHGS 
 
151 TGILVFPNED LHVKDLNETI HYMYKHKMYR KMVFYIEACE SGSMMNHLPD 
 
201 NINVYATTAA NPRESSYACY YDEKRSTYLG DWYSVNWMED SDVEDLTKET 
                  
251 LHKQYHLVKS HTNTSHVMQY GNKTISTMKV MQFQGMKRKA SSPVPLPPVT 
                  
301 HLDLTPSPDV PLTIMKRKLM NTNDLEESRQ LTEEIQRHLD ARHLIEKSVR 
 
351 KIVSLLAASE AEVEQLLSER APLTGHSCYP EALLHFRTHC FNWHSPTYEY     
                     
401 ALRHLYVLVN LCEKPYPLHR IKLSMDHVCL GHY  
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Primary ALL bone marrow cells: AEP transcript and protein expression and ASNase digestion profile  
 
   
                  Immunoblotting     ASNase digestion inhibition 
Patient Relative  AEP 
RNA expression* 
Relative AEP 
enzyme activity** 
AEP  CTSB  
heavy chain 
AEPi 
only  
CTSBi 
only  
AEPi & 
CTSBi  
UPN1    1.06 0.378 Prepropeptide Yes —  —  Yes 
UPN2    
     
     
     
     
     
     
     
     
     
      
0.54 1.817 Yes Yes —  —  Yes 
UPN3 2.12 1.261 Yes Yes —  —  Yes 
UPN4 0.30 0.283 No Yes —  Yes — 
UPN5 0.37 0.141 No Yes —  Yes — 
UPN6 0.20 0.054 No Yes —  Yes — 
UPN7 0.09 0.259 No Yes —  Yes — 
UPN8 0.16 0.531 No Yes —  Yes — 
UPN9 2.83 1.063 Yes Yes —  —  Yes 
UPN10 1.13 0.023 No Yes —  Yes — 
UPN11 0.51 0.161 No Yes —  Yes — 
UPN12 0.94 2.513 Yes No Yes —  — 
* β2M transcript expression as reference, HRC57 expression as calibrator ** Normalised to HRC57 AEP activity 
AEPi, whole cell lysates pre-treated with the AEP inhibitor MV026630; CTSBi whole cell lysates pre-treated with the 
CTSB inhibitor CA-074Me 
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